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Summary
Highly concentrated protein therapeutics offer a convenient way for subcutaneous (sc) drug adminis-
tration by the patient him-/herself or a healthcare professional. As the therapy e.g. with monoclonal
antibodies requires quite high doses in the range of mg per kg body weight, the development of highly
concentrated protein formulations is needed due to the limited injection volume, generally considered
being 1 – 2 mL for sc administration. The development of highly concentrated formulations exceeding
50 – 100 mg/mL poses several challenges including chemical and physical stability (e.g. aggregation) as
well as solution viscosity. Thereby, the increase in viscosity observed with higher protein concentration
may cause severe limitations during product development as well as processing and drug administration.
These limitations are defined by the flow rate/injection rate depending on the applied pressure which is
needed during manufacture (fill-finish), in particular during filtration, and drug administration.
The focus of this work was to investigate the rheological behavior of protein solutions at high protein
concentrations. The main objective was to obtain a profound understanding of two critical, hydrody-
namic processes for highly concentrated protein solutions, which were drug administration and filtration,
and to elucidate the role of viscosity with regard to potential limitations.
The current work provides a detailed overview on product characteristics of ten commercially available,
highly concentrated protein therapeutics (Chapter 1). This technical overview summarizes formulation
properties like viscosity and number of visible and sub-visible particles, physico-chemical properties like
pH and osmolality as well as injection device characteristics, such as device dimensions. The analysis
of marketed products revealed significant differences between the products. The current benchmark
for maximum protein concentration and of viscosity was identified as a liquid formulation at a protein
concentration of 200 mg/mL with a dynamic viscosity of 102 mPas (20◦C). This product, which is
provided in a pre-filled syringe, also exhibits the largest inner needle diameter of 25 G compared to other
commercial products using 27 G needle for the injection device.
In the following (Chapter 2), advantages and limitations of different methods for viscosity determination
of protein formulations are discussed. Moreover, a high-throughput method to measure viscosity was
established. This method uses a capillary electrophoresis instrumentation without operation of the
electrical field. The established method has the advantage of being automated offering the possibility for
high-throughput by use of low sample amounts in the microliter range at the same time. (Allmendinger
et al., J Pharm Biomed Anal, 99 (2014) 51-58)
Based on these studies, the present work investigated and characterized the subcutaneous drug adminis-
tration process of highly concentrated protein formulations providing quantitative in vitro (Chapter 3)
and in vivo data (Go¨ttingen minipigs) of injection forces (Chapter 4).
Chapter 3 describes in detail the establishment of an in silico model to predict injection forces depending
on syringe and needle dimensions, solution viscosity, and injection rate. Importantly, this model
accounts for shear thinning behavior (non-Newtonian flow behavior) of highly concentrated protein
solutions, which leads to lower effective injection forces than expected from current literature models.
(Allmendinger et al., Eu J Pharm Biopharm, 87 (2014) 318-328)
To address the in vivo situation, Chapter 4 investigates and quantifies the contribution of the subcu-
taneous tissue backpressure and specifically reports the additional influence of body temperature on
injection forces, which was found to compensate the tissue backpressure to some parts. Overall, an
extended model, which addresses the injection force as a function of viscosity, volumetric flow/injection
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rate, needle/device dimensions, shear-thinning behavior, sc backpressure, and body temperature, was
developed to predict injection forces representative for the in vivo situation. This knowledge is of key
importance for the development of combination products (e.g. autoinjectors or pre-filled syringes) as
a detailed understanding of injection forces depending on various parameters is required. It may be
also supportive for the definition of limits during the evaluation, planning, and design phase during the
development of injection devices. (Allmendinger et al., submitted to J Control Release, 2014)
Besides drug administration, filtration was investigated as another critical hydrodynamic process for
highly concentrated protein formulations, depending on formulation composition and filter material
(Chapter 5). For both processes, filtration and drug administration, shear thinning behavior was found
for some of the products depending on viscosity and protein concentration, shear rate, and formulation
composition.
Within the present work it was shown, that the two investigated hydrodynamic processes, filtration
and drug administration by injection, are two highly complex processes which are influenced by various
factors. Thereby, the final limiting parameter for the injection process is given by the user capability
of the patient population. However, the needle inner diameter was shown to have major influence on
injection forces. It is related to injection forces by the power of four compared to other parameters
like viscosity, injection rate, and contribution of sc backpressure being directly proportional. For the
filtration process, the final limiting parameter may be discussed controversially. The study showed
that the filtration pressure is mainly defined by the pore size distribution of the filter material, which
was furthermore found to trigger the rheological behavior at high protein concentrations dependent on
filtration rate. Moreover, literature data reported that the influence of filtration pressure on product
quality might not be the limiting parameter during filtration. For the formulations previously tested,
the shear stress exposure during manufacture was not considered important for final product quality,
however only tested up to a protein concentration of 100 mg/mL. More important causes of aggregation
were suggested to be the presence of air-bubbles, adsorption to solid surfaces, or contamination by
particulates. Nevertheless, the stability of formulations showing pronounced shear-thinning behavior at
high shear rates, which is most likely only the case for higher protein concentrations than previously
tested, needs further experiments and has to be evaluated on a case-by-case basis dependent on product
and process characteristics. (Allmendinger et al., submitted to J Pharm Sci, 2014)
With respect to viscosity, the current work has demonstrated for both processes, drug administration
and filtration, that the potential limitation defined by the proportional increase in pressure based on
Newtonian flow behavior was overestimated due to the presence of shear-thinning behavior which was
shown for highly concentrated protein formulations.
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Zusammenfassung
Subkutane Injektionen stellen fu¨r den Patienten einen angenehmeren Weg der parenteralen Medika-
mentenverabreichung dar, da sie dem Patienten die Mo¨glichkeit geben, das Medikament selbst zu injizieren
oder durch medizinisches Fachpersonal zu Hause verabreichen lassen zu ko¨nnen. Da die Therapie mit
beispielsweise monoklonalen Antiko¨rpern in der Regel relativ hohe therapeutische Dosen im Bereich von
mehreren Milligramm pro Kilogramm Ko¨rpergewicht beno¨tigt und das Injektionsvolumen fu¨r subkutane
Verabreichung oftmals auf ungefa¨hr 1 – 2 mL begrenzt wird, besteht die Notwendigkeit hochkonzentrier-
te Proteinformulierungen zu entwickeln. Die Entwicklung von hochkonzentrierten Formulierungen die
eine Proteinkonzentration von 50 – 100 mg/mL u¨berschreiten fu¨hrt dabei zu Herausforderungen im Hin-
blick auf chemische und physikalische Stabilita¨t, wie beispielsweise Aggregation, sowie erho¨hte Viskosita¨t
der Formulierung. Der Viskosita¨tsanstieg, der mit ho¨herer Proteinkonzentration beobachtet wird, kann
dabei zu starken Limitationen wa¨hrend der Produktentwicklung, der Herstellung und der Injektion selbst
fu¨hren. Diese Limitationen sind durch die begrenzte Flussrate/Injektionsrate definiert, die abha¨ngig vom
ausgeu¨bten Druck ist, der wa¨hrend der Herstellung (Fertigabfu¨llung), vor allem wa¨hrend der Filtration,
und wa¨hrend der Medikamentenverabreichung durch Injektion ausgeu¨bt wird.
Der Fokus dieser Arbeit lag darauf, das rheologische Verhalten von Proteinlo¨sungen bei hohen Pro-
teinkonzentrationen zu untersuchen. Das Hauptziel war es ein tiefgehendes Versta¨ndnis sowohl des In-
jektionsprozesses/der Medikamentenverabreichung als auch der Filtration zu erlangen, und den Einfluss
der Viskosia¨t in Bezug auf potentielle Grenzen/Limitationen aufzuzeigen.
Zu Anfang gibt die vorliegende Arbeit einen detaillierten U¨berblick u¨ber die Eigenschaften von zehn
sich derzeit auf dem Markt befindenden konzentrierten Proteintherapeutika (Kapitel 1). Der technische
U¨berblick beinhaltet die Charakterisierung von Formulierungseigenschaften wie z.B. Viskosita¨t und An-
zahl sichtbarer und subvisueller Partikel, physiko-chemische Eigenschaften, wie pH und Osmolalita¨t, sowie
die Charakterisierung von Eigenschaften des Injektionshilfsmittels. Die Charakterisierung der Marktpro-
dukte zeigte signifikante Unterschiede zwischen den Produkten. Die ho¨chste Proteinkonzentration und
Viskosita¨t wurde dabei fu¨r eine Flu¨ssigformulierung mit 200 mg/mL und 102 mPas (20◦C) bestimmt.
Dieses Produkt, das als Fertigspritze auf dem Markt ist, hat unter anderem den gro¨ssten Nadelinnen-
durchmesser von 25 G im Vergleich zu anderen Marktprodukten, die eine 27 G Nadel fu¨r die Fertigspritzen
verwenden.
Im darauffolgenden Kapitel werden die Vorteile und Grenzen verschiedenster Methoden, die zur Messung
der Viskosita¨t von Proteinformulierungen eingesetzt werden, diskutiert (Kapitel 2). Desweiteren wurde
eine Hochdurchsatzmethode zur Bestimmung der Viskosita¨t entwickelt. Dieser Ansatz verwendet zur
Probenmessung ein Kapillarelektrophorese-Instrument, jedoch ohne das elektrische Feld zu nutzen, und
hat den Vorteil einer automatisierten Methode. Damit bietet sie die Mo¨glichkeit eines hohen Durchsatzes
bei gleichzeitiger Verwendung kleiner Probenmengen im Bereich von einigen Mikrolitern. (Allmendinger
et al., J Pharm Biomed Anal, 99 (2014) 51-58)
Basierend auf diesen beiden Studien untersucht und charakterisiert die vorliegende Arbeit den Injektions-
prozess von hochkonzentrierten Proteinformulierungen zur subkutanen Verabreichung. Dazu wurden
quantitative Daten von Injektionskra¨ften sowohl in vitro (Kapitel 3) als auch in vivo (Go¨ttingen Mini-
schwein) erhoben (Kapitel 4). Im Detail beschreibt Kapitel 3 die Etablierung eines in silico Models zur
Vorhersage von Injektionskra¨ften abha¨ngig von Spritzen- und Nadelkonfiguration, Viskosita¨t der Lo¨sung
und Injektionsrate. Besonders wichtig ist dabei, dass das Model fu¨r scherverdu¨nnendes Fliessverhal-
v
ten (nicht Newton’sches Fliessverhalten) anwendbar ist. Es wurde gezeigt, dass hochkonzentrierte Pro-
teinlo¨sungen scherverdu¨nnendes Fliessverhalten wa¨hrend des Injektionsprozesses/bei hohen Scherraten
zeigen ko¨nnen, das zu niedrigeren Injektionskra¨ften fu¨hrt als von bisherigen Modellen in der Literatur
vorhergesagt. (Allmendinger et al., Eu J Pharm Biopharm, 87 (2014) 318-328)
Um die in vivo Situation abzudecken wird in Kapitel 4 der Beitrag des subkutanen Gewebegegendrucks
untersucht und quantifiziert. Im Besonderen wurde der zusa¨tzliche Einfluss der Ko¨rpertemperatur zu
Injektionskra¨ften aufgezeigt, der den Beitrag des Gewebegegendrucks zu Teilen aufhebt. Insgesamt kon-
nte ein erweitertes Model zur Vorhersage von Injektionskra¨ften entwickelt werden, das repra¨sentativ fu¨r
die tatsa¨chliche in vivo Situation im Tier ist. Das Model beschreibt die Injektionskraft als Funktion der
Viskosita¨t, des Volumenstroms/der Injektions-rate, der Nadel- und Device-Dimensionen, abha¨ngig von
scherverdu¨nnendem Verhalten, dem subkutanen Gewebegegendruck, und der Ko¨rpertemperatur. Diese
Daten sind von grundlegender Bedeutung fu¨r die Entwicklung von Kombinationsprodukten (z.B. Autoin-
jektoren oder Fertigspritzen), da diese ein grundlegendes Versta¨ndnis von Injektionskra¨ften abha¨ngig von
verschiedenen Parametern beno¨tigt. Gleichzeitig kann es fu¨r die Festlegung der Grenzen wa¨hrend der
Evaluierungs-, Planungs- und Designphase wa¨hrend der Entwicklung der Kombinationsprodukte dienen.
(Allmendinger et al., eingereicht bei J Control Release, 2014)
Neben dem Injektionsprozess wurde die Filtration als weiterer kritischer hydrodynamischer Prozess fu¨r
hochkonzentrierte Proteinformulierungen abha¨ngig von Filtermaterial und Formulierungszusammenset-
zung untersucht (Kapitel 5). Bei beiden Prozessen, sowohl Filtration als auch wa¨hrend des Injek-
tionsprozesses, wurde fu¨r einige Produkte scherverdu¨nnendes Verhalten beobachtet, das abha¨ngig von
Viskosita¨t und Proteinkonzentration, Scherrate und Formulierungszusammensetzung war. Innerhalb
dieser Arbeit wurde gezeigt, dass die beiden untersuchten hydrodynamischen Prozesse der Filtration
und Injektion zwei hochkomplexe Prozesse darstellen, die von verschiedensten Faktoren beeinflusst
werden. Der eigentliche limitierende Faktor des Injektionsprozesses stellt dabei die Leistungsfa¨higkeit
(Kraftaufwand) der Patientenpopulation dar. Desweiteren konnte gezeigt werden, dass der Innen-
durchmesser der Injektionsnadel den gro¨ssten Einfluss auf die Injektionskraft darstellt, da er mit der
vierten Potenz eingeht im Vergleich zu anderen Parametern wie Viskosita¨t, Injektionsrate und der Beitrag
des Gewebegegendrucks, die direkt proportional zur Injektionskraft sind.
Fu¨r die Filtration kann der limitierende Faktor kontrovers diskutiert werden. Innerhalb dieser Arbeit
wurde gezeigt, dass der Filtrationsdruck vor allem durch die Verteilung der Porengro¨sse des Filtermate-
rials beeinflusst wird, die auch das rheologische Verhalten bei hohen Proteinkonzentrationen abha¨ngig
von der Filtrationsrate bestimmt. Dabei wurde in der Literatur berichtet, dass der Einfluss des Filtra-
tionsdruckes auf die Produktqualita¨t nicht der limitierende Faktor wa¨hrend der Filtration sein ko¨nnte,
da fu¨r die getesteten Formulierungen der Scherstress wa¨hrend der Herstellung nicht bestimmend fu¨r die
finale Produktqualita¨t war. Wichtigere Ursachen fu¨r Aggregation wa¨hrend der Herstellung ko¨nnten Luft-
blasen, Adsorption an feste Oberfla¨chen oder Partikelkontamination darstellen. Dabei wurde allerdings
lediglich bis zu einer Proteinkonzentration von 100 mg/mL getestet. Deshalb beno¨tigt es weitergehender
Experimente um die Stabilita¨t von Formulierungen mit scherverdu¨nnendem Verhalten zu untersuchen,
das in den meisten Fa¨llen in der Regel bei ho¨heren Proteinkonzentrationen auftreten wird, als bisher
gestestet. Die Produktstabilita¨t muss von Fall zu Fall fu¨r jedes Produkt einzeln abha¨ngig von Produk-
tcharateristika und Prozess evaluiert werden. (Allmendinger et al., eingereicht bei J Pharm Sci, 2014)
Mit Bezug auf die Viskosita¨t konnte innerhalb dieser Arbeit fu¨r beide Prozesse, der Injektion und der
Filtration, gezeigt werden, dass durch das scherverdu¨nnende Verhalten, das fu¨r einige hochkonzentrierte
Proteinformulierungen gezeigt werden konnte, die potentiellen Limitationen durch den proportionalen
Anstieg des Druckes basierend auf Newtonschem Fliessverhalten, u¨berscha¨tzt wurden.
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Introduction
Highly concentrated protein formulations
The biotechnological sector is one of the fastest growing segments within the pharmaceutical market
with sales of over $163 billion worldwide in 2012 and an expected growth of the total global market of
9% annually over the next several years. [1-4] Technical innovations like genetic engineering have led to
a rapid development especially in the field of monoclonal antibody-based (mAb) products. [4, 5] They
reached global sales of $51.5 billion in 2012 and are expected to reach $89.9 billion in 2017 constituting
the largest biopharmaceutical product category besides vaccines from a sales point of view (Figure 1). [3]
Figure 1: Global sales of biotechnological sector for 2012 and expected sales including annual growth
rate until 2017 divided into therapeutic segments. [3]
Biotherapeutics cover a broad range of indications including cancer treatment as well as autoimmune
and inflammatory diseases to name only the largest groups. [4] In most cases, patients receive their
treatment at the hospital where the drug is administered intravenously usually over several hours.
A more convenient way for the patient is the possibility for home-treatment or ambulant, shorter
administration by sc injection, especially for those indications requiring frequent dosing, for chronic
diseases like rheumatoid arthritis or even for cancer therapies. Formulations which are applicable using
the subcutaneous (sc) route of injection may allow the patient to administer the drug by him/herself
or receive injections by a healthcare professional. The injection volume for sc drug administration is
currently considered to be limited to 1 – 2 mL and mAb treatment requires high therapeutic doses in the
rage of mg per kg bodyweight. [6-9] This generates the need to develop highly concentrated formulations
exceeding the 100 mg/mL applicable for sc use.
For a more convenient and safe drug administration, concentrated protein formulations are developed
as combination products especially in cases where convenience of self-administration is required. These
are e.g. injection devices like pre-filled syringes, autoinjectors, or injection pumps. Picture 1 shows three
examples of combination products which are currently approved by EMA and FDA. These examples
are Actemra sc R© which is approved as a pre-filled syringe with a safety device (A), Herceptin sc
Single-injection-device R© (B), and the Humira R© Pen (C).
The development of highly concentrated formulations exceeding the 50 – 100 mg/mL poses several
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challenges, including chemical, and physical stability (e.g. aggregation), as well as solution viscosity.
[11-13] In particular, the increase in viscosity with higher protein concentration may cause limitations
during product development and processing, which may occur during manufacture (filtration, pumping,
filling) as well as during drug administration (injectability). [6, 8, 11, 12] These limitations arise due to
an increase in pressure/force which is needed for manufacturing or injection of the sample in a defined
(injection) time. The increase in pressure is triggered by (elevated) viscosity and the smallest orifice
diameter of the process (law of Hagen-Poiseuille). [14, 15] For drug administration, this is the inner
diameter of the injection needle that is critical, which is e.g. 0.21 mm for a 27 G needle (0.19 – 0.24 mm
according to DIN EN ISO 7864:1993). A 27 G needle is used for most of the marketed products for sc
injection as outlined later in this work. An overview of the commercial manufacturing process of protein
therapeutics will be provided in the following.
Fill-finish manufacturing process of protein solutions
Parenterally administered protein formulations are typically formulated and manufactured as either
liquid formulation in a vial, pre-filled syringe, or cartridge in an injection device, or as a lyophilisate in
a vial or dual-chamber syringe. Figure 2 provides an overview of a typical fill-finish process of a liquid
formulation. After thawing of the usually frozen API bulk solution (active pharmaceutical ingredient),
the solution is transferred into a compounding vessel. In the compounding vessel, the solution is
2
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homogenized and additional excipients can be added, as required. After a bioburden reduction filtration
using a 0.22 µm filter into a holding tank, the formulation is sterile-filtered through a 0.22 µm filter
prior or during filling. Filling into primary packaging material such as glass vials is performed in class
A environment (isolator or RAB = restricted access barrier) using e.g. peristaltic pumps. A surge tank
might be included into the fill-finish process serving for venting. After filling, the vials are stoppered and
further transported for capping. For lyophilisates, vials are only stoppered partially and then transported
and loaded to the lyophilizer. After subsequent lyophilization and stoppering in the lyophilizer, vials are
unloaded and capped.
The fill-finish process of a sterile solution includes several hydrodynamic processes which are driven by
the applied pressure during the respective process steps. The applied pressure defines the flow rate which
is directly proportional to viscosity and the smallest passage diameter during the process, which are the
pores of the sterile filters with a nominal pores size of 0.22 µm.
Figure 2: Typical fill-finish process of a liquid formulation. API = active pharmaceutical ingredient.
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Viscosity of highly concentrated protein solutions
Viscosity of concentrated protein solutions is governed by multiple factors including, but not limited to
protein concentration [16, 17], temperature [18-22], formulation pH, and solution composition [23-25].
Dynamic viscosity increases in an exponential fashion at higher protein concentration and is governed
by two factors. This is on the one hand volume exclusion which is based on the increase in volume
fraction of the protein as well as of the excipients, leading to crowding of the molecules. [26-28] On the
other hand, viscosity is governed by protein-protein interactions (PPI). PPIs are manifold in nature and
dependent on the intermolecular distance (r) and therefore protein concentration. [23] The interplay of
volume exclusion and PPIs can be described by the potential of mean force W22 between two molecules
dependent on the intermolecular distance as follows [29-31]:
W22(r) = WHS(r) +Wq(r) +Wµ(r) +WV dW (r) +Wosmotic(r)
withWq(r) +Wµ(r)
= Wq−q(r) +Wq−µ(r) +Wq−iµ(r) +Wµ−µ(r) +Wµ−iµ(r)
The negative derivative of W22, which is −∂W (r)/∂r, is equal to the force between two protein
molecules and is averaged over all possible orientations and configurations of the molecule. [32] The
main contribution to the potential of mean force is derived from the hard-sphere potential (HS ),
which accounts for volume exclusion of the protein molecules, as well as electrostatic interactions (q).
Both are repulsive in nature and were shown to dominate at low protein concentrations dependent
on formulation composition/ at low salt conditions. [24] Attractive forces might be also present at
low protein concentrations but are considered as negligible at large intermolecular distances (low salt
conditions). At high protein concentrations and conclusively smaller inter-molecular distance, Van
der Waals forces (VdW ) and dipole/induced dipole (µ/iµ) potentials as well as the combination of
µ/iµ and q potentials increase, which are attractive in nature. Moreover, the osmotic/excluded-volume
effect Wosmotic of added salt contributes to the attractive potential at high protein concentrations, but
becomes only predominant at salt concentrations >1 M. [33]
The relative contribution of the potentials changes with protein concentration and formulation compo-
sition. Figure 3 shows the mean force potential as a function of the intermolecular distance indicating
that the sum of all potentials, i.e. attractive and repulsive interactions, govern the interaction potential
and therefore viscosity behavior at small intermolecular distances. [23, 24, 31]
Besides the non-specific contributions, also specific interactions like hydrogen-bonding or interactions
driven by local geometry may contribute to the interaction potential in some cases as reported by Kanai
et al. in 2007 and Yadav et al. in 2009 for a specific mAb. [34, 35]
The importance of electrostatic PPIs for the viscosity behavior of mAbs was recently investigated by
Yadav and colleagues. [36] Especially the distribution of surface charge was shown to play an essential
role and governs viscosity behavior. The viscosity of concentrated mAb formulations can be reduced by
the addition of chaotropic cations or anions like e.g. Hofmeister salts [34]. The increase of ionic strength
likely leads to shielding of the electronic surface charges which leads to a decrease in viscosity for most
protein formulations. [23] This is explained by the potential of mean force as the molecular charge of
the protein is shielded by the ions and therefore the contribution of electrostatic PPIs to the repulsive
4
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Figure 3: Interaction potential energy as a function of intermolecular distance. The green line (repulsive
potential) is obtained by adding hard-core (WHS) and screened coulombic (Wq−q) potential. The blue line
represents Van der Waals potentials (WvdW ; attractive). The interplay of these potentials is historically
known as DLVO theory. The values of minima and maxima as well as their position depend on the
solution characteristics. (From Malescio, Nature Materials 2, 501-503, August 2003)[31]
interaction potential decreases. [16, 37] Viscosity lowering excipients for protein formulations were studied
intensively in the past. Du and co-workers have recently reported that hydrophobic salts significantly
lowered the viscosity of concentrated bovine serum albumin and γ-globulin solutions. [38] Guo et al. have
previously proposed that cations/anions being hydrophobic, bulky, and aliphatic in nature were most
effective to reduce viscosity of mAb formulations. [39] Promising candidates for lowering viscosity of
highly concentrated mAb formulation are currently amino acid derivatives like arginine salts as reported
by Liu and co-workers. [40]
Viscosity of protein solutions is exponentially dependent on protein concentration and can be described
mathematically using the modified Mooney equation [41]:
η = η0 · e
c · [η]
1 − c · [η] · k/ν
The dynamic viscosity η (mPas) is described as the product of placebo viscosity η0 (mPas) multiplied
by an exponential term consisting of the product of protein concentration c (g/L) and intrinsic viscosity
[η] which is equal to 6.3 mL/g for monoclonal antibodies [42], as well as the fraction of a crowding factor
divided by a form factor k/ν accounting for the dependence of viscosity on size and shape of the protein.
These two parameters are both dimensionless and obtained by fitting of the Mooney equation to the
experimental data. The Mooney equation was recently applied to several mAb formulations to describe
the concentration dependence of viscosity. However, deviation in experimental data from the model were
ascribed to PPIs and protein-solvent interaction, as the Mooney equation describes the concentration
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dependence of dynamic viscosity of dispersed hard-sphere, non-interacting molecules only accounting for
volume exclusion. [17, 34, 37]
A direct measure of the protein-protein pair potential is the osmotic second virial coefficient, B22 (also
termed A2), which can be analytically quantified by various methods. B22 is thereby related to the
potential of mean force W22 by the molar mass of the protein as described by Hill and colleagues
in 1957. [29, 43] The most commonly used methods are static light scattering [44-46], analytical
ultracentrifugation [37, 47], membrane osmometry [48-50], self-interaction chromatography [51, 52], and
dynamic light scattering [25, 44, 53]. However, these methods measure at low protein concentrations
and are thus limited in the application to protein concentrations exceeding 50 mg/mL. At high protein
concentrations, the second term of the virial equation is no longer sufficient to describe PPIs, as
higher interactions between three or more molecules contribute to the overall interaction potential.
[17] Nevertheless, correlation of the second virial coefficient A2 with viscosity at high protein concentra-
tion was intensively studied in the past revealing quantitative relation of viscosity and attractive PPIs
for some mAb formulations. [25, 54] Methods applicable at high protein concentrations are limited and
include small-angle X-ray scattering (SAXS) [55, 56] as well as small-angle neutron scattering (SANS)
[57-59]. Saluja and co-workers have recently used characterization of elastic properties by the storage
modulus G as a measure for PPIs at high protein concentrations. [60-62] They also showed that G
correlated qualitatively with viscosity in their studies.
Viscosity at high protein concentrations is governed by higher order interactions as outlined. Recently
published data suggested the formation of transient mAb networks, so-called clusters, due to reversible
self-association. [36, 37, 63-66] Wayne et al. proposed that only small anisotropic PPIs between surfaces
are required to initiate cluster formation. They found that the size of clusters was directly correlated to
solution viscosity. [63] Yadav and colleagues reported that the charge distribution on the mAb surface
plays an essential role during self-association. [36] The formation of clusters with increasing volume
fraction is a commonly known phenomenon observed in polymer chemistry. [67] Thereby, the formation
of higher order structures leads among others to non-ideal solution and flow behavior at high shear
rates. [67, 68] Thus, non-ideal/ non-Newtonian flow behavior would be of high relevance during drug
administration as well as filtration of highly concentrated protein formulations and will be investigated
within this work.
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The increasing demand for subcutaneous formulations of protein therapeutics results in the increasing
request for highly concentrated formulations exceeding 50 – 100 mg/mL. However, severe limitations
are given by the rheological behavior during product development as well as during processing and drug
administration. The elevated viscosity at high protein concentrations leads to an increase in pressure/
resulting force required to manufacture, especially filter, or administer the protein solution.
The focus of this work is to investigate the rheological behavior of protein solutions at high protein
concentrations. The main objective is to obtain a profound understanding of the drug administration as
well as of the filtration process and to elucidate the role of viscosity with regard to potential limitations.
The present work provides an overview of commercially available highly concentrated protein for-
mulations for subcutaneous or intramuscular administration as well as of methods used for viscosity
characterization with establishment of a high-throughput method for viscosity determination. Based
on these studies, the present work targets to investigate and characterize in detail the two outlined
hydrodynamic processes which are filtration as well as the injection process for highly concentrated mAb
formulations.
In detail, ten commercial highly concentrated biotherapeutics were investigated to provide a technical
overview of commercial protein products and to summarize requirements defined by the European
Pharmacopoeia (Chapter 1). The products were characterized for formulation, packaging as well as for
injection forces and device components, and served as a benchmark for the subsequent studies.
Succeeding the depiction of landscape of commercial products, an automated high-throughput method
was developed to measure dynamic viscosity using capillary electrophoresis equipment, due to the
limited number of commercially available methods suitable to measure viscosity of protein formulations.
Chapter 2 reports the development of this method as well as the application to protein therapeutics.
Based on these preliminary studies, injectability and filtration of highly concentrated protein formulations
were investigated in Chapter 3, 4, and 5.
Injection forces of a monoclonal antibody at maximum protein concentration feasible (250 mg/mL)
as well as of different commercial products were investigated in Chapter 3. A mathematical in silico
model was established for prediction of injection forces applicable for Newtonian solutions and especially
extended for non-Newtonian fluids. The model was experimentally verified (in vitro) by use of surrogate
samples (Carbopol gels) and applied to injection force measurements of the protein samples.
For a complete and comprehensive picture of parameters contributing to injection forces based on
Chapter 3 representative for the in vivo situation, the potential influence of the backpressure of the sc
tissue layer to injection forces was investigated in Go¨ttingen minipigs (in vivo) dependent on viscosity,
injection rate, and injection volume. The minipigs received injections of a surrogate solution (dextran)
into the plica inguinalis by use of an instrumental set-up built for this purpose (Chapter 4).
To complete the work, filtration of different mAb formulations was investigated in a lab-scale set-up
(Chapter 5) as the second hydrodynamic process. Filtration forces were determined dependent on filter
material, protein concentration, and viscosity, and differences were linked to filter resistance, pore size
distribution, and formulation composition.
11
...
12
Chapter 1
Technical overview
– Characterization of commercial protein
therapeutics for subcutaneous and
intramuscular administration
Research Document Repository Hoffmann-La Roche, 2013
Technical Report
Authors:
Andrea Allmendinger
Stefan Fischer
Hanns-Christian Mahler
Edward Schwarb
Robert Mueller
The following study provides a technical overview of highly concentrated biotech therapeutics for
subcutaneous or intramuscular use currently approved by the European Medicines Agency. Ten different
commercial products were characterized in terms of formulation properties like osmolality, pH, turbidity,
color, viscosity, number of visible and sub-visible particles, level of soluble aggregates and fragments as
well as for forces required for simulated administration (glide force, removal of needle cover). A summary
of device characteristics (e.g. needle dimensions), patient Information for correct administration (e.g.
equilibration time, injection angle), and secondary packaging are provided. Additionally, requirements of
the European Pharmacopoeia for protein therapeutics for subcutaneous and intramuscular administra-
tion are outlined.
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1.1. INTRODUCTION
1.1 Introduction
In 2012, nine highly concentrated (>50 mg/mL) biotech therapeutics were approved by the EMA for
intramuscular (im) or subcutaneous (sc) injection. They have been launched as either liquid and/or
lyophilized formulation resulting in 12 different formulations on the market. [1] Stelara R©, Ilaris R©,
Prolia R©, Humira R©, Simponi R©, and Cimzia R© were approved as liquid formulations; Enbrel R©, Xolair R©,
and Synagis R© are available as liquid and lyophilized formulations. Five of these highly concentrated
biotech products were commercialized in 2009 and 2010 alone, which are Stelara R©, Ilaris R©, Prolia R©,
Simponi R©, and Cimzia R©, showing the rapid development of this expanding market. [2] A number of
criteria for biotech products are defined in the Pharmacopeias. The following enumeration lists the
applicable Monographs:
• Clarity and degree of opalescence of liquids (Ph. Eur. 2.2.1.) [3]
• Degree of coloration of liquids (Ph. Eur. 2.2.2.) [4]
• Osmolality (Ph. Eur. 2.2.35.) [5]
• Test for extractable volume of parenteral preparations (Ph. Eur. 2.9.17.) [6]
• Particulate contamination: sub-visible particles (Ph. Eur. 2.9.19.) [7]
• Particulate contamination: visible particles (Ph. Eur. 2.9.20.) [8]
• Monograph: Monoclonal antibodies for human use (Ph. Eur. 2031.) [9]
• Monograph: Parenteral preparations (Ph. Eur. 0520.) [10]
A number of routinely performed analytics for characterization of highly concentrated protein formu-
lations is not defined in the Pharmacopeia, including viscosity to name only one example. Thus, the
characterization of formulation as well as the investigation of device properties of currently marketed
high-concentration products is desirable in order to benchmark internal development programs.
The following study provides a technical overview of highly concentrated protein therapeutics currently
approved by the EMA (European Medicines Agency). Ten different products were characterized in terms
of osmolality, pH, turbidity, color, viscosity, number of visible and sub-visible particles, level of soluble
aggregates and fragments as well as for forces required for simulated administration (glide force, removal
of needle cover). A summary of device characteristics (e.g. needle dimensions), patient Information for
correct administration (e.g. equilibration time, injection angle), and secondary packaging are provided,
and requirements of the European Pharmacopoeia for protein therapeutics for subcutaneous and intra-
muscular administration are summarized.
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1.2 Product information
Ten highly concentrated protein therapeutics were investigated in this study, comprising concentrations
between 50 to 200 mg/mL. Table 1.1 summarizes the date of approval, manufacturer, indication, active
pharmaceutical ingredient, IgG subtype, target, route of administration, and formulation of the products.
Eight out of ten investigated formulations are currently (2012) approved for the European market. One
investigated product (Raptiva R©) was withdrawn after the start of this study, in 2008. The Roche product,
Actemra sc R©, was close to market launch.
As active ingredient, the investigated products contain therapeutic monoclonal antibodies of the isotype
IgG1κ (Simponi
R©, Humira R©, Actemra sc R©, Raptiva R©, Synagis R©, Xolair R©) or IgG2 (Prolia
R©). Enbrel R©
contains a fusion protein with a conjugated Fc-fragment, and Cimzia R© contains a pegylated Fab-fragment.
Solely five products are approved for rheumatoid arthritis (Cimzia R©, Enbrel R©, Simponi R©, Humira R©, and
Actemra sc R©). Prolia R© is approved for bone loss and osteoporosis, Synagis R© for respiratory-synctial-virus,
Raptiva R© for plaque psoriasis, and Xolair for persistent allergic asthma. The route of administration is
either im (Synagis R©) or sc injection (all other products).
Six products were obtained as liquid formulations (Prolia R©, Cimzia R©, Enbrel R©, Simponi R©, Humira R©,
and Actemra sc R©). These products were provided as prefilled syringes (PFS) and are shown in Picture
1. Picture 2 shows the liquid formulations which are also available as autoinjectors. These are Enbrel R©,
Simponi R©, and Humira R©. As lyophilisates, Enbrel R©, Raptiva R©, Synagis R©, and Xolair R© were obtained,
as shown in Picture 3 – 6
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1.3 Materials and Methods
1.3.1 Materials
Cimzia R© 200 mg (UCB GmbH, Brussels, BE) (lot: 35613, expiry date: 03.12., date of testing: 07.11.),
Prolia R© 60 mg (Amgen Europe B.V., Breda, NL) (lot: 1026050A, expiry date: 04.12., date of testing:
07.11.), Simponi R© 50 mg (Essex Pharma, Leiden, NL) (lot: 10L041AD01 and 10L041AL, expiry date:
11.11., date of testing: 07.11.), Humira R© 40 mg (Abbott Laboratories Ltd, Maidenhead, UK) (lot:
9611OXD07, expiry date: 11.12., date of testing: 07.11.) and Enbrel R© 50 (Wyeth Europe Ltd, Maiden-
head, UK) (lot: F20467, expiry date: 06.12., date of testing: 07.11.) were purchased as prefilled syringes.
Actemra sc R© 180 mg (prefilled syringe) was kindly provided by F. Hoffmann-La Roche Ltd (Basel, CH).
Enbrel MyClic R© prefilled pen 50 mg (Wyeth Europe Ltd, Maidenhead, UK) (lot: E12839, expiry date:
03.11.), Simponi Smartject R© 50 mg (Essex Pharma, Leiden, NL) (lot: 09D101.AF, expiry date: 05.10.)
and Humira R© 40 mg prefilled pen (Abbott Laboratories Ltd, Maidenhead, UK) (lot: 6005812, expiry
date: 07.11.) were obtained as autoinjector. Enbrel R© 50 mg (Wyeth Europe Ltd, Maidenhead, UK)
(expiry date: 06.09., date of testing: 03.08.), Raptiva R© 100 mg (Merck Serono Europe Ltd., Rome, IT)
(expiry date: 08.09., date of testing: 03.08.), Synagis R© 100 mg (Abbott Laboratories Ltd, Maidenhead,
UK) (expiry date: 09.09., date of testing: 03.08.) and Xolair R© 150 mg (Novartis Europharm Ltd., West
Sussex, UK) (expiry date: 07.10., date of testing: 03.08.) were purchased as lyophilisates. All samples
were kept at 2 to 8◦C until use and are referred to as CPTs (=commercial protein therapeutics) in the
following.
Information on manufacturer, indication, active pharmaceutical ingredient, IgG subtype, target, route of
administration, formulation, device characteristics, primary and secondary packaging, room equilibration
time, reconstitution time for lyophilisates, holding time and extractable volume were compiled from
the Summary of Product Characteristics (SPC) and the Patient Information leaflets (PIL). Dates of
approval were acquired from the European commissions website, referring to the European approval
numbers of the product. [1]
1.3.2 Methods
Visual inspection
Visible particles were detected by visual inspection using (1) a black-and-white panel as outlined in
Ph. Eur. 2.9.20. [12], (2) an Optima I 1351 lamp (Simplex PR Apparate, Berlin, DE), (3) a Seidenader
V 90-T instrument (Seidenader Maschinenbau GmbH, Markt Schwaben, DE), and (4) a VHX digital
microscope VH-S30K (Keyence, Urdorf, CH).
The Optima lamp was equipped with a twofold magnifying glass and two polarization filters. Light passed
from the back through the sample, originating from an opal glass lamp. The Seidenader instrument was
equipped with a magnifying glass, with the light passing through the bottom, the side, and top of the
sample. The samples were set in rotation by rollers, and particles were detected by the reflected light
due to the Tyndall effect. The digital microscope consisted of a 10-times magnifier and also allowed
hands-free inspection by a speed control unit AXU-D40-CX (Oriental Motor Europe GmbH, Stuttgart,
DE). The sample was illuminated from the side. As prefilled syringes could not be set in rotation under
the digital microscope, samples were transferred under laminar air flow into washed, particle-free 11 mm
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glass tubes (Hach Lange GmbH, Dsseldorf, DE). They were left at 5◦C prior to analysis until all visible
air bubbles were removed from the sample. As a negative control, 10 mL ampoules of Aqua ad iniectabilia
Fresenius (Fresenius Kabi AG, Stans, CH) were prepared in the same way.
The number of visible particles was classified into (1) free of particles (internal standard: 0 particles),
(2) practically free of particles (internal standard: 0 – ≤ 2 particles), (3) several/few particles (internal
standard: >2 – ≤ 7 particles), and (4) many particles (internal standard: >7 particles).
Turbidity (opalescence) and color
Sample preparation was performed by transferring the samples under laminar air flow into washed,
particle-free 11 mm glass tubes (Hach Lange GmbH, Dsseldorf, DE). They were left at 5◦C prior to
analysis until all visible air bubbles were removed from the sample.
Turbidity was measured as outlined in Ph. Eur. 2.2.1. [3] using a Hach 2100AN turbidimeter (Hach
Company, Loveland, Co) in the ratio mode. The results were reported in Formazin turbidity units
(FTU), as the instrument was calibrated against formazin reference suspensions. Results were classified
into five subclasses: clear (0 – 3 FTU), slightly opalescent (3 – 6 FTU), opalescent (6 – 18 FTU), strong
opalescent (18 – 30 FTU), and very strong opalescent (>30 FTU).
The color of the samples was measured with a Dr. Lange LICO 200 colorimeter (Hach Lange GmbH,
Rheineck, CH) with automatic selection of color scale.
Light obscuration
Quantification of sub-visible particles was performed under laminar air flow by light obscuration based
on the method described in Ph. Eur. 2.9.19. [13] The method was adapted to reduced sample volumes
using a HIAC/ROYCO 9703 Liquid Syringe Sampler 3000A with a HRLD-150 sensor. 1.2 mL of sample
were used for three measurements at a fill and ejection rate of 10 mL/min. From the second and the third
injection, a mean value was obtained using the PharmSpec v1.4 software (Skan AG, Allschwill, CH). The
amount of sub-visible particles was reported as cumulative counts/mL for particle sizes ≥ 2 µm, ≥ 5 µm,
≥ 10 µm, ≥ 25 µm, and ≥ 50 µm.
Digital fluid imaging
Sub-visible particles were characterized by high-speed digital fluid imaging using a Benchtop FlowCam R©
VII instrument (Fluid Imaging Technologies, Yarmouth, Me). The FlowCam R© was equipped with a
100 µm flow cell, a digital camera with a resolution of 1280 x 960 pixels, and an objective with 10-times
magnification. The instrument was placed under a laminar air flow bench. 0.8 mL of sample were analyzed
with a flow rate of 0.15 mL/min, taking 20 colored frames per second, which resulted in a maximal sample
efficiency of 30%. Prior to analysis, samples were prepared by emptying the prefilled syringe at a constant
velocity of 342 mm/min (0.5 mL/10 s) using a TA.XT2i Texture Analyzer (Stable Microsystems, Surrey,
UK). Samples were then pipetted into the FlowCam R© and analysis was started 2.5 min after excertion
of the syringe, thus standardizing the preparation procedure. Images were captured when sample flowed
through the flow cell, which was centered in the field of view. Each individual particle was extracted by
the VisualSpreadsheet V2.4.10 software (Fluid Imaging Technologies, Yarmouth, Me) and quantified as
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counts/mL. By visually inspection of the pictures, the particles were manually classified into silicone oil
droplets, air bubbles, amorphous particles including protein aggregates, and unidentified counts. They
were reported as relative counts/mL referring to the total particle count/mL.
Size exclusion high performance liquid chromatography (SE-HPLC)
SE-HPLC was performed using a TSK G3000 SWXL, 7.8 x 300 mm column (Tosoh Bioscience, Stuttgart,
DE) on an Alliance 2695 HPLC instrument (Waters Corporation, Baden-Daettwil, CH). The HPLC
system was equipped with a 2487 UV detector (Waters Corporation, Baden-Daettwil, CH). Detection
occured at a wavelength of 280 nm. The mobile phase consisted of 200 mM K2HPO4/KH2PO4 and
250 mM KCl (pH 7.0). The measurement was run with a flow rate of 0.5 mL/min at 25◦C and a loading
volume of 15 µL. Prior to injection, samples were diluted to 10 mg/mL with mobile phase and stored
at 5◦C in the auto sampler. Species were classified into monomer, low molecular weights (fragmentation
and degradation products; LMW) and high molecular weights (dimers and higher soluble oligomers;
HMW). The percentage of peak area relative to the total peak area was reported using the Empower 2
Chromatography Data System software (Waters Corporation, Baden-Daettwil, CH).
Osmolality and pH
The osmolality was measured by freezing point depression based on Ph. Eur. 2.2.35. [5] using a Gonotec
Osmomat 030 cryoscopic osmometer (Huslab GmbH, Ostermundingen, CH) and by vapor pressure eleva-
tion using a Wescor VP osmometer (Wescor, Logan, Ut). The pH value was determined potentiometrically
using a Methrom biotrode glass electrode that was connected to a Methrom 781 pH-meter (Metrohm
Schweiz AG, Zofingen, CH). The measurements were performed at room temperature.
Imaged capillary electrophoresis (iCE)
The isoelectric point was determined by use of isoelectric focusing performed on an iCE280-iEF-Analyzer
(Convergent Bioscience, Toronto, CA). It was connected to a Prince micro injector auto sampler. Mea-
surements were performed at 8◦C with a focusing period of 1 min at 1 V followed by 7 min at 3000 V using
a fluorocarbon-coated cartridge (d = 50 µm; Convergent Bioscience, Toronto, CAN). Prior to injection,
the samples were diluted to 0.07 mg/mL with water and then diluted 1:1 with the mobile phase. It con-
sisted of 1% methylcellulose (Convergent Bioscience, Toronto, CAN), two carrier ampholytes pH 3 – 10
and pH 8 – 10.5 (GE Healthcare, Uppsala, S), two pI marker pH 4.65 and pH 9.5 (Convergent Bioscience,
Toronto, CAN), and water. The electrodes were placed into a mixture of 0.1 M NaOH and 0.1% methyl-
cellulose (cathode) and 0.08 M H3PO4 in 0.1% methylcellulose (anode) (Convergent Bioscience, Toronto,
CAN). Detection occured at 280 nm by a UV CCD imaging camera (CCD = charge-coupled device sen-
sor). Determination of the main peak was performed using the ICE280CFR software 2.3. (Convergent
Bioscience, Toronto, CAN) and it was defined as the isoelectric point.
Viscosity measurement
Dynamic viscosity was measured at 5◦C, 10◦C, 15◦C, 20◦C, and 25◦C using a MCR 301 cone and plate
rheometer (Anton Paar AG Switzerland, Zofingen, CH) and the Rheoplus/32 V3.40 software (Anton
Paar AG Switzerland, Zofingen, CH). The rheometer was equipped with a measuring cone with an angle
of 5◦C and a diameter of 50 or 25 mm (Anton Paar AG Switzerland, Zofingen, CH). After one minute
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equilibration time at a shear rate of 10 s−1, the shear rate was increased from 100 up to 2000 s−1 during
one minute. The dynamic viscosity was then determined as an average value of six data points measured
at a shear rate of 2000 s−1 during 15 s. To obtain a complete shear rate profile, the shear rate was again
decreased from 2000 to 100 s−1 during one minute.
Force measurements
All force measurements were performed at 25◦C on a force testing instrument with a 500 N force sensor
(Zwick GmbHandCoKG, Ulm, DE). Data analysis was performed with the Test Xpert II V2.2 software
(Zwick GmbHandCoKG, Ulm, DE).
...Removing of needle cover of prefilled syringes
The needle cover (also known as RNS = rigid needle shield) was pulled off of the prefilled syringe at a
constant velocity of 3 mm/s and the maximal force was determined. 3 mm/s is thereby a reference speed
and does not represent user behavior.
...Injectability from a generic plastic syringe
To compare liquid and lyophilized formulations, a generic set-up was chosen to test the injection forces
of the products. The samples were transferred into a 1 mL BD PlastipakTM syringe (BD, Madrid, ES)
and a BD MicrolanceTM3 27 G needle ( 34
′′, Luer) (BD, Drogheda, IE) was attached. The needle diameter
was chosen based on the needle size of the commercial prefilled syringes for CPT 1 and CPT 3–6, which
is 27 G. The generic syringes were emptied at a constant velocity of 342 mm/min which corresponds to a
volumetric flow of 1 mL/10 s and the maximal force of the injection force was determined. A volumetric
flow of 1 mL/10 s was chosen representing a commonly accepted speed which is relevant for the end-user,
and which is also used for QC testing. For the product CPT 2, a Sterican R© 25 G 1′′ needle (B. Braun,
Melsungen, DE) was used as it was not possible to inject the product through a 27 G needle without
damage of the set-up.
...Injectability from the original primary container
The prefilled syringes were emptied at a constant injection speed of 342 mm/min and the maximal force
was determined from the injection force profile. The speed of 342 mm/min corresponds to a volumetric
flow of 0.5 mL/10 s for all prefilled syringes. This speed, which is smaller than the one used for the
generic set-up, was chosen to ensure that the forces from all prefilled syringes can be compared.
Needle dimensions and head space of prefilled syringes
External needle diameter, needle length, bevel of the needle and head space of prefilled syringes were
determined using a digimatic caliper CD-15CXR (Mitutoyo America Corporation, Chicago, Il) and a
Leica MZ 12 microscope (Leica Microsystems AG, Heerbrugg, CH).
Density and extractable volume
Prefilled syringes were weighed before and after expelling of the product (N = 3). The density was
measured at 20◦C by using a DMA38 density meter (Anton Paar AG Switzerland, Zofingen, CH) (N =
2). As outlined in Ph. Eur. 2.9.17., the extractable volume was calculated from the mass of the liquid
divided by the density. [14] For prefilled syringes with a nominal volume of less than 3 mL the European
Pharmacopoeia demands five containers to be tested. In this study we investigated only three.
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Reconstitution time
The reconstitution time of lyophilisates was measured with a Zyliss R© Switzerland digital timer (DKB
Household Switzerland AG, Zrich, CH) and was defined as the time between addition of liquid and
complete dissolution without shaking.
1.4 Result summary
Appearance of the product: Visible particles, turbidity, and color
Visible particles were analyzed using (1) a black-and-white panel as outlined in Ph. Eur. 2.9.20.
[12], (2) an Optima lamp, (3) a Seidenader instrument, and (4) a VHX digital microscope. Table 1.2
summarizes the visible particle count for the different methods. Except for CPT 3 PFS, all products were
characterized as ’free of particles’ when analyzed by the black-and-white panel or using the Optima lamp.
CPT 3 PFS showed in average two particles per container and was therefore classified as ’practically free
of particles’. For CPT 9 lyophilisate (L), detection of visible particles by visual inspection was difficult
due to the presence of air bubbles and foam formation at the surface of the liquid.
Referring to the European Pharmacopeia, the Monograph of monoclonal antibodies requires products
to contain no visible particles unless otherwise authorized/justified. [15] The Monograph of parenteral
preparations which applies for CPT 2 and CPT 3 requires the products to be only ’practically free of
particles’. [10]
In addition, the products were inspected visually using a Seidenader instrument and a digital microscope.
The literature describes the human eye as able to resolve objects slightly smaller than approximately
80µm. [16] With a magnifying lens, automated handling, inspector training, and interdependent with
the number and type of particles, the limit of detection can even extend to 25µm. [17] The Seidenader
instrument and the digital microscope are therefore two more sensitive inspection methods compared
to the black-and-white panel which is the required method by the European Pharmacopoeia. Using the
Seidenader instrument, visible particles were detected in CPT 3 PFS and CPT 5 PFS. These products
were therefore classified to contain ’many particles’.
Figure 1.1 shows the turbidity and the color of the investigated products. The color of the products
was almost colorless or slightly brownish. The European Pharmacopoeia used to require monoclonal
antibody formulations to be colorless or slightly yellow and to be clear or slightly opalescent. [10, 15] Up
to date, this criterion is defined specifically to the product.
The turbidity lay between 1.5 ±<0.1 FTU (CPT 2 PFS) and 17.2 ±0.8 FTU (CPT 5 PFS). The products
were therefore classified into clear (three products), slightly opalescent (two products), and opalescent
(five products). The turbidity depends on various factors including but not limited to formulation
components (buffer, ionic strength, excipients, and pH), temperature, type of antibody, and especially
to protein concentration. [18-20]
Sub-visible particles
Sub-visible particles were analyzed by light obscuration. Figure 1.2 shows the sub-visible particle counts
≥ 10µm and ≥ 25µm. For particles larger or equal to 10µm, the cumulative counts/mL lay between
7 ±7 counts/mL (CPT 8 L) and 1280 ±340 counts/mL (CPT 3 PFS). For particles larger or equal to
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Table 1.1: Summary of product information including date of approval, manufacturer, indication, active
pharmaceutical ingredient (API), IgG subtype, target, route of administration and formulation. (PFS =
prefilled syringe; AI = autoinjector; L = lyophilisate) * Raptiva was taken off the market in 2009 as ’the
benefits (. . . ) no longer outweigh(ed) its risks, because of safety concerns, including the occurrence of
progressive multifocal leukoencephalopathy’. [11]
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Product Black/white panel Optima Seidenader Digital
microscope
CPT 1 PFS Free of particles Free of particles Free of particles Free of particles
CPT 2 PFS Free of particles Free of particles Free of particles Free of particles
CPT 3 PFS Practically Practically Many particles Many particles
free of particles free of particles
CPT 4 PFS Free of particles Free of particles Free of particles Free of particles
CPT 5 PFS Free of particles Free of particles Many particles Many particles
CPT 6 PFS Free of particles Free of particles Free of particles Free of particles
CPT 7 L Not determined Not determined Free of particles Free of particles
CPT 8 L Not determined Not determined Free of particles Free of particles
CPT 9 L*
CPT 10 L Not determined Not determined Free of particles Free of particles
Table 1.2: Visible particle count analyzed by visual inspection using the black-and-white panel (Ph.
Eur. 2.9.20.), the Optima lamp, the Seidenader instrument, and the digital microscope. Measurements
were performed as triplicates. The number of visible particles were classified into (1) free of particles, (2)
practically free of particles, (3) several particles, and (4) many particles. (PFS = prefilled syringe; L =
lyophilisate, *difficult to determine due to foam formation and many air bubbles.)
25µm the cumulative counts/mL varied between 0 ±<1 counts/mL (CPT 8 L) and 65 ±19 counts/mL
(CPT 3 PFS). The sub-visible particle count of particle sizes ≥ 2µm, ≥ 5µm, and ≥ 50µm is reported
in Table 1.3. Referring to the European Pharmacopoeia, less than 6000 cumulative counts per container
is required for particles equal to or bigger than 10µm, and 600 cumulative counts/mL for particles equal
to or bigger than 25µm. [13] For all tested products, the sub-visible particle count was found far below
this threshold. Up to date (2012), there is no requirement by the European Pharmacopoeia concerning
smaller particle sizes.
For the liquid products, sub-visible particles were further characterized using digital fluid imaging. The
particles were classified into four subpopulations: These were silicone oil droplets, air bubbles, amorphous
particles including protein aggregates, and unidentified counts. Figure 1.3 shows the relative particle count
of each subclass for particle sizes ≥ 10µm and ≥ 25µm. Corresponding numbers are presented in Ta-
ble 1.10 in the appendix. Representative pictures of each product and subclass are displayed in Table
1.4. Amorphous particles, which may include protein aggregates and other particles, varied between 0.1
±0.1% (CPT 1 PFS) and 69.4 ±14.0% (CPT 3 PFS) for particles equal to/bigger than 10µm and be-
tween 0.1 ±0.2% (CPT 5 PFS) and 79.9 ±14.8% (CPT 3 PFS) for particles bigger than/equal to 25µm.
For silicone oil droplets the range was quantified as 13.9 ±1.1% (CPT 2 PFS) to 86.1 ±3.2% (CPT 5
PFS) (≥ 10µm) and 8.8 ±3.6% (CPT 2 PFS) to 99.7 ±0.5% (CPT 5 PFS) (≥ 25µm). Air bubbles were
found to vary between 2.3 ±1.0% (CPT 3 PFS) and 24.7 ±11.5% (CPT 2) (≥ 10µm) and between <0.1
±<0.1% (CPT 1 PFS) and 34.2 ±17.8% (CPT 2 PFS) (≥ 25µm). Only a small number of particles
could not be identified. For particles bigger than 10µm, this subclass varied between 0.1 ±0.1% (CPT 5
PFS) and 7.5 ±10.4% (CPT 6 PFS), and for particles equal to/bigger than 25µm between no counts (5
products) and 7.1 ±12.2% (CPT 6 PFS).
The European Pharmacopoeia stipulates a limit for the overall amount of sub-visible particles ≥ 10µm
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Figure 1.1: Turbidity and color of the investigated products. Measurements were performed as trip-
licates. The average and standard deviation of the mean are reported. (PFS = prefilled syringe; L =
lyophilisate)
and ≥ 25µm measured by light obscuration. However, in some cases it may be relevant to differentiate
between silicone oil droplets and air bubbles in contrast to amorphous particles including protein aggre-
gates given the regulatory concern on the latter being immunogenic. [21-24]
Quantification of the sub-visible particles/mL of each class was carried out with reference to the to-
tal sub-visible particle count/mL in %. However, it should be considered that the absolute amount of
sub-visible particles differs among the products. Furthermore, it should be taken into account that the
absolute counts of sub-visible particles measured by light obscuration cannot be directly compared to the
absolute count obtained by digital fluid imaging, as translucent and irregular shaped particles might be
missed by the light obscuration method.
Monomer content, soluble aggregates, and fragments
Monomer, soluble aggregates, and fragments were analyzed by size exclusion chromatography using a
generic method for all products. Species were classified into monomer, low molecular weights consisting
of fragmentation and degradation products, and high molecular weights comprising dimers and higher
soluble oligomers. Table 1.5 shows the monomer content, low molecular weights, and high molecular
weights for each product. The relative peak area of monomers as the active ingredient varied between
95.8 ±0.1 (CPT 7 L) and 99.8 ±<0.1% (CPT 4 PFS, CPT 8 L). Dimers and higher soluble oligomers
are present to a very low extent in all products (0.2 ±<0.1% for CPT 4 PFS, CPT 5 PFS, and CPT 8 L
to 2.3 ±<0.1% for CPT 3 PFS) and fragmentation and degradation product levels are even lower (<0.1
±0.1% for CPT 1 PFS, CPT 2 PFS, CPT 4 PFS, CPT 5 PFS, CPT 8 L and CPT 10 L to 2.6 ±0.1% for
CPT 7 L). Figure 1.4 shows the chromatogram of CPT 1 and CPT 3 as a representative example.
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Figure 1.2: Sub-visible particles ≥ 10µm and ≥ 25µm measured by light obscuration. Sub-visible par-
ticles are presented as cumulative counts/mL. Measurements were performed as triplicates. The average
and standard deviation of the mean are reported. The dotted line represents the threshold defined by the
European Pharmacopeia per container for particles ≥ 10µm (6000 counts) and ≥ 25µm (600 counts).
The data is also summarized in Table 1.3 including particle sizes ≥ 2µm, ≥ 5µm, and ≥ 50µm. (PFS =
prefilled syringe; L = lyophilisate)
pH, isoelectric point, and osmolality
The pH value and the isoelectric point of the investigated products are reported in Table 1.6. The
isoelectric point was determined by isoelectric focusing. The pH values lie between 4.7 ±<0.1 (CPT 2
PFS) and 7.4 ±0.1 (CPT 7 L). The isoelectric points varied between 5.2 ±<0.1 (CPT 3 PFS/L) and 9.2
±<0.1 (CPT 6 PFS). The isoelectric point of CPT 8 L, CPT 9 L, and CPT 10 L was not determined.
Based on these results, the difference between the isoelectric point and the pH value was calculated. The
biggest difference was found for CPT 2 PFS, with 3.6 units, and the smallest was found for CPT 3 PFS
with a formulation pH of only 1 unit away from the isoelectric point. The consideration of the difference
between the formulation pH and the isoelectric point of the active ingredient is essential as proteins may
aggregate close to the isoelectric point due to lack of repulsive charges. [25] Nevertheless, it is crucial to
find a compromise for the pH of the formulation to increase physical as well as chemical stability and
take into account physiological compatibility at the same time. Thereby, a formulation pH far below or
above isohydric conditions (pH 7.4) may lead to pain during injection or to damage of endothelial tissue.
[26-29] However, during intravenous injection, pain was only reported at pH values exceeding 10.5 (11)
and below a pH of 3 (4). For other extravascular routes such as intramuscular or subcutaneous injection,
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Product ≥ 2µm ≥ 5µm ≥ 10µm ≥ 25µm ≥ 50µm
CPT 1 PFS 6861 ±809 1495 ±339 195 ±92 0 ±1 0 ±<1
CPT 2 PFS 2439 ±361 500 ±24 139 ±23 0 ±1 0 ±<1
CPT 3 PFS 25128 ±1931 6329 ±1023 1280 ±340 65 ±19 3 ±1
CPT 4 PFS 18881 ±265 4460 ±220 550 ±73 1 ±1 0 ±<1
CPT 5 PFS 4478 ±486 1220 ±91 118 ±26 2 ±1 1 ±1
CPT 6 PFS 11535 ±1740 1442 ±137 152 ±56 2 ±4 0 ±<1
CPT 7 L 2091 ±1453 353 ±225 29 ±13 3 ±<1 0 ±1
CPT 8 L 664 ±191 59 ±12 7 ±7 0 ±<1 0 ±<1
CPT 9 L 13081 ±3035 1122 ±581 99 ±128 3 ±5 0 ±<1
CPT 10 L 4692 ±726 385 ±73 16 ±4 0 ±1 0 ±1
Table 1.3: Sub-visible particles ≥ 2µm, ≥ 5µm, ≥ 10µm, ≥ 25µm, and ≥ 50µm measured by light
obscuration. Sub-visible particles are presented as cumulative counts/mL. Measurements were performed
as triplicates. The average and standard deviation of the mean (sd) are reported. (PFS = prefilled syringe;
L = lyophilisate)
the range is even smaller with approximately a pH of 4 up to 9. Tolerance maxima are reached at a
pH of 2 and 13, respectively. [26, 27, 30] Even more important than the pH value itself is the buffer
capacity of the formulation. If the buffer capacity of the formulation is much higher than the one of the
human blood system (carbonate, phosphate, hemoglobin, and albumin buffer), the formulation cannot
be neutralized by the intrinsic buffer system. This may lead to disruption of the pH homoeostasis and
among others to damage of the endothelial tissue as outlined.
The osmolality was measured by freezing point depression and is summarized in Table 1.6. The
osmolality of the products was determined between 295 ±<0.1 (CPT 7 L) and 466 ±7.6 mOsm/kg
(CPT 9 L). However, cryoscopic artifacts may occur during freezing point depression measurements
due to high viscosity or suspended particles. [31, 32] For this reason, the osmolality of CPT 2 PFS
was determined additionally by vapor pressure elevation as it showed elevated viscosity of 102.3 ±0.7
mPas during viscosity characterization. The osmolality of CPT 2 PFS was found as 451 ±4.0 mOsm/kg
measured by freezing point depression and only 334 ±1.5 mOsm/kg by vapor pressure elevation. This
indicates that cryoscopic artifacts influence the result during measurement of freezing point depression
for the product CPT 2. Parentally administered pharmaceuticals are tried to be formulated close to
isotonic conditions corresponding to an osmolality of 295 mOsm/kg. Formulations below or above these
conditions may lead to pain during injection and even tissue damage may occur. However, pain was only
reported during intravenous injection if osmolality exceeded 3 Osm/kg. [26-29]
Dynamic viscosity
Dynamic viscosity of the products was measured by plate/cone rheometry at 5◦C, 10◦C, 15◦C, 20◦C,
and 25◦C and is reported in Table 1.7. The viscosity of CPT 7 L, CPT 8 L, and CPT 10 L was only
measured at 20◦C due to sample shortage. Dynamic viscosity of the products was found to lie between
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Table 1.4: Representative pictures of sub-visible particles of the products purchased as prefilled syringes
(PFS) measured by digital fluid imaging. The sub-visible particles were classified into silicone oil droplets,
air bubbles, unidentified particles, and amorphous particles (size range of examples 15 – 25µm).
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Figure 1.3: Characterization of sub-visible particles of the products purchased as prefilled syringes
measured by digital fluid imaging. Sub-visible particles are classified into 4 classes with either a particle
size of (A) ≥ 10µm or (B) ≥ 25µm: amorphous sub-visible particles including protein aggregates (black),
silicone oil droplets (green), air bubbles (white), and unidentified particles (blue). Quantification of the
sub-visible particles/mL of each class was carried out with reference to the total sub-visible particle
count/mL in %. Measurements were performed as triplicates and the average is reported. (PFS = prefilled
syringe)
1.6 ±<0.1 (CPT 5 PFS) and 10.8 ±0.2 mPas (CPT 6 PFS) measured at 20◦C. Two products showed
elevated viscosity with 102.3 ±0.7 mPas (CPT 2 PFS) and 86.4 ±4.1 mPas (CPT 10 L).
Table 1.7 shows that the viscosity is temperature dependent with increasing viscosity at lower tempera-
tures. This temperature dependence is of great importance as an increase in temperature and therefore
decrease in viscosity can be used to facilitate manufacturing of the product (filtering, pumping) if product
stability is warranted. [33] Furthermore, during storage of the product at 2 to 8◦C, the product has a
higher viscosity compared to its viscosity at room temperature. As injection forces are directly dependent
on viscosity, lower viscosities are desired to reduce injection forces and facilitate injection. This is one of
the reasons why the product should be equilibrated to the desired target temperature before administra-
tion according to the related instructions.
Figure 1.5 shows the dynamic viscosity as a function of shear rate between 100 and 2000 s−1 for CPT
10 L and CPT 3 PFS as representative example. CPT 3 PFS showed constant viscosity over the whole
shear rate range indicating Newtonian behavior. The other products exhibited this behavior, too. CPT
10 in the contrary showed reversible shear thinning when the shear rate was increased/decreased to/from
2000 s−1.
During drug administration, shear rates in the range of 100 000 – 200 000 s−1 depending on the inner di-
ameter of the needle may occur. [34, 35] If fluids exhibit non-Newtonian flow behavior at high shear rates,
this may lead to reduced forces during injection compared to solutions with Newtonian flow behavior.
However, further experiments have to be performed to confirm the rheological behavior of the products
at these shear rates which is subject of ongoing research.
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Product Monomer [%]±sd HMW [%]±sd LMW [%]±sd
CPT 1 PFS 99.4 ±<0.1 0.6 ±<0.1 <0.1±<0.1
CPT 2 PFS 98.3 ±0.2 1.7 ±0.2 <0.1±<0.1
CPT 3 PFS 96.4 ±0.1 2.3 ±<0.1 1.3 ±0.1
CPT 4 PFS 99.8 ±<0.1 0.2 ±<0.1 <0.1±<0.1
CPT 5 PFS 99.7 ±<0.1 0.2 ±<0.1 <0.1±<0.1
CPT 6 PFS 99.4 ±<0.1 0.6 ±<0.1 0.1 ±<0.1
CPT 7 L 95.8 ±0.1 1.6 ±<0.1 2.6 ±0.1
CPT 8 L 99.8 ±<0.1 0.2 ±<0.1 <0.1 ±<0.1
CPT 9 L 99.5 ±0.1 0.5 ±0.1 0.4 ±<0.1
CPT 10 L 99.6 ±0.1 0.4 ±<0.1 <0.1±<0.1
Table 1.5: Soluble species measured by SE-HPLC. They were classified as monomer, high molecular
weights (HMW) and low molecular weights (LMW). The percentage of peak area relative to the total
peak area is reported. Measurements were performed as triplicates. The average and standard deviation
of the mean are reported. (PFS = prefilled syringe; L = lyophilisate)
Injectability and removal of needle cover
Injectability of the products into air was tested with a generic device system to compare liquid formu-
lations as well as the lyophilisates. The injection force can be differentiated into the break loose force of
the plunger and the subsequent glide force. In our experiment, the maximal injection force at 25◦C was
determined and was found to correspond to the glide force for all products. The data are presented in
Table 1.8. The glide force at a volumetric flow of 1 mL/10 s lie between 3.1 ±0.1 N (CPT 1 PFS) and 21.9
±0.5 N (CPT 10 L). For CPT 2 PFS, the injection force through a 27 G needle could not be determined
without damage of the system due to its highly viscous content. By replacing the 27 G needle with a 25
G needle, which is the needle diameter used for the original PFS, the maximum force was reduced and
the glide force determined as 10.7 ±1.2 N.
To evaluate forces experienced by the patient during the application process, injection forces were ana-
lyzed by use of the original primary container as well as forces to remove the needle cover, also known as
rigid needle shield (RNS). The corresponding data are summarized in Table 1.8. The glide force varied
between 3.7 ±0.1 N (CPT 5 PFS) and 39.9 ±1.8 N (CPT 2 PFS) at a volumetric flow of 0.5 mL/10 s.
This flow, which is smaller than the one used for the generic set-up, was chosen to ensure that the forces
from all prefilled syringes could be compared including CPT 2 PFS. The constant test speed was chosen
for standardized injection although not entirely representing end-user behavior as patients are known to
make speed compensation based upon resistive force, capability, and own preference.
The maximal force to remove the needle cover was found between 5.4 ±1.2 N (CPT 4 PFS) and 15.8
±2.1 N (CPT 6 PFS). As an example, Figure 1.6 shows the injection force profile into air for CPT 3 PFS
as a function of distance (A) and the force profile of the removal of the needle cover for CPT 1 PFS (B).
In the injection force profile, the force was differentiated into the break loose and the glide force.
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Figure 1.4: Representative chromatogram of CPT 3 PFS (red) and CPT 1 PFS (green) measured by
SE-HPLC. Species were classified as monomer, high molecular weights (HMW) and low molecular weights
(LMW). (A) unzoomed (B) zoomed in. (PFS = prefilled syringe)
Figure 1.5: Dynamic viscosity as a function of shear rate at 20◦C. CPT 3 PFS shows Newtonian
behavior with a constant viscosity; CPT 10 L shows reversible shear thinning (Non-Newtonian behavior)
with increasing shear rate to 2000 s−1. (PFS = prefilled syringe; L = lyophilisate)
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Product pH ±sd Isoelectric Difference Osmolality
point ±sd between pH and [mOsm/kg]±sd
isoelectric point (Freezing point)
CPT 1 PFS 5.2 ±<0.1 8.1 ±0.1 2.9 311.3 ±1.5
CPT 2 PFS 4.7 ±<0.1 8.3 ±0.1 3.6 451.7 ±4.0
(Vapor pressure:
334.0 ±1.5 )
CPT 3 PFS 6.2 ±<0.1 5.2 ±<0.1 -1.0 311.7 ±0.6
CPT 4 PFS 5.6 ±<0.1 8.5 ±<0.1 2.9 295.0 ±<0.1
CPT 5 PFS 5.2 ±<0.1 8.3 ±0.1 3.1 307.0 ±1.0
CPT 6 PFS 6.1 ±<0.1 9.2 ±0.1 3.1 312.3 ±4.7
CPT 7 L 7.4 ±0.1 5.2 ±<0.1 -2.2 273.7 ±8.5
CPT 8 L 6.1 ±<0.1 - - 366.0 ±7.0
CPT 9 L 6.1 ±<0.1 - - 466.0 ±7.6
CPT 10 L 6.2 ±<0.1 - - 374.7 ±7.4
Table 1.6: pH, isoelectric point, difference between pH and isoelectric point, and osmolality of the
investigated products. Measurements were performed as triplicates. The average and standard deviation
of the mean are reported. (PFS = prefilled syringe; L = lyophilisate).
Device charaterization
Picture 1 to 6 shows the primary packaging of the liquid formulations provided as pre-filled syringes.
Cimzia PFS, Enbrel PFS, and Humira PFS show a special accessory attached to the prefilled syringe.
This accessory supports the index and the middle finger to facilitate injection. Simponi PFS and Prolia
PFS consist of the prefilled syringe and a safety device that covers the needle after injection. Cimzia
PFS shows additionally a special ring-shaped needle cover that simplifies preparation of the device which
facilitates injection for patients with rheumatoid arthritis (indication of Cimzia) with limited mobility.
[36]
Picture 2 shows the autoinjectors of Enbrel, Simponi, and Humira being even more appealing/convenient
to the patient compared to prefilled syringes. For autoinjectors, the injection process is initiated by a me-
chanical process driven by a strained spring. Interestingly, the activation button of Simponi Smartject R©
is located at the side of the autoinjector compared to the other two devices having the activation button
on the top. Therefore, the Smartject R© autoinjector uses the grip force for activation which is higher than
the force exerted solely by the thumb.
The injection forces are influenced by different parameters. These are besides the product viscosity the
inner diameter and the length of the needle, the inner diameter of the syringe, and the frictional forces oc-
curring at the contact area between stopper and syringe barrel. The frictional forces are thereby influenced
be the thickness and viscosity of the lubricant layer (silicon oil) and by the injection speed. [35] Table 1.9
summarizes the syringe and needle type/dimensions of the products. All liquid formulations are filled into
1 mL glass syringes with staked-in needle from different manufacturers (BD and Ompi). Five out of six
prefilled syringes are equipped with a 27 G 12 inch needle and only CPT 2 PFS with a 25 G
1
2 inch needle.
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Product 5◦C 0◦C 15◦C 20◦C 25◦C
CPT 1 PFS 3.0 ±0.1 2.8 ±<0.1 2.4 ±0.1 2.0 ±0.1 1.9 ±<0.1
CPT 2 PFS 213.2 ±1.4 161.0 ±2.6 128.9 ±1.8 102.3 ±0.7 91.8 ±<0.1
CPT 3 PFS 6.4 ±0.1 5.8 ±0.1 4.7 ±0.1 3.7 ±<0.1 3.6 ±0.1
CPT 4 PFS 5.1 ±0.3 4.4 ±0.1 3.8 ± < 0.1 3.0 ±<0.1 2.9 ±<0.1
CPT 5 PFS 3.0 ±<0.1 2.4 ±<0.1 2.0 ±<0.1 1.6 ±<0.1 1.6 ±<0.1
CPT 6 PFS 16.8 ±<0.1 13.8 ±0.2 12.0 ±0.7 10.8 ±0.2 9.6 ±<0.1
CPT 7 L - - - 5.4 ±0.4 -
CPT 8 L - - - 3.5 ±0.1 -
CPT 9 L 4.7 ±0.2 4.4 ±0.1 3.6 ±<0.1 3.5 ±0.1 2.9 ±<0.1
CPT 10 L - - - 86.4 ±4.1 -
Table 1.7: Dynamic viscosity of the investigated products (mPas) at a shear rate of 2000 s−1 at different
temperatures (5◦C, 10◦C, 15◦C, 20◦C, and 25◦C). Measurements were performed as triplicates. The
average and standard deviation of the mean are reported. (PFS = prefilled syringe; L = lyophilisate)
As already outlined, CPT 2 showed a high viscosity of 102.3 ±0.7 mPas measured at 20◦C. Therefore, it
was not feasible to inject the solution through a 27 G needle. With regard to needle dimensions, it was
not determined whether the needles had a normal or a thin wall. For the lyophilisates, a separate needle
was included only for CPT 3 and CPT 8. These were a 27 G and 25 G 12 inch needle, respectively. For
CPT 10 L there is an explicit recommendation on the packaging insert that a 25 G needle should be used
due to the high viscosity of the product.
Picture 7 shows the needle tips of the prefilled syringes investigated under the light microscope. The
needle tip of CPT 1 PFS, CPT 3 PFS, CPT 4 PFS, and CPT 5 PFS was characterized to show 5 bevels;
CPT 2 PFS and CPT 6 PFS are equipped with a needle of three bevels. The number of bevels may
directly influence the compliance of the patient as a higher number of bevels is considered to lead to less
pain during injection. [37]
A requirement by the European Pharmacopoeia is the test for extractable volume which was investi-
gated in this study for the prefilled syringes. The European Pharmacopoeia requires in the Monograph
for Extractable Volume 2.9.17. that the measured volume must be ’not less than the nominal volume’.
[14] Figure 1.7 shows the measured extractable volume in comparison to the volume as written on the
product. The measured extractable volume varied between 1% underfill (CPT 3 PFS and CPT 5 PFS)
up to 8% overfill (CPT 4 PFS). However, there is no statistical significant difference between measured
and labeled extractable volume for CPT 3 PFS and CPT 5 PFS (tested by student-t-test with α = 0.05
and 2 degrees of freedom). If underfill occurs, the question arises if the target dose can be provided to
the patient. An overfill on the other side might be a severe safety issue. However, this depends on the
safety data.
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Figure 1.6: (A) Injection force profile into air for CPT 3 PFS as a function of distance with differentiation
into break loose and glide force. (B) Force profile of the removal of the needle cover of CPT 1 PFS as a
function of distance. Measurements were performed and reported as triplicates.
Figure 1.7: Measured and nominal extractable volume for prefilled syringes (PFS). Measurements were
performed as triplicates and the average and standard deviation of the mean are reported. * = Statistical
significant difference between measured and nominal extractable volume tested by student-t-test (α=0.05;
2 degrees of freedom).
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Product Generic set-up: Original primary container: Force needed
Glide force Glide force to remove
±sd [N] ±sd [N] needle cover
(1 mL/10 s) (0.5 mL/10 s) ±sd [N]
CPT 1 PFS 3.1 ±0.1 11.0 ±6.1 8.1 ±0.4
CPT 2 PFS 27 G: - 39.9 ±1.8 10.8 ±0.5
25 G: 10.77 ±1.2
CPT 3 PFS 4.3 ±0.3 11.0 ±0.9 12.0 ±8.2
CPT 4 PFS 4.1 ±0.2 13.1 ±4.8 5.4 ±1.2
CPT 5 PFS 3.7 ±0.8 3.7 ±0.1 10.3 ±2.2
CPT 6 PFS 7.6 ±1.6 24.0 ±2.0 15.8 ±2.1
CPT 7 L 5.3 ±<0.1 - -
CPT 8 L 5.2 ±0.4 - -
CPT 9 L 3.8 ±0.6 - -
CPT 10 L 21.9 ±0.5 - -
Table 1.8: Glide force of injection into air from a generic device system and from the original primary
container and maximal force needed to remove the needle cover of the prefilled syringes. Measurements
were performed as triplicates. The average and standard deviation of the mean (sd) are reported. (PFS
= prefilled syringe; L = lyophilisate)
Information on the administration process
Information on correct preparation and handling of the product and device is compiled in the Summary
of Product Characteristics (SPC) and the Patient Information leaflets (PIL) to provide guidance for
safe and complete administration of the product. Important data are summarized in Table 1.9: Before
administration, autoinjectors must be equilibrated to room temperature between 15 and 30 minutes in
advance (see Table 1.9). For three out of five prefilled syringes, an equilibration time between 15 and
30 minutes is proposed in the packaging insert. For the remaining two products (CPT 1 PFS, CPT 5
PFS), there is no recommendation. For lyophilisates, a reconstitution time between 5 minutes (CPT 8
L) and >20 minutes (CPT 10 L) is recommended. In Figure 1.8, the measured reconstitution times were
compared to the recommended reconstitution times and were found to vary between 1:25 ±0:16 min:s
(CPT 9 L) and 15:25 ±3:37 min:s (CPT 10 L). The difference between measured and recommended
reconstitution time in general may account for product variability. As an example, the recommended
reconstitution time for CPT 9 was 20 minutes. Compared to the measured time of 1:25 ±0:16 min:s, the
recommended reconstitution time exceeded the measured one by more than 18 minutes.
After equilibration of the pre-filled syringes or autoinjector, correct handling of the device during the
administration process is crucial. This includes preparation of the autoninjector before administration
with either unlocking of the safety interlock (CPT 3 and CPT 4), or removal of an extra cap from the
activation button to avoid pre-activation (CPT 5).
Table 1.9 summarizes the recommended injection times for the prefilled syringes as recommended in the
packaging insert and the waiting time after activation for the autoinjectors: for CPT 5 PFS, the injection
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Table 1.9: Device characteristics and information on the administration process including syringe and
needle type/dimensions, head space of prefilled syringes (PFS) (N = 3), recommended (recom.) room
equilibration time for PFS and autoinjectors (AI), recom. injection time (PFS), recom. holding time after
activation (AI) and information on the safety of the device. For triplicates, the average and standard
deviation of the mean (sd) are reported. (nd = not determined)
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Figure 1.8: Measured and recommended reconstitution time for lyophilisates (L). Measurements were
performed as triplicates and average and standard deviation of the mean are reported.
Figure 1.9: Secondary packaging of marketed products obtained as prefilled syringes (PFS). (A) Prolia,
(B) Cimzia, (C) Simponi, (D) Enbrel, (E) Humira.
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time is recommended as 2 s and for CPT 2 PFS up to 10 s. For CPT 1 PFS and CPT 4 PFS, the
injection time is defined until activation of the needle shield, and for CPT 3 PFS it is not recommended
at all. For CPT 6 PFS, the data is not included in Table 1.9 as it is subject of ongoing discussion with
the health authorities. For the three investigated autoinjectors, the holding time after activation varies
between 3 and 15 s.
Two additional features of the autoinjector ensure the correct application of the product. These are an
audible signal (click) at the beginning of injection for CPT 3, CPT 4 and CPT 5 and a second click after
completed injection (CPT 3 and CPT 4). Additionally, a visual signal indicates the complete adminis-
tration of the product by a color change seen through the control window for all three autoinjectors.
The injection angle is recommended as 90◦C for all autoinjectors and 45◦C for the prefilled syringes
except of CPT 3 PFS (45–90◦C) and CPT 1 PFS (without any recommendation). The injection sites
for the sc administered products are the top of the thigh, the lower part of the abdomen, and the outer
areas of the upper arms (the latter solely for CPT 5 PFS and CPT 2 PFS). For the prefilled syringes,
injection into a skin fold is recommended whereas for the autoinjectors it is not required to inject into
a pinched skin fold (excluding CPT 5 PFS). For the lyophilisates, the manufacturers do not provide
injection time, angle, or give recommendation to inject into a skin fold. These products are typically
administered by a healthcare professional. Three out of five prefilled syringes exhibit a safety device
that covers the needle after injection (CPT 1 PFS, CPT 4 PFS, and CPT 6 PFS) for safe handling
and disposal of the syringes after administration. This is also a FDA requirement in the US. All of the
investigated autoinjectors cover the needle after administration, and CPT 4 AI even retracts the needle
after a completed injection (see Table 1.9).
Secondary packaging of prefilled syringes
Figure 1.9 shows the pictures of the secondary packaging for each product. The secondary packaging
of the prefilled syringes consisted either of a simple folding box (B,C) or the syringe was additionally
enclosed in a blister (A, D, E). It was not tested if water vapor can penetrate the blister. However, blister
- which are impermeable for water vapor - might protect the product additionally from environmental
changes such as a decrease in humidity or evaporation, and could prevent drying of the product.
1.5 Conclusion
This study provides an overview of commercial highly concentrated biotech products and summarizes
requirements defined by the European Pharmacopoeia. In total, ten commercial protein therapeutics
were characterized which are currently approved by the EMA.
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1.8 Appendix
Product Amorphous Silicone oil Air bubbles Unidentified
Particles droplets Particles
(A)
CPT 1 PFS 0.1 ±0.1 86.1 ±3.2 10.1 ±2.2 3.7 ±2.2
CPT 2 PFS 56.9 ±9.3 13.9 ±1.1 24.7 ±11.5 4.6 ±2.8
CPT 3 PFS 67.4 ±14.0 30.1 ±14.6 2.3 ±1.0 1.6 ±0.3
CPT 4 PFS 2.0 ±1.8 73.1 ±5.4 18.4 ±3.4 6.7 ±2.8
CPT 5 PFS 0.2 ±0.2 86.0 ±1.2 13.7 ±1.3 0.1 ±0.1
CPT 6 PFS 0.9 ±1.0 82.1 ±8.0 10.3 ±3.6 7.5 ±10.4
(B)
CPT 1 PFS 0.3 ±0.4 99.7 ±0.5 <0.1 ±<0.1 <0.1 ±<0.1
CPT 2 PFS 57.1 ±16.0 8.8 ±3.56 34.2 ±17.8 <0.1 ±<0.1
CPT 3 PFS 79.9 ±14.8 22.4 ±17.8 0.3 ±0.2 <0.1 ±<0.1
CPT 4 PFS 1.7 ±2.6 96.0 ±2.5 2.2 ±1.1 <0.1 ±<0.1
CPT 5 PFS 0.1 ±0.2 99.1 ±0.8 0.8 ±0.7 <0.1 ±<0.1
CPT 6 PFS 0.5 ±0.8 64.1 ±9.9 29.2 ±5.6 7.1 ±12.2
Table 1.10: Characterization of sub-visible particles of the products purchased as prefilled syringes
(PFS) measured by digital fluid imaging. Sub-visible particles were classified into four subclasses with
either a particle size of (A) ≥10 µm or (B) ≥25 µm: amorphous particles including protein aggregates,
silicone oil droplets, air bubbles and unidentified particles. Quantification of the sub-visible particles/mL
of each class was carried out with reference to the total sub-visible particle count/mL in %. Measurements
were performed as triplicates. The average and standard deviation of the mean (sd) are reported.
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Viscosity characterization of protein formulations is of utmost importance for the development of
subcutaneously administered formulations. However, viscosity determinations are time-consuming and
require large sample volumes in the range of hundreds of microliters to a few milliliters, depending
on the method used. In this article, an automated, high-throughput method is described to determine
dynamic viscosity of Newtonian fluids using standard capillary electrophoresis (CE) equipment. CE is an
analytical method routinely used for the separation and characterization of proteins. In our set-up, the
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capillary is filled with the test sample, and a constant pressure is applied. A small aliquot of riboflavin
is subsequently loaded into the capillary and used as a dye to monitor movement of protein samples.
Migration time of the riboflavin peak moving through the filled capillary is converted to the viscosity
by applying the Hagen-Poiseuille’s law. The instrument is operated without using an electrical field.
Repeatability, robustness, linearity, and reproducibility were demonstrated for different capillary lots and
instruments, as well as for different capillary lengths and diameters. Accuracy was verified by comparing
the viscosity data obtained by CE instrumentation with those obtained by plate/cone rheometry. The
suitability of the method for protein formulations was demonstrated, and limitations were discussed.
Typical viscosities in the range of 5 to 40 mPas were reliably measured with this method. Advantages
of the CE instrumentation-based method included short measurement times (1 – 15 min), small sample
volumes (few microliters) for a capillary with a diameter of 50 µm and a length of 20.5 cm as well as
potential to be suitable for high-throughput measurements.
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2.1 Introduction
Viscosity of protein formulations is a key challenge during formulation development of biologics, such
as monoclonal antibodies, for subcutaneous use. At high protein concentrations (>50 – 100 mg/mL),
antibodies form viscous solutions due to volume exclusion, protein-protein interactions, and macromolec-
ular crowding [1]. The viscosity increases exponentially with increasing protein concentration leading
to limitations during manufacture (e.g., filtration) and drug administration/injection [2-4]. Therefore,
it is essential to characterize viscosity during formulation and process development. However, only a
limited number of rheological methods suitable for viscosity characterization of protein formulations are
available. Preferably, viscosity determination should require small amounts of material (in the microliter
range) as only limited quantities tend to be available during formulation development. Moreover,
viscosity determination should cover a broad viscosity range (preferably between 1 and approximately
100 mPas) [5], and the method should be manageable in an automated, high-throughput mode. Current
methods are sample- and time-consuming and allow a throughput of only a few samples per hour.
Capillary viscosimeters have been used for over a century. The best-known and most frequently used
capillary viscosimeters are instruments based on the Ostwald-viscosimeter, the Ubbelohde-, and the
Canon-Fenske-viscosimeter. These viscometers consist of a glass capillary which is filled with the sample
fluid. The sample flows through the capillary driven by gravity, and the migration time for a defined
sample volume is measured. The migration time can be converted into the dynamic viscosity of the
sample by applying the Hagen-Poiseuille’s law. However, large sample volumes in the milliliter range
are needed for the commercially available instruments. In the recent decades, various efforts have been
made to optimize capillary viscometers for smaller sample consumption [6-12]. However, these methods
do not fulfill all requirements for protein preparations. In 1994, Bello et al. have described a method
to determine the viscosity using CE instrumentation which was taken as a basis for the present study
[13]. In this study, accurate results were only obtained for viscosities up to 3 mPas due to non-linearity
leading to revision of the basic method principle and further optimization for the present study.
It was the aim of the present study to establish an automated, high-throughput method to determine
the dynamic viscosity of Newtonian liquids using standard capillary electrophoresis (CE) equipment.
The method was tested for repeatability, robustness, linearity, accuracy, and reproducibility using
different capillary lots, instruments, capillary lengths, and diameters. Viscosity data obtained by the CE
instrument were compared to viscosity data obtained by plate/cone rheometry. Application of the CE
instrumentation-based method was demonstrated for different protein formulations, and the advantages
and limitations of the CE instrumentation-based method were explored in comparison to different
rheological methods (plate/cone rheometry, capillary viscosimeters, falling ball viscosimeter) used in
protein formulation development.
2.2 Materials and Methods
Materials
Aqueous sucrose and glycerol solutions
For calibration of the CE instrument, standard solutions with defined viscosities consisting of 0% to 60%
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(m/v) sucrose (Ferro Pfanstiehl, Waukegan, IL, USA) were prepared. The aqueous sucrose solutions
covered a viscosity range from 1 to 75 mPas. Viscosity was verified by plate/cone rheometry. For
accuracy testing, glycerol/water mixtures were produced by diluting glycerol (99.9%, Acros Organics,
Morris Planes, NJ, USA) with water for injection to achieve concentrations between 0% and 80% (m/m)
covering a viscosity range of 1 to 65 mPas.
Commercial protein therapeutics
Five commercial protein therapeutics (CPT) were used which were obtained as either prefilled syringes
for CPT 1 (IgG, 60 mg/mL), CPT 2 (IgG, 100 mg/mL), CPT 3 (IgG, 50 mg/mL), and CPT 4 (fusion
protein, 50 mg/mL), or as a lyophilisate for CPT 5 (IgG, 100 mg/mL). The products were stored at 2 –
8◦C and were used before expiry.
Monoclonal antibody formulation
The purified monoclonal antibody mAb1 (IgG1, pI = 8.5; Mr = ˜150 kDa; kD = 5.97 mL/g determined
according to Lehermayr et al. [14]) was provided by F. Hoffmann-La Roche Ltd (Basel, CH), and was
formulated in a 20 mM histidine-acetate buffer (Ajinomoto, Louvain-la-Neuve, Belgium) pH 5.5 at
concentrations of 20 to 150 mg/mL.
Methods
Viscosity measurement using a CE instrument
A ProteomeLab PA 800 CE instrument (Beckman Coulter Inc., Fullerton, CA, USA) equipped with a
photodiode array detector was used. The temperature for sample storage and the capillary was set to
20◦C. Bare fused-silica capillaries eCapTM with inner diameters of 50 µm and 75 µm were obtained
from Beckman Coulter Inc. (Brea, CA, USA). The instrument was operated without application of an
electrical field. After rinsing steps with water, 0.1 M HCl, and 0.1 M NaOH at 70 psi (equivalent to 4.8
x 105 Pa, 5 min), the capillary was filled with the test sample at high pressure (80 psi equivalent to 5.5
x 105 Pa) during 5 min. To load the dye consisting of a 0.02% (m/v) riboflavin 5’-phosphate sodium salt
hydrate solution (Sigma Aldrich, St. Louis, MO, USA), a pressure of 1 psi (6.9 x 103 Pa) was applied
for 15 s. Before and after loading, the inlet of the capillary was placed in a vial filled with water to
remove remaining dye/sample from the surface of the capillary inlet. After performing an autozero,
constant pressure was applied to the system (4 ±0.05 psi equivalent to 2.76 ±0.03 x 104 Pa) with the
sample vial positioned at the capillary entrance. The dye moved towards the detection window and was
detected at 445 nm. Migration time was recorded and related to viscosity. The sample volume for a
single measurement was dependent on the capillary properties. A volume of 100 µL in the storage vial
with a sample consumption of a few microliters was found to be sufficient for the tested viscosities and
set-ups.
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Plate/cone rheometry
For comparison, dynamic viscosity was measured on a MCR 301 plate and cone rheometer (Anton Paar
AG Switzerland, Zofingen, CH) at 20◦C (N = 2). The rheometer was equipped with a measuring cone
with an angle of 0.5◦ and a diameter of 25 mm (Anton Paar AG Switzerland, Zofingen, CH), and a
sample volume of 80 µL was used. After equilibration of the sample at a shear rate of 100 s−1 for 1 min,
the shear rate was increased from 100 s−1 to 2 000 s−1 over 1 min. Dynamic viscosity was determined
as the mean of 6 consecutive measurements at a shear rate of 2 000 s−1.
2.3 Theoretical Basis
Fig. 2.1 shows the instrumental set-up and measuring principle based on a capillary with an inner
diameter D and total length L. The distance between the capillary entrance and window for UV detection
corresponds to the capillary length l. At time zero (t0), the capillary is completely filled with the sample.
A small amount of dye (riboflavin) is injected into the capillary by applying constant pressure by the
CE apparatus (t1). The instrument is operated without use of an electrical field. The volume of the
dye is considered negligible compared to the sample volume in the capillary. When applying a constant
pressure ∆P, the dye migrates through the capillary. During this time period, the fluid is continuously
drawn up into the capillary which remains completely filled (t2). At t3, the dye is detected as a peak at
the capillary window. The migration time t is converted into dynamic viscosity as follows:
The flow of a fluid through a capillary driven by a constant pressure can be described by the Hagen-
Poiseuille’s law (Equation 2.1). Equation 2.1 describes the dynamic viscosity η [Pas] as a function of the
applied pressure ∆P [Pa], inner capillary diameter D [m], and time t [s] that the sample takes to flow
through the capillary with the length l [m].
η =
∆P ·D2
32 · l2 · t (2.1)
In our set-up, the migration time t was equal to the migration time of the dye, representing the time
needed for the sample to flow from the inlet of the capillary to the detection window. This distance is
equal to the capillary length l. Equation 2.1 shows that the dynamic viscosity η of the fluid is directly
proportional to the migration time t. To ensure consistent flow and applicability of the Hagen-Poiseuille’s
law, special attention has to be paid to the completely filled capillary during the measurement.
The Hagen-Poiseuille’s equation is valid for laminar flow in a tube defined by a Reynolds number Re2300
[15-17]. For all tested set-ups, the Reynolds number was equal to 4.5 or smaller and was calculated for
the worst case as follows: Re = l D ρη t = 4.5 with l = 30 cm, D = 50 µm, density ρ(20◦C) = 1 g/mL, ν(20◦C)
= 1 mPas, and migration time t = 33 s.
Fig. 2.2 shows the migration time of the dye as a function of dynamic viscosity determined by plate/cone
rheometry for different concentrations of sucrose solutions. With increasing viscosity, the migration time
increased linearly. Fig. 2.2 compares the measured and calculated migration times based on Equation 2.1.
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Figure 2.1: Instrumental set-up and measuring principle of viscosity measurement using CE instrumen-
tation. ∆P = applied pressure [Pa], L = total length of capillary [m], l = length of capillary from inlet
to detection window [m], D = inner capillary diameter [m], OD = optical density.
A shift to higher values was found for the measured values due to a lag phase at the beginning of the
measurement where the pressure is built up. Therefore, calibration of the system is required before start
of the measurement.
Fig. 2.3 (A) shows representative examples of riboflavin peaks with corresponding migration times for
different glycerol and sucrose solutions with viscosities between 1 and 25 mPas (D = 50 µm and l = 20.5
cm). The migration time increases with increasing viscosity. The symmetrical peaks are broadening and
their intensity decreases with increasing migration time due to Taylor dispersion [18, 19]. This leads to
an upper viscosity limit of the method. Exceeding this limit leads to detection of asymmetrical peaks.
Representative examples are shown in Fig. 2.3 (B) for viscosities of 41, 63, and 74 mPas (D = 50 µm, l =
20.5 cm). However, the viscosity limit changes depending on the capillary diameter and capillary length as
described below. The sample volume required for one measurement depends on the diameter and length
of the capillary. A volume of 100 µL (storage vial) with a sample consumption of a few microliters was
found to be sufficient for the tested viscosities and set-ups.
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Figure 2.2: Comparison of measured and calculated migration times based on Hagen-Poiseuille’s law.
Different concentrations of sucrose solutions were analyzed as a function of dynamic viscosity determined
by plate/cone rheometry (2 000 s−1; 20◦C). Mean values and standard deviations are reported.
2.4 Results and Discussion
The present study aimed to establish an automated method for high-throughput measurement of dynamic
viscosity using standard CE equipment. CE is routinely used for the separation and characterization of
macromolecules, such as monoclonal antibodies for example [20-24]. In 1994, Bello et al. have described
a method to determine the viscosity using CE instrumentation. They determined the migration time of a
boundary between the test liquid and a reference fluid, which was related to the dynamic viscosity of the
sample. However, accurate results were only obtained for viscosities up to 3 mPas due to non-linearity
[13]. This limitation was overcome in our set-up by the completely filled capillary thus complying with
Hagen-Poiseuille’s law. A small amount of dye (riboflavin) was injected into the capillary to monitor
the movement of protein samples. The CE instrumentation-based method was tested with respect to
linearity, robustness, accuracy, reproducibility, and limitations. The results are shown in Fig. 2.4 for
different (A) capillaries, (B) instruments, (C) capillary lengths, and (D) capillary inner diameters. After
calibration of the equipment set-up with the sucrose solutions (1 – 75 mPas, Fig. 2.4 left column),
dynamic viscosity data for different glycerol concentrations (1 – 65 mPas) were compared to viscosity
data obtained by plate/cone rheometry (Fig. 2.4, right column). The method was then applied to analyze
highly concentrated therapeutic protein formulations.
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Figure 2.3: Determination of viscosity limits. (A) Representative examples of dye peaks (445 nm) for
viscosities between 1 and 25 mPas at 20◦C. (B) Representative examples of dye peaks (445 nm) below
and above the viscosity limit of approximately 40 mPas at 20◦C (hatched area). Capillary: l = 20.5 cm,
D = 50 µm.
Linearity
In all set-ups used, migration time and dynamic viscosity for the different sucrose solutions (0 –
60% (m/v); 1 – 75 mPas) correlated in a linear fashion (Fig. 2.4). The correlation coefficients were
between R = 0.9993 and 0.9999. This confirms the direct proportionality of viscosity and migra-
tion time in accordance with Hagen-Poiseuille’s law. For further details see Supporting Information,
Table 2.2, which also includes a summary of corresponding slope, y-intercept, and residual sum of squares.
Repeatability (intra-assay precision) and robustness
Repeatability and robustness were tested by triplicate measurements of different sucrose solutions using
three different capillary lots (D = 50 µm, l = 20.5 cm, Fig. 2.4, A). Maximal relative standard deviations
of 0.5%, 0.7%, and 4.3% were found for the three different capillary lots and different sucrose solutions.
Details are provided in the Supporting Information, Table 2.2.
Accuracy and viscosity limit
Fig. 2.4 (A, right column) shows the correlation between CE and plate/cone viscosity data for the
glycerol solutions and the three different capillary lots. Good agreement between viscosity data obtained
from plate/cone rheometry and CE instrumentation was found for viscosities between 5 and 40 mPas.
The upper viscosity limit was defined at approximately 40 mPas due to the irregular shape of the
riboflavin peak. Accuracy was determined as 97.4% ±3.5%, 99.7% ±3.1%, and 104.4% ±6.9% for the
three tested capillaries (for details see Supporting Information, Table 2.2).
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Figure 2.4: Repeatability, linearity, accuracy, and limit of viscosity measurements at 20◦C for different
(A) capillaries, (B) instruments, (C) capillary lengths, and (D) capillary diameters. Measurements were
performed in triplicates (CE) or duplicates (plate/cone), and mean values and standard deviation are
reported. (D = inner capillary diameter, l = capillary length from inlet to detection window)
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Reproducibility
For reproducibility testing, measurements were performed on two different CE instruments in differ-
ent laboratories on different days. Sucrose calibration curves were almost identical for the two CE
instruments (Fig. 2.4, B, left column). Reproducibility was found as 3.1% maximal relative standard
deviation. Further details are summarized in the Supporting Information, Table 2.2, including minimal
relative standard deviation and maximal standard deviation. The viscosity range ensuring accurate
measurements was 5 to 40 mPas as shown also for the first set-up (Fig. 2.4, A). Accuracies of 97.4%
±3.5% (first instrument) and 97.9% ±3.6% (second instrument) were found when comparing the viscosity
data obtained by CE and plate/cone instrumentation.
Optimization: Capillary length
To optimize the method in terms of a shorter measuring time and larger viscosity range, two different
capillary lengths (Fig. 2.4, C) and capillary diameters (Fig. 2.4, D) were tested. Fig. 2.4 (C) shows the
results for two different capillary lengths, namely 20.5 cm and 30 cm (D = 50 µm). The shorter capillary
(20.5 cm) was the shortest length feasible and represented the smallest distance between inlet vial and
the detection window of the capillary. Comparison of the calibration curves showed that elongation of the
capillary led to a shift of the calibration curve to longer migration times, in accordance with Equation
2.1, indicating that the migration time t is directly proportional to the capillary length l. Comparison of
viscosity data of the glycerol solutions obtained by plate/cone rheometry and the CE instrument showed
good agreement in the range of 5 to 40 mPas (20.5 cm) and 5 – 60 mPas (30 cm), respectively. Although
migration time for the 30 cm capillary increased leading to peak broadening and lower intensity, the
upper viscosity limit increased to approximately 60 mPas. For the 30 cm capillary, an accuracy of 96.1%
±3.4% was found.
Optimization: Capillary diameter
Fig. 2.4 (D) shows the comparison of two different capillary diameters, i.e., 50 µm and 75 µm (l =
20.5 cm). The calibration curve for the 75 µm capillary shifted to shorter migration times. This is again
explained by the Hagen-Poiseuille’s equation (Equation 2.1) as the capillary diameter D is inversely
proportional to the migration time t. Comparison of viscosity data of the glycerol solutions obtained
by plate/cone rheometry and the CE instrumentation-based method revealed good agreement in the
viscosity range of 5 to 40 mPas for the 50 µm capillary. However, the upper viscosity limit decreased
to approximately 15 mPas when using the 75 µm capillary. An accuracy of 99.6% ±6.8% was found for
the 75 µm capillary. We conclude that a short capillary with a larger inner diameter should be chosen
for optimization/reduction of measuring time. However, expansion of the viscosity range requires longer
capillaries with a small inner diameter. Therefore, a capillary with a diameter of 50 µm and a length
of 20.5 cm represents a good compromise of short measuring time (1 – 15 min) and a viscosity range
relevant for protein formulations.
52
CHAPTER 2. HIGH-THROUGHPUT VISCOSITY MEASUREMENT USING CAPILLARY
ELECTROPHORESIS INSTRUMENTATION AND ITS APPLICATION TO PROTEIN
FORMULATIONS
Application of the CE instrumentation-based method to protein formulations
Application of the CE instrumentation-based method to protein formulations The method to measure
viscosity using a CE instrument (D = 50 µm, l = 20.5 cm) was applied to protein formulations.
Riboflavin, which has an absorption maximum at 445 nm, was chosen as a dye. At this wavelength,
the absorption of protein formulations was tested and is considered negligible. Therefore, the protein
formulations do not interfere with the detection of the dye during UV absorption measurement which
shows the specificity of the method.
Commercial protein therapeutics
Table 2.1 compares the viscosity data obtained by plate/cone rheometry with those obtained by the CE
instrumentation for the CPT 1 to 5 (20◦C). Viscosities were within the range of 5 to 40 mPas. Good
agreement was found between the two methods. Maximum deviation between the viscosity data obtained
by the two methods was found for CPT 5 (3.5 mPas) with a deviation of 0.7 mPas.
Product Protein Dynamic viscosity Dynamic viscosity
concentration (CE) [mPas] (plate/cone) [mPas]
[mg/mL]
CPT 1 60 2.1 ±0.1 2.0
CPT 2 100 3.2 ±0.1 3.0
CPT 3 50 1.6 ±0.1 1.6
CPT 4 50 3.9 ±0.1 3.7
CPT 5 100 4.2 ±0.1 3.5
Table 2.1: Viscosity of commercial protein therapeutics measured using a CE instrument and
by plate/cone viscosimeter (20◦C). Measurements were performed in triplicates (CE) or duplicates
(plate/cone). Mean values and standard deviations are reported. (CPT = commercial protein thera-
peutic)
Concentration series of a monoclonal antibody formulation
Viscosity of a monoclonal antibody formulation (mAb1) was determined by the CE instrumentation-based
method and plate/cone rheometry at different protein concentrations. Fig. 2.5 (A) shows representative
peaks of the dye riboflavin obtained by the CE instrument with the corresponding migration times
for the different protein concentrations. With increasing protein concentration and viscosity, migration
time increased as expected; the peaks were broadening, and the intensity decreased. As an example, a
migration time of 7.8 min was measured for the highest protein concentration of 151 mg/mL with a
viscosity of 13.1 mPas. Fig. 2.5 (B) shows the correlation between the viscosity data obtained by the CE
instrumentation-based method and plate/cone rheometry. Generally, the viscosity of the different protein
concentrations agreed well although a small systematic deviation was found for this example for higher
viscosities and higher migration times for the data obtained by the CE instrument. One explanation
might be an increase/change in capillary wall-protein interaction. We speculate that this increase might
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Figure 2.5: (A) Representative examples of riboflavin peaks during viscosity measurement (CE) for
different concentrations of mAb1 at 20◦C. Riboflavin was used as a dye. (B) Correlation of dynamic
viscosity determined by plate/cone rheometry (N = 2) and CE instrumentation (N = 3) as a function
of protein concentration of mAb1. Mean values and standard deviations are reported. The solid line
represents the line of identity.
have resulted from a change in protein-protein interaction (PPI) with increasing protein concentration. As
reported in the literature, attractive PPIs may become predominant with increasing protein concentration
for some antibodies [25-27]. Even a change from repulsive forces at low protein concentration to the
predominant attractive forces at high protein concentration was reported [27]. The interaction parameter
kD between two molecules can be determined by dynamic light scattering (DLS) experiments, as was
previously described by our group [14]. This was found to be positive (5.97 mL/g) for mAb1, indicating
repulsive interaction at low protein concentration. Therefore, the change from repulsive interaction at
low protein concentration to predominating attractive forces at higher protein concentration might be
responsible for the altered interaction between capillary wall and protein sample. As the deviation was
systematic, it can be overcome by calibration with the drug product or studies requiring only relative
viscosity determination. Another possibility is the use of differently coated capillaries, which is the subject
of ongoing research.
Viscosity characterization of protein formulations
Viscosity characterization is essential during protein formulation and process development. Methods
involving low material consumption (in the microliter range) and a high throughput at a viscosity
range between approximately 1 and 100 mPas are desirable. Compared to other rheological methods
used in protein formulation development, such as capillary viscosimeters (e.g., Micro-Ubbelohde-
Viscosimeter/ViscoClock, Schott instruments [2 – 4 mL]; Texture Analyzer milliliters] [28, 29]), falling
ball viscosimeters (e.g., AMVn Microviscosimeter, Anton Paar [150 – 300 µL]), or standard plate/cone
rheometer (e.g., MCR301, Anton Paar [80 µL]), the established CE instrumentation-based method
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requires a small sample volume in the storage vial (100 µL) and a sample consumption of only a few
microliters. The volume of 100 µL is a limitation of the instrument used and may be optimized by
vial design or optimization of the inlet position. The CE instrumentation is a closed system which is
temperature-controlled. The latter is a critical prerequisite for viscosity measurements. Most impor-
tantly, a unique feature of the CE instrumentation is that no time-consuming cleaning is needed due to
automation of the method and cleaning process. This constitutes an advantage over other viscosimeters
(including also e.g. the micro-viscosimeter m-Vroc RheoSense [10]). As a result, the CE instrumentation
allows for measurements in an automated manner with a throughput of approximately 30 samples per
load defined by the capacity of the sample tray of the instrument used.
A method that provides a significantly higher throughput is based on DLS. This method measures
the diffusion coefficient of polystyrene beads added to the sample solution. The diffusion coefficient is
related to the dynamic viscosity according to the Stokes-Einstein equation [29]. The system involves a
disposable 384-well plate (e.g., DynaoPro Plate Reader, Wyatt, 45 µL) and also requires no cleaning. A
drawback of the DLS method is that it requires the addition of the polystyrene beads leading to dilution
of the sample by 10% thus inducing a change of sample composition. This limits the method to the
non-exponential viscosity range at low protein concentrations or to studies requiring relative rather than
absolute determination of viscosity. Additionally, prior exclusion of the risk of interaction/aggregation of
protein with the polystyrene beads is mandatory.
A limitation of the CE instrumentation-based method may be the potential for clogging of the capillary
with particles. However, since filtration of protein samples (using sterilizing-grade filters) is routinely
performed during sample preparation, particles >0.2 µm are typically excluded. Furthermore, potential
interaction of the sample with the capillary wall at high protein concentration might require coated
capillaries. An alternative approach is the calibration of the capillary with the specific product itself or
the measurement of relative viscosity values.
Our method reliably determined the viscosity of Newtonian solutions between 5 and 40 mPas. Variation
in capillary length and capillary diameter led to different minimal and maximal viscosities. The subject
of ongoing research is the variation of the applied pressure which leads to measurements at differ-
ent/adjustable shear rates. Therefore, the method would also be applicable to non-Newtonian liquids
showing shear-rate-dependent behavior. This is of considerably importance as we have recently reported
that protein formulations can show shear-thinning behavior especially at high protein concentrations [28].
A complete list of methods to determine viscosity in protein formulations, including the established CE
instrumentation-based method, is provided in the Supporting Information, Table 2.3. The table details
the measuring principle, application, required volume, advantages, and limitations from an experimental
point of view, highlighting that each method has its advantages and limitations. Therefore, the viscosity
method most suited to the formulation in question has to be carefully chosen.
2.5 Conclusions
There is an increasing need for therapeutic protein formulations, which can be administered by the patient
him-/herself using subcutaneous injections. Injection volumes by this route are currently considered to
be limited to 1.5 mL. This necessitates the use of highly concentrated protein formulations (>50 mg/ml),
which show an elevated viscosity with increasing protein concentration. Viscosity needs to be monitored
since this parameter has an impact on e.g. syringeability and consequently patient convenience and
55
2.6. ACKNOWLEDGMENTS
compliance. The automated method presented in the present work allows for a high-throughput analysis
of protein formulations using small sample volumes. This will facilitate the development of parenteral
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Linearity (R, slope, y-intercept, RSS)
Parameter Repeatability and Reproducibility Accuracy
(MIN/MAX RSD)
(Sucrose solutions) (Glycerol solutions)
Capillary 1: Capillary 1:
·R = 0.9998 ·Accuracy = 97.4% ±3.5%
·Slope = 0.04 mPa
·y-intercept = -0.25 mPas Capillary 2:
·RSS = 0.05 mPas2 ·Accuracy = 99.7% ±3.1%
·MIN/MAX RSD = 0.3%0.7%
Capillary 3:
(A) Capillary 2: ·Accuracy = 104.4% ±6.9%
·R = 0.9993
Capillary 1 – 3 ·Slope = 0.04 mPa
D = 50 µm ·y-intercept = -0.23 mPas
l = 20.5 cm ·RSS = 0.06 mPas2
ϑ = 20◦C ·MIN/MAX RSD = 0.1%4.3%
Capillary 3:
·R = 0.9998
·Slope = 0.05 mPa
·y-intercept = -0.28 mPas
·RSS = 0.05 mPas2
·MIN/MAX RSD = 0.1%0.5%
Instrument 1: Instrument 1:
·R = 0.9998 ·Accuracy = 97.4% ±3.5%
·Slope = 0.04 mPa
(B) ·y-intercept = -0.25 mPas Instrument 2:
·RSS = 0.05 mPas2 ·Accuracy = 97.9% ±3.6%
Instrument 1 and 2
Instrument 2:
D = 50 µm ·R = 0.9999
l = 20.5 cm ·Slope = 0.04 mPa
ϑ = 20◦C ·y-intercept = -0.01 mPas
·RSS = 0.09 mPas2
Reproducibility:
·MIN/MAX RSD = 0.1%3.1%
20.5 cm 20.5 cm
·R = 0.9998 ·Accuracy = 97.4% ±3.5%
·Slope = 0.04 mPa
(C) ·y-intercept = -0.25 mPas 30 cm
·RSS = 0.05 mPas2 ·Accuracy = 96.1% ±3.4%
l = 20.5 and 30 cm
30 cm
D = 50 µm ·R = 0.9998
ϑ = 20◦C ·Slope = 0.02 mPa
·y-intercept = -0.10 mPas
·RSS = 0.05 mPas2
50 µm 50 µm
·R = 0.9998 ·Accuracy = 97.4% ±3.5%
·Slope = 0.04 mPa
(D) ·y-intercept = -0.25 mPas 75 µm
·RSS = 0.05 mPas2 ·Accuracy = 99.6% ±6.8%
D = 50 and 75 µm
75 µm
l = 20.5 cm ·R = 0.9994
ϑ = 20◦C ·Slope = 0.07 mPa
·y-intercept = 0.55 mPas
·RSS = 0.19 mPas2
Table 2.2: Supplementary data to Table 2. Linearity is represented by the correlation coefficient R, slope, y-intercept, and
residual sum of squares (RRS). Repeatability and reproducibility are represented by the minimal (MIN) and maximal (MAX)
relative standard deviations (RSD). Accuracy of viscosity measurements is shown for different (A) capillaries, (B) instruments,
(C) capillary lengths, and (D) capillary diameters. Abbreviations: D = inner capillary diameter, l = capillary length from inlet to
detection window, = temperature. Measurements were performed as triplicates and means and standard deviations are reported.
RSD values are indicated for either the characterization of individual capillaries (repeatability) or the comparison of instruments
(reproducibility).
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Table 2.3: Overview of commercially available methods for the determination of dynamic viscosity during protein for-
mulation development. The measuring principle, application, required volume, advantages, and limitations are summarized.
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Development of injection devices for subcutaneous drug administration requires a detailed understanding
of user capability and forces occurring during the drug administration process. Injection forces of
concentrated protein therapeutics are influenced by syringe properties (e.g., needle diameter) and
injection speed, and are driven by solution properties such as rheology. In the present study, it is
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demonstrated that concentrated protein therapeutics may show significantly reduced injection forces
because of shear-thinning (non-Newtonian) behavior. A mathematical model was thus established
to predict/correlate injection forces of Newtonian and non-Newtonian solutions with viscosity data
from plate/cone rheometry. The model was verified experimentally by glide-force measurements of
reference and surrogate solutions. Application of the suggested model was demonstrated for injection
force measurements of concentrated protein solutions to determine viscosity data at high shear rates
(3 x 104 – 1.6 x 105 s−1). By combining these data with viscosity data obtained by different viscosity
methods (plate/cone and capillary rheometry), a viscosity-shear rate profile of the protein solution
between 102 and 1.6 x 105 s−1 was obtained, which was mathematically described by the Carreau
model. Characterization of rheological properties allows to accurately predict injection forces for different
syringe-needle combinations as well as injection rates, thus supporting the development of injection
devices for combination products.
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3.1 Introduction
For subcutaneous drug administration, concentrated protein therapeutics are typically required to achieve
clinical doses in the magnitude of mg per kg bodyweight in a small volume (<1.5 mL) [1-3]. In contrast
to dried dosage forms, liquid formulations can easily be provided in pre-filled syringes or injection devices
and thus can offer convenience for the patient or healthcare provider. Advantages of these systems
in comparison with vials are the ease of administration, the potential for self-administration, and the
fewer handling steps by the patient or healthcare provider before administration [4, 5]. However, the
development of high-concentration protein formulations is accompanied by technical challenges such as
concentration-dependent protein degradation (e.g., aggregation or precipitation) and increased solution
viscosity [6-9]. The latter might lead to challenges during manufacturing (e.g., ultrafiltration/diafiltration,
sterile filtration, filling) and drug administration. [1-3]. More precisely, increased viscosity leads to higher
injection forces potentially affecting the suitability of pre-filled syringes for self-administration and the
energy required for injection – and thus design for autoinjectors. The first limitation is of particular
concern for patients with a functional impairment and dexterity limitation, such as patients suffering
from rheumatoid arthritis [10]. To ensure complete and safe administration of the product, it is therefore
important to characterize, control, and possibly minimize injection forces for pre-filled syringe products.
Moreover, the design of such devices must take the specific limitations of the targeted patient population
into account.
The estimation of injection forces based on rheological data was recently described. Burckbuchler et al.
have studied the injection behavior of a concentrated human polyclonal immunoglobulin solution by
applying the Hagen-Poiseuille’s law to calculate injection forces [11]. They used viscosity data from a
plate/cone viscosimeter assuming Newtonian behavior of the immunoglobulin solutions. Overcashier et
al. have added the contribution of the friction between stopper and syringe barrel to the hydrodynamic
force model [5]. The frictional forces are dependent on contact area between stopper and syringe barrel,
thickness and viscosity of the lubricant layer (silicone oil), and injection speed [12].
A previously published study reported that concentrated protein solutions can show shear-thinning
behavior leading to reduced viscosity with increasing shear rate [13]. In order to correctly predict
injection forces from viscosity data of concentrated protein solutions, a new model is needed which
considers both Newtonian and Non-Newtonian flow behavior. Rathore et al. extended the existing model
to predict injection forces for shear-thinning behavior [12, 13]. The authors used viscosity data at the
shear rate occuring at the needle wall, which is described by the Weissenberg-Rabinowitsch-Mooney
equation for non-Newtonian solutions [14-16].
The aim of the present project was to study the viscosity and injection behavior of highly concentrated
protein solutions in comparison with Newtonian liquids (glycerol/water solutions). To describe the
experimental data, an alternative mathematical model to predict injection forces of non-Newtonian
liquids was developed. This model allows to use/correlate viscosity data from plate/cone rheometry.
The model was verified by experimental data using plate/cone viscosity data of Carbopol gels as a
model substance for non-Newtonian behavior and glycerol/water mixtures as a surrogate solution for
Newtonian behavior.
In the following, the model was further discussed and compared to the approach based on the
Weissenberg-Rabinowitsch-Mooney equation using the shear rate at the needle wall. Application of
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the established model was demonstrated for the measured injection forces of a concentrated protein
formulation of a monoclonal antibody mAb1 to obtain viscosity data at high shear rates (3 x 104 –
1.6 x 105 s−1). These viscosity data were combined with rheological data obtained by plate/cone and
capillary rheometry resulting in a rheological profile of the protein solutions between 102 and 1.6 x 105 s−1.
3.2 Materials and Methods
Materials
Monoclonal antibodies
The purified monoclonal antibodies mAb1 (IgG1, pI 8.4; estimated Mw 145.5 kD) and mAb2 (IgG1, pI
9.4; estimated Mw 148 kD) were provided by F. Hoffmann-La Roche Ltd (Basel, Switzerland). mAb1
was formulated in a 5 mM L-histidine/L-histidine-HCl buffer (Ajinomoto, Louvain-la-Neuve, Belgium)
pH 6.0 with 0.06% polysorbate 20 (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) at protein
concentrations of 120, 170, 210, and 225 mg/mL, respectively.
Commercial protein therapeutics
The commercial protein therapeutics (CPT) CPT 1 (IgG2, 60 mg/mL), CPT 2 (IgG1, 100 mg/mL),
CPT 3 (fusion protein, 50 mg/mL), CPT 4 (IgG1, 180 mg/mL), CPT 5 (IgG1, 50 mg/mL), and CPT 10
(pegylated Fab fragment, 200 mg/mL) were purchased as pre-filled syringes. The commercial products
CPT 6 (IgG1, 100 mg/mL), CPT 7 (fusion protein, 50 mg/mL), CPT 8 (IgG1, 100 mg/mL), and CPT
9 (IgG1, 125 mg/mL) were purchased as lyophilisates. All therapeutics, except CPT 8, are currently
approved on the EU market. The commercial proteins contained different pharmaceutical excipients
which are listed as follows:
• Sodium acetate/phosphate/citrate/histidine/TRIS buffer
• Polysorbate 20 or 80
• Sorbitol, mannitol, glycine, sucrose
• Arginine-HCl, NaCl
• Methionine
The products were stored at 2 – 8◦C and were used before the expiry date.
Carbopol gels
Carbopol 981 NF (BF Goodrich, Dsseldorf, Germany) gels were manufactured in a melamine-coated
mortar with pistil by dissolution of the powder in water to achieve concentrations of 0.2% to 0.8%
(w/w). The gel-forming process was initiated by addition of 1 N sodium hydroxide solution (Merck,
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Darmstadt, Germany) until a pH of 7.0 ± 0.1 was reached. The gel was centrifuged at 2 000 rpm for 2
min to remove potential air bubbles.
Glycerol/water solutions
Glycerol/water solutions were produced by dilution of glycerol 99.5% (Acros Organics, Morris Planes,
NJ) with water for injection to concentrations between 45% and 80% (w/w).
Syringes and needles
For measuring the injection force of the commercial protein products, the samples were drawn up into
a 1 PlastipakTM syringe (BD, Madrid, Spain) and a MicrolanceTM 3 27 G 3/4” needle (BD, Drogheda,
Ireland) or a Sterican R© 25 G 1” needle (B. Braun, Melsungen, Germany) was attached. For all other
injection force measurements, 1 mL Hypak SCFTM Luer CCT pre-fillable glass syringes (BD, Le pont-
de-ClaixCedex, France) were used in combination with Sterican R© 27 G 1” needles (B. Braun, Melsungen,
Germany). Filling of the glass syringes and stopper setting were done manually, ensuring that there was
no air space between the stopper and contents of the syringe.
Frictional force [N] Syringe inner radius [mm]
1 mL Hypak SCFTM Luer CCT 1.62 (0.5 mL/10s)
pre-fillable glass syringe 3.60 (1 mL/10s) 4.3
6.73 (2 mL/10s)
1 mL PlastipakTM syringe 1.26 (1 mL/10s) 3.2
Needle inner diameter [µm] Needle length s [mm]
MicrolanceTM3 27 G 3/4” needle 237 20.9
Sterican R© 27 G 1” needle 217 27.1
Sterican R© 25 G 1” needle 276 27.1
Table 3.1: Needle and syringe dimensions.
Materials
Injection force measurements
Fig. 3.1 shows the experimental set-up of the injection force measurements. All force measurements
were performed on a material testing instrument with a 500 N force sensor (Zwick GmbH Co.KG,
Ulm, Germany). The samples were equilibrated to controlled room temperature for at least 1 h before
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Figure 3.1: Schematic description of experimental set-up of injection force measurements. A constant
speed ν was applied by the material testing instrument (1) which measured the counteracting force (F).
(2) plunger, (3) stopper, (4) syringe (Rsyringe = inner radius of syringe), (5) needle (Rneedle = inner
radius of needle, l = length of needle).
starting the measurement. The syringes were emptied by pushing down the plunger at a constant
speed corresponding to a volumetric flow of 0.05 mL, 0.1 mL, and 0.2 mL/s (protein formulations and
glycerol/water solutions) or 0.004 mL and 0.008 mL/s (Carbopol gels and glycerol/water solutions).
The counteracting force was measured as a function of distance and the maximal force of the plateau
as representative for glide force at the end of injection was read off from the force-travel distance graph
and defined as glide force as shown in Figure 3.9 in the supporting information. The temperature was
25 ±0.5◦C.
Table 3.1 summarizes the syringe and needle dimensions used for the calculations. Syringe inner diameter
and needle length were measured with a digimatic caliper CD-15CXR (Mitutoyo America Corporation,
Chicago, IL). The inner needle diameter and the frictional forces between stopper and syringe barrel
were determined for each syringe-needle set-up and injection speed as follows: Representative syringe
samples were either left empty or filled with either 45% or 60% (w/w) glycerol/water solution. At the
desired volumetric flow, the maximal force of the plateau was read off from the force-travel distance
graph representative for glide force at the end of injection (N = 3). The linear regression of the glide
force as a function of viscosity gives the needle diameter from the slope and the frictional force as the
intercept using the Hagen-Poiseuille’s law [5]. The frictional force represents the sliding friction as well
as the contribution from the compression of the plunger which is in equilibrium in the gliding force
plateau. The instrumental set-up does not account for static friction which is relevant at the beginning
of injection and has to be overcome by the break loose force.
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Viscosity measurements
Plate/cone rheometry
Dynamic viscosity was measured on a MCR 301 plate and cone rheometer (Anton Paar AG Switzerland,
Zofingen, Switzerland) between shear rates of 102 and maximal 4 x 104 s−1 at a fixed temperature
between 5 and 25◦C. The rheometer was equipped with a measuring cone with an angle of 0.5◦ and a
diameter of 25 mm (Anton Paar AG Switzerland, Zofingen, Switzerland) using 80 µL of sample.
Micro-capillary viscosimeter
Viscosity at an apparent shear rate between ∼103 to 105 s−1 was measured on a micro-capillary
rheometer m-VROCTM 3.0 (RheoSense Inc., San Ramon, CA) at 25◦C. The viscosimeter was equipped
with a RD05-100-116 flow cell with 50 µm cell depth. The samples were filled into a 10 mL Hamilton
syringe (not containing any air bubbles) which was mounted on the viscosimeter. Depending on the
viscosity of the sample and the shear rate, a few microliters up to a few milliliters of sample were
required for one measurement at a defined shear rate.
3.3 Results and Discussion
Injection forces of concentrated protein therapeutics
In a first study, the injection forces of different commercial protein solutions (CPT 1 – CPT 10) were
measured and correlated with viscosity data. A standardized set-up was chosen consisting of a 1 mL
plastic syringe with an attached 27 G 3/4” needle. For the product CPT 10, a 25 G 1” needle instead of
a 27 G 3/4” needle was used as the glide force exceeded the technical limit of the instrumental set-up
(>>50 N) at the chosen test speed. An injection rate of 1 mL/10s was chosen as this is an injection rate
which is appropriate for the end-user [10] and commonly used for testing. Fig. 3.2 shows the relationship
between glide force and dynamic viscosity (2 x 103 s−1) of the concentrated protein solutions. Glide
forces of the products were compared to glide forces calculated based on the modified Hagen-Poiseuille’s
equation [5] which served as a control for Newtonian flow behavior. All products (except CPT 9 and CPT
10) showed good agreement with the calculated values based on the Newtonian model. Consequently,
all tested products exhibited apparent Newtonian behavior except for CPT 9 and 10, which showed a
significant reduction in glide force in our set-up.
In a second set of experiments, injection force of the mAb1 formulation was determined for protein
concentrations between 120 mg/mL and 225 mg/mL. Fig. 3.3 (B) shows the glide force of mAb1 as
a function of dynamic viscosity (2 x 103 s−1) and protein concentration for three different injection
rates (0.5 mL/10s, 1 mL/10s, and 2 mL/10s). When comparing the measured glide forces to glide
forces calculated according to the Newtonian model [5], the concentrated mAb1 solutions showed a
progressively higher deviation from the Newtonian model with increasing protein concentration and
injection rate.
Data on protein integrity and particle load (visible, sub-visible) before and after injection are given for
a worst case scenario (injection rate 2 mL/10s) for mAb1 225 mg/mL in the supporting information
(Figure 3.11). The data show no difference before and after injection force experiments indicating that
the protein integrity of mAb1 is not affected by shear stress during injection.
In addition, injection forces of different concentrations of glycerol/water solutions were analyzed for the
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Figure 3.2: Glide force of commercial protein therapeutics determined at a volumetric flow of 1 mL/10s
(25◦C) as a function of dynamic viscosity (2 x 103 s−1, 25◦C). CPT 1 (x), CPT 2 (x), CPT 3 (x),
CPT 4 (x), CPT 5 (x), CPT 6 (x), CPT 7 (x), CPT 8 (x), CPT 9 (x), CPT 10 (x). Mean values and
standard deviation are reported (N = 3). The dashed lines represent glide forces calculated based on the
Hagen-Poiseuille’s model [5]. These served as a control for Newtonian flow behavior.
same viscosity range as that obtained for the mAb1 formulations. The glycerol/water solutions, used as
control samples for Newtonian behavior (Fig. 3.3, A), fitted well with the Newtonian model. Therefore,
it can be excluded that the observed deviation of the mAb1 formulations from the Newtonian model is
caused by sample heating during viscous flow through the needle.
In summary, mAb1, CPT 9, and CPT 10 showed lower injection forces than expected from the linear
viscosity-glide force correlation (Fig. 3.2 and Fig. 3.3, B). We speculate that this observation could be
shear-thinning behavior occurring at high shear rates. Therefore, we studied the viscosity profile as a
function of shear rate of the different protein solutions. Fig. 3.4 (A) shows the viscosity profile of mAb1
(225 mg/mL). Fig. 3.4 (B) and Fig. 3.4 (C) show the viscosity profiles of the commercial products
CPT 4 and CPT 10 which showed apparent Newtonian and non-Newtonian behavior during glide-force
measurements, respectively. As expected, constant viscosity regardless of the shear rate was found for
CPT 4 at all temperatures tested (5 – 25◦C), indicating Newtonian behavior of the CPT 4 formulation
at these shear rates. In contrast, rheological profiles of mAb1 and CPT 10 showed shear-rate dependent
viscosity revealing shear-thinning behavior with increasing shear rate and decreasing temperature.
Simulated injections using a 27 G needle (needle diameter 0.21 mm) with injection rates between
0.5 mL and 2.0 mL/10s produce needle shear rates between ∼3.3 x 104 and 1.3 x 105 s−1 (calculation
of shear rate based on Eq. 3.6 for a Newtonian formulation with a power law index of n = 1). This
exceeds the shear rates applied during standard plate/cone rheometry measurements by more than one
magnitude. Thus, a capillary rheometer was additionally used to obtain viscosity data at an apparent
shear rate between 104 and 105 – 106 s−1 depending on sample viscosity. Fig. 3.4 (D) shows the viscosity
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Figure 3.3: Glide forces as a function of viscosity determined at 2 x 103 s−1 (25◦C) compared to glide
forces calculated based on the Hagen-Poiseuille’s equation (solid lines). The glide forces were measured
at a volumetric flow of 0.5 mL/10s (triangle), 1 mL/10s (square), and 2 mL/10s (circle). Mean values and
standard deviation are reported (N = 3). (A) Different concentrations of glycerol/water solutions which
serve as a control for Newtonian flow behavior. (B) Different concentrations of mAb1. The dotted lines
are presented to guide the eye.
profile of mAb1 as a function of the apparent shear rate at 25◦C obtained by the capillary rheometer
for different protein concentrations (120 – 225 mg/mL). Shear-rate dependent viscosity was found with
shear-thinning behavior at increasing shear rate and increasing protein concentration. These findings are
consistent with the glide-force measurements where a deviation from Newtonian behavior was observed
with increasing injection rate (shear rate), as well as with increasing protein concentration.
Due to the direct evidence of shear-thinning behavior during rheological characterization studies by
plate/cone and capillary rheometry measurements, we conclude that concentrated protein therapeutics
can show reduced injection forces compared to Newtonian fluids due to shear-thinning behavior. There-
fore, the correct prediction of glide forces from rheological characterization data requires a sophisticated
mathematical model which considers the non-Newtonian behavior of the solution.
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Figure 3.4: Dynamic viscosity as a function of shear rate measured on a plate/cone rheometer at 5◦C
(black), 10◦C (dark grey), 20◦C (light grey), and 25◦C (white): (A) mAb1 at 225 mg/mL, (B) CPT
4, and (C) CPT 10. For mAb1, the dynamic viscosity was additionally measured on a micro-capillary
viscosimeter at 25◦C and is presented for 120, 170, 210, and 225 mg/mL as a function of shear rate (D).
The dashed and dotted lines are presented to guide the eye. The hatched region indicates that the sample
would be ejected from the measuring gap.
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Mathematical model to predict the glide force of non-Newtonian liquids from
plate/cone viscosity data
In the following section, a mathematical model was developed based on hydrodynamic equations [5, 11,
24-26] in order to correlate glide forces with viscosity data obtained by plate/cone rheometry. Injection
of a liquid through a needle results in a counteracting force which is described by the Hagen-Poiseuille’s
law (Eq. 3.1) [5, 11]. Entry losses and the conical symmetry of the syringe are considered to be negligible
(see Fig. 3.1).
F =
8∂V
∂t
· l ·R2syringe
R4needle
· η + F
friction;f( ∂V∂t )
(3.1)
Eq. 3.1 describes the glide force F [N] as a function of dynamic viscosity η [Pas], volumetric flow rate
δV /δt [m3/s], length of needle l [m], inner syringe radius Rsyringe [m], and inner needle radius Rneedle
[m]. Besides hydrodynamic forces, frictional forces between stopper and syringe barrel are considered
(Ffriction [N]) [5] and were determined as described in the Materials and Methods section. Eq. 3.1 is
valid for laminar flow in a tube which is defined by a Reynolds number Re << 2 300 [17-23]. For all
tested set-ups, the Reynolds number was equal or smaller than 1 312 and was calculated for the worst
case as follows:
Re =
2∂V
∂t
ρ
piRneedleη
= 1312 (3.2)
with ∂V
∂t
= 2ml10 s , density ρ25◦C = 1 g/mL, Rneedle(27G1′′) = 0.109mm, and η25◦C = 0.89mPa s..
The Hagen-Poiseuille’s law requires a defined viscosity for the correct prediction of the glide force.
However, the viscosity of a non-Newtonian solution is dependent on the shear rate.
The most commonly used equation to describe the viscosity-shear rate relationship of non-Newtonian
fluids is the Ostwald-de Waele equation (Eq. 3.2) [24, 25].
η = K · γ˙n−1 (3.3)
The viscosity is described as a product of the flow consistency index K [Pasn], and the shear rate γ˙
[s−1] to the power of n (power law index; dimensionless). Double log transformation of Eq. 3.2 results in
a linear viscosity-shear rate profile of the sample. From this profile, K and n were obtained as intercept
(log K) and slope (n-1), which is shown in Fig. 3.6 further below. n <1 represents shear thinning
behavior, n = 1 Newtonian behavior, and n >1 shear thickening behavior.
Based on the knowledge of the power law index n, the shear rate profile of non-Newtonian fluids in a
needle is derived in the following.
The velocity ν of a non-Newtonian fluid flowing through the needle can be expressed in terms of the
average velocity νaverage applied to the system during injection and the variable distance r between the
center of the needle (r = 0) and the needle wall (r = Rneedle) [26]:
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ν = νaverage ·
[
3n+ 1
n+ 1
] [
1−
[
r
Rneedle
]n+1
n
]
(3.4)
Differentiation of Eq. 3.3 gives the shear rate γ˙ dependent on the power law index n:
γ˙ = −
dν
dr
= νaverage ·
[
3n+ 1
n+ 1
]
R
−(n+1)
n
needle · r
1
n (3.5)
The velocity and shear rate profile according to Eq. 3.3 and 3.4 are shown in Fig. 3.5 (A) and (B),
respectively. Here, n = 1 represents a Newtonian fluid, and n = 0.4 and n = 0.8 represent two examples
of non-Newtonian liquids. For Newtonian fluids, the velocity profile is a parabola where the maximum
velocity is 2ν at the center of the tube (r = 0) and zero velocity at the tube wall (r = Rneedle = 1).
Maximum velocity of a non-Newtonian solution at the same volumetric flow is thereby smaller than
that of a Newtonian solution (see Fig. 3.5, A). The maximum shear rate occurs at the wall of the tube,
and zero shear rate occurs at the center of the pipe as presented in Fig. 3.5 (B) for a 27 G needle and
a volumetric flow of 1 mL/10s. However, the shear rate is not only a function of the distance r between
the center and needle wall, but it is also dependent on the rheological properties of the solution. The
shear rate of a Newtonian solution increases linearly from the center of the needle (γ˙ = 0) to the needle
wall. In contrast, the shear rate of a non-Newtonian solution is initially smaller than the shear rate of a
Newtonian solution, but subsequently exceeds the Newtonian shear rate as the needle wall is approached
(Fig. 3.5, B).
Because the viscosity of a non-Newtonian solution is shear-rate dependent, it changes continuously over
the needle cross-section in response to the varying shear rate and is therefore a function of the distance
r between the center and the needle wall. As the Hagen-Poiseuille’s law (Eq. 3.1) requires a defined
viscosity to predict the glide force during injection, we defined an average shear rate (here termed
effective shear rate) from the shear rate profile in the needle. The appropriate viscosity at the effective
shear rate was then obtained from the viscosity-shear rate profile of the sample.
The effective shear rate γ is derived by integration of Eq. 3.5 over the tube cross-section divided by the
circular area of the needle. The average velocity is expressed as a fraction of volumetric flow and needle
cross section νaverage =
∂V /∂t
piR2needle
:
γ =
1
piR2needle
R∫
0
2pir · γ˙ (r) dr =
2∂V
∂t
piR3needle
3n+ 1
2n+ 1
(3.6)
To eventually predict the glide force based on the viscosity-shear rate profile, Eq. 3.6 is inserted into Eq.
3.2 to calculate the viscosity at the effective shear rate. This viscosity is then used in the Hagen-Poiseuille
equation (Eq. 3.1) to predict the glide force. As a result, combination of Eq. 3.1, 3.2, and 3.5 gives:
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Figure 3.5: Velocity and shear rate profiles for a Newtonian (n = 1) and for two non-Newtonian fluids
(n = 0.4, n = 0.8). (A) Normalized velocity profile based on Eq. 3.3 (ν = velocity, νaverage = average
velocity, r = distance between needle center (r = 0) and needle wall (r = Rneedle)). (B) Shear rate profile
in a 27 G needle (Rneedle = 0.109 mm) for an injection rate of 1 mL/10s as a function of r based on Eq.
3.5.
F = 2n+2pi1−n · l ·R2syringe ·K ·
(
∂V
∂t
)n
·R
−(3n+1)
needle ·
(
3n+ 1
2n+ 1
)n−1
+ F
friction;f( ∂V∂t )
(3.7)
Eq. 3.7 describes the glide force of a non-Newtonian fluid based on the viscosity-shear rate profile from
plate/cone rheometry dependent on the syringe/needle dimensions, volumetric flow, and rheological
properties of the solution.
Dynamic viscosity is highly dependent on temperature. This relation is predictable and can be described
and quantified by the Arrhenius equation. Application to monoclonal antibodies was recently reported
by Zarraga et al. [40]. Control experiments of the present study confirm these findings and are shown in
the supporting information for mAb1 at protein concentration of 120, 170, 210, and 225 mg/mL (Figure
3.10).
In the current set-up, temperature dependence was not considered as injection force experiments as well
as viscosity measurements were performed at 25◦C. An increase in temperature during injection however
was excluded by control measurements (glycerol water solutions) as these measurements showed a linear
increase in injection forces with increasing injection rate and viscosity following the Hagen-Poiseuille’s
law. This will be discussed further below in context to Figure 3.3 (A, Injection forces of concentrated
protein therapeutics).
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Figure 3.6: Dynamic viscosity of Carbopol 981 gels as a function of shear rate at 25◦C: 0.2% (filled
circle), 0.4% (triangle), 0.6% (square), 0.8% (open circle). The linear fit was used to determine the
consistency index K and the power law index n from the intercept ans the slope (n−1), respectively.
Model verification using Carbopol gels as a surrogate for non-Newtonian
liquids
The suitability of Eq. 3.7 to predict the glide force of non-Newtonian liquids was experimentally verified
using Carbopol R© 981 NF gels. Carbopol was chosen as it is highly water soluble, and concentrations
can be achieved exhibiting shear thinning behavior at a shear rate below 104 s−1. This is the typical
shear-rate range of plate/cone viscosity measurements. Furthermore, such concentrations have a viscosity
in the range of concentrated protein products (1 – 100 mPas) at 104 s−1.
Fig. 3.6 shows the dynamic viscosity of the Carbopol gels at concentrations of 0.2%, 0.4%, 0.6%, and 0.8%
(w/w) as a function of the shear rate measured by plate/cone rheometry. The Carbopol preparations
showed shear-thinning behavior with a viscosity between 437 mPas (0.2% w/w) and 1 126 mPas (0.8%
w/w) at a shear rate of 102 s−1 and 41 mPas (0.2% w/w) and 99 mPas (0.8% w/w) at 104 s−1. From
these viscosity-shear rate profiles (double-logarithmized diagram), the consistency index K and the
power law index n were determined from the linear fit as intercept (K) and slope (n-1), respectively
(see Eq. 3.2). Table 3.2 summarizes the values of K and n for the different Carbopol concentrations.
The consistency index increased with the Carbopol concentration from 5.4 (0.2% w/w) to 15.3 n (0.8%
w/w). The power law index n remained constant with increasing Carbopol concentration (n = 0.46) as
indicated by the parallel viscosity profiles (Fig. 3.6).
To summarize, Eq. 3.2 (Ostwald-de Waele law) is suitable to fit the viscosity-shear rate profile of the
Carbopol gels. This allows to determine the consistency index K and the power law index n of the
solutions needed to predict the glide forces.
In a next step, the glide forces of the Carbopol samples were compared to predicted values using several
approaches (Fig. 3.7, B – Fig. 3.7, D). Glide forces were determined at two injection rates (0.04 and
0.08 mL/10s). The injection rates corresponded to shear rates in the range of those obtained during
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cCarbopol K n R
2
(w/w) [Pasn] [dimensionless] (Fig. 3.6)
0.2% 5.4 0.46 1.0
0.4% 9.5 0.46 0.999
0.6% 12.5 0.46 0.999
0.8% 15.4 0.46 0.999
Table 3.2: Rheological parameters of Carbopol gels (25◦C). (cCarbopol= Carbopol concentration; K =
consistency index; n = power law index)
plate/cone viscosity measurements (102 – 104 s−1). Two injection rates were chosen representing a shear
rate range where the slope of the viscosity profile changes only minor (few mPas) with an increase in
shear rate (0.008 mL/s), and an injection speed (0.004 mL/s) where viscosity is changing over few 100
mPas as shown in Figure 6 (continuous log-log plot).
Different concentrations of glycerol/water solutions served as a control for Newtonian flow behavior and
warming effects. Fig. 3.7 (A) compares the measured and the predicted glide forces of the glycerol/water
solutions by applying Eq. 3.1 (Hagen-Poiseuille’s law). The good agreement (minimum to maximum
deviation = <0.1 to 2.5 N) confirms the suitability of the Hagen-Poiseuille’s equation to predict glide
forces for Newtonian fluids. Furthermore, warming of the solutions was excluded at these shear rates as
the samples did not show any deviation from Newtonian behavior.
Fig. 3.7 (B) and (C) show the application of the Hagen-Poiseuille’s law (Eq. 3.1) to non-Newtonian
fluids. As pointed out, Eq. 3.1 requires a defined viscosity for the prediction of the glide force. In a first
attempt, viscosity of the Carbopol samples was read off the viscosity-shear rate profile (Fig. 3.6) at a
shear rate of 102 and 103 s−1 and was used for the prediction of the glide force by Eq. 3.1 . Fig. 3.7
(B) shows that the measured glide forces were overestimated by the model with increasing deviation at
higher glide forces and lower shear rate.
In Fig. 3.7 (C), the viscosity corresponding to the shear rate at the needle wall γ˙wall was used for the
prediction of the glide force by Eq. 3.1 (γ˙wall = 645 and 1.29 x 10
3 s−1 for 0.04 mL/10s and 0.08 mL/10s,
respectively). The shear rate at the wall is described by the Weissenberg-Rabinowitsch-Mooney equation
(Eq. 3.8) [14-16] and was recently used for description of injection forces/viscosity data [13] as discussed
in detail further below. This corresponds to Eq. 3.5 solved for the boundary condition r = Rneedle:
γ˙wall =
∂V
∂t
piR3needle
(3n+ 1)
n
(3.8)
Fig. 3.7 (C) shows that the measured glide forces for the different Carbopol concentrations were
underestimated by this model. The deviation increased with increasing glide force. This indicates that
the selected shear rates (102 and 103 s−1 in Fig. 3.7, B, and wall in Fig. 3.7, C) did not correspond
to the correct shear rate for prediction of glide forces based on viscosity data obtained by plate/cone
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Figure 3.7: Correlation between measured and predicted glide forces at two injection rates (0.04 and
0.08 mL/10s). (A) Different concentrations of glycerol/water solutions (Newtonian fluid) correlated with
glide force calculated according to Hagen-Poiseuille’s law (Eq. 3.1). (B) (D) Glide forces of Carbopol
gels (non-Newtonian fluids) correlated with glide forces calculated according to (B) Eq. 3.1 using the
measured viscosity at a shear rate of 102 and 103 s−1, (C) Eq. 3.1 using the measured viscosity at the
shear rate at the wall γ˙wall (Eq. 3.8), and (D) Eq. 3.7 which was based on the effective shear rate γ (Eq.
3.6). The mean values and standard deviation are reported (N = 3).
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rheometry.
In the previous section, the glide force of a non-Newtonian solution was described (Eq. 3.7) by definition
of the effective shear rate (Eq. 3.6). Thereby, the effective shear rate is smaller than the shear rate
at the wall by the factor of [1 + (2n)−1]. Fig. 3.7 (D) shows the application of Eq. 3.7 and compares
the measured and predicted glide forces of the Carbopol samples. The correlation plot indicates good
agreement between our model and the measured values of the glide force (range: 1.5 N - 35 N) with a
deviation ranging from 0.1 N to 2.4 N.
The advantage of our proposed model is that the derivation of the effective shear rate allows to predict
glide forces based on viscosity obtained by plate/cone rheometry. The shear rate during plate/cone
viscosity measurements remains constant across the gap of the conical measuring device [22]. Our data
confirmed that this shear rate corresponded to the effective shear rate during injection through a needle,
defined as an average shear rate over the needle cross section.
Another approach to predict glide forces involves the use of viscosity data obtained by a capillary
rheometer. This approach is less complex because the principle of operation is the same as for the
injection force measurements. A liquid flows through a tube in line with gravity or applied pressure, and
the shear rate in the tube is a function of distance between the center of the tube and the tube wall.
Therefore, the only prerequisite to predict glide forces based on viscosity data obtained by capillary
rheometry is to use the equivalent shear rates. This can be the shear rate at the wall (described by
the Weissenberg-Rabinowitsch-Mooney Equation), the apparent shear rate which is the shear rate at
the wall for a Newtonian solution, or the effective shear rate. The latter is another advantage of the
suggested model as viscosity data from different viscosity methods, such as plate/cone and capillary
rheometry, can be used to predict the glide force of a solution.
An advantage of capillary viscosimeters over typical plate/cone instrumentations is the possibility of
measuring at higher shear rates (>4 x 104 s−1). However, a limitation is the large sample volumes
required (in the milliliter range depending on sample viscosity) while measuring at only one specific shear
rate per experiment. An advantage of plate/cone rheometry is that it is an established method which is
widely used for characterization of protein viscosity [6, 11, 27, 28]. Moreover, viscosity measurements
require only small sample volumes (∼80 µL) and a large range of shear rates (1 s−1 up to maximal 4 x
104 s−1) can be measured in a single experiment.
In summary, the suggested model to predict glide forces of non-Newtonian solutions was experimentally
verified by Carbopol gels. Definition of the effective shear rate allows to predict glide forces and correlate
them to viscosity data obtained by plate/cone rheometry.
Rheological characterization of concentrated protein therapeutics using the
model
Generation of viscosity-shear rate profiles from force measurements was recently reported by Rathore
et al. The authors used force measurements which were performed on a mechanical testing system
(Instron 5564) by applying the Weissenberg-Rabinowitsch-Mooney equation (Eq. 3.8) [13]. Viscosity was
presented as a function of the apparent shear rate which is the shear rate at the wall for Newtonian
solutions.
The advantage of using force measurements is to obtain viscosity data at high shear rates (105 – 106 s−1).
However, application of our model (Eq. 3.7) offers the possibility to obtain viscosity data from glide
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force measurements/capillary viscosimeters which can be combined with viscosity data from plate/cone
rheometry to produce a single shear-rate profile. This approach allows to generate a broad viscosity
profile over several shear rate decades.
The approach of calculating viscosity data from glide force measurements was applied to the mAb1
solutions. Viscosity of the mAb1 samples was determined from the glide force measurements (Fig. 3.3,
B) by applying Eq. 3.1. To define the corresponding effective shear rate of the mAb1 solutions, the power
law index n of the different mAb1 concentrations was determined based on the following equation:
log η = (n− 1) · logC + (n− 1) · log
(
∂V
∂t
)
(3.9)
with C =
2K1−n (3n+ 1)
piR3needle (2n+ 1)
Eq. 3.9 is obtained by insertion of Eq. 3.6 into Eq. 3.3, followed by taking the logarithm. Fig. 3.8 (A)
shows the application of Eq. 3.9 to the experimental data of mAb1 and displays the viscosity (log η) as
a function of injection rate (log δV /δt). The power law indices were determined from the slope (n−1) of
the linear viscosity profiles (R2 = 0.972 – 0.999). For the mAb1 solutions, the power law index decreased
with increasing protein concentrations indicating an increase in shear thinning properties. For the lowest
protein concentration (120 mg/mL) tested, a power law index of 0.84 was found and n = 0.57 for the
225 mg/mL solution. Table 3.3 summarizes the power law indices and correlation coefficients for all
concentrations.
After determination of the power law indices, the effective shear rate was calculated by Eq. 3.6. This
allows the generation of the viscosity-shear rate profile for the mAb1 formulations shown in Fig. 3.8
(B). The dynamic viscosity is presented as a function of the effective shear rate with viscosity data from
the plate/cone rheometer (shear-rate range: <1 s−1 – 104 s−1), the capillary viscosimeter (shear-rate
range dependent on flow cell and viscosity: e.g. ∼2 x 103 – 1.5 x 105 s−1 for a 10 mPas sample), and
the glide force measurements (shear-rate range: variable due to injection rate and syringe-needle set-up;
presented: 3 x 104 – 1.6 x 105 s−1). The viscosity of the mAb1 solutions increased with increasing protein
concentration. The different protein solutions showed a Newtonian plateau at low shear rates which is
known from polymer chemistry as the zero shear-rate plateau [22, 27]. Between 8 x 103 and 1.6 x 105 s−1,
the mAb1 solutions showed shear-thinning behavior depending on the protein concentration. This is
known as the power law region of a sample. The 225 mg/mL solution, for example, shows a viscosity
of 46 mPas at the low shear-rate plateau followed by a decrease in viscosity to 21.5 mPas at ∼1.6 x
105 s−1. With lower protein concentrations, the beginning of the power law region is shifted to higher
shear rates. Additionally, the shear-thinning properties are diminishing with almost no shear-thinning
behavior at 120mg/mL.
The rheological profile of the mAb1 solutions resembles the rheological behavior of various polymers
such as polyacrylamide or xanthan gum solutions, for example [28-32]. This is characterized by a
Newtonian plateau with the zero shear rate viscosity η0 followed by the power law region and converging
to a secondary plateau (infinite shear rate viscosity η∞) [33], which was not yet reached for the mAb1
solutions at the measured shear rates. This three-step behavior can be described mathematically by the
Carreau-model (Eq. 3.10).
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Figure 3.8: mAb1 at 120 mg/mL (diamond), 170 mg/mL (square), 210 mg/mL (triangle), and 225
mg/mL (circle). (A) Dynamic viscosity (log η) obtained by force measurements as a function of injection
rate (log ∂V /∂t). The power law indices n were determined from the slope (n−1) of the linear fit (solid
line) based on Eq. 3.9 and are summarized with the corresponding correlation coefficients in Table 3. (B)
Viscosity profile of different concentrations of mAb1 as a function of the effective shear rate (25◦C). The
viscosity was measured using a plate/cone rheometer (grey, filled symbols), the capillary viscosimeter
mVROC (empty symbols), and glide force experiments (black symbols). The viscosity profile was mod-
eled by the Carreau model (solid line) based on Eq. 3.10 and the corresponding fitting parameters are
summarized in Table 3.3.
η = η∞ + (η0 − η∞) ·
(
1 + Γ2γ˙2
)n−1
2 (3.10)
The shear thinning region is defined by a modified power law term in Eq. 3.10 containing the factor(
1 + Γ2γ˙2
)n−1
2 similar to Eq. 3.3 (Ostwald-de Waele equation) which was used to generate the model.
However, the difference is that the Ostwald-de Waele equation breaks down in the region of the first
Newtonian plateau [33]. In contrast, the Carreau model includes the Newtonian plateau (η0) and extends
the power law by the factor +1 giving the sigmoidal shape to the shear thinning region. Γ [s] is a time
constant reflecting the critical shear rate γ˙crit = Γ
−1 marking the end of the zero shear-rate plateau and
the onset of the shear thinning region [33, 34].
Fitting of Eq. 3.10 to the viscosity-shear rate profiles of the different concentrations of mAb1 using the
software Origin 7.5 (OriginLab Corporation, MA) is shown in Fig. 3.8 (B). Here, η0 was defined as the
viscosity at 2 x 103 s−1, n was already determined as described above, and η∞ was set to the minimal
viscosity possible (1 mPas) corresponding to the viscosity of water. γ˙crit = Γ
−1 was set as a variable
parameter. Table 3.3 lists the values for the different protein concentrations. The quality of the fittings
is indicated by the correlation coefficients which were 0.939 and 0.984 for the protein concentrations
of 210 mg/mL and 225 mg/mL, respectively. The coefficients imply that the Carreau model allows to
describe the rheological behavior of the mAb1 solutions at high protein concentrations. For the lower
protein concentrations however, only a poor fit was obtained (R2 = 0.219 and 0.817 for 120 mg/mL
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cprotein η n Γ
−1 R2 R2
[mg/m] [mPas] [dimensionless] [103 s] (Fig. 3.8, A) (Fig. 3.8, B)
120 4.4 0.84 33 ±10 0.996 0.219
170 13.1 0.82 57 ±67 0.972 0.817
210 26.3 0.68 41 ±5 0.999 0.939
225 46.0 0.57 31 ±2 0.981 0.984
Table 3.3: Rheological parameters of mAb1 (25◦C). (cprotein = protein concentration; η = dynamic
viscosity at 2 x 103 s−1; n = power law index; Γ = time constant)
and 170 mg/mL, respectively). The assumption for application of the Carreau model is that the data
points for determination of the power law index n by Eq. 3.9 are in the exponentially decreasing power
law region. At lower protein concentration however, the power law region shifts to higher shear rates
limiting the shear-thinning region to a few data points for the tested shear-rate range (Fig. 3.8, B).
Additionally, for the 120 mg/mL for example, viscosity data obtained by the glide-force measurements
were in the shear-rate region close to the Newtonian plateau where the Ostwald-de Waele equation
breaks down. Therefore, the shear-thinning behavior cannot be accurately described by the Carreau
model at the tested shear-rate range for the protein concentrations of 120mg/mL (i.e., at lower protein
concentrations).
The Carreau model describes the rheological profile of a solution acting at high shear rates like a
Newtonian fluid with a viscosity of η∞ and like a Newtonian fluid with a viscosity of η0 at low shear rates
connected by a shear-thinning region. The origin of shear-thinning behavior characterized by a power
law index 1 can be manifold. In the literature, dissociation of aggregates or polymeric entanglements,
deformation or degradation, and alignmentorientation of three-dimensional structures to the flow field
are described for polymers [22]. For the Carbopol gels, it is suggested that the shear-thinning properties
originate from deformation of the three-dimensional network of the polymer [35]. Moreover, the power
law index was found to be constant with increasing Carbopol concentrations (Table 3.2). This indicates
that the shear-thinning properties are independent of polymer concentration suggesting a consistent
microstructure (e.g. similar physical entanglement) with increasing polymer concentrations.
For the mAb1 solutions in contrast, the power law index was found to decrease with increasing protein
concentrations. This indicates an increase in shear-thinning properties with increasing protein concentra-
tion implying an increase in the microstructural arrangements. The formation of these microstructural
arrangements/oligomeric networks/clusters was recently proposed for a monoclonal antibody solution
at high(er) protein concentrations [6, 9, 36-41]. The strength of the microstructure formed can increase
rapidly with concentration [40]. The disruption or deformation of these self-associating mAb networks
clusters (e.g. held together by weak non-covalent attractive forces) might be a possible explanation for
the shear-thinning behavior of concentrated mAb solutions. We use the phrase ’self-associating mAb
clusters’ in accordance with e.g. Zarraga et al. [40], Yadav et al. [36]. These mAb self-associations
responsible for increasing the viscosity are reversible, and unlikely to be physical entanglements or long
range elasticity such as observed in polymer systems (e.g. the mAb solutions have low G’/G”, data not
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shown). Instead, the mAb clusters are likely to be governed by colloidal interactions with electrostatic
and hydrophobic attractive wells that are rendered anisotropic by the mAb shape and heterogeneous
surface charge distribution [37-41]. The timescales for association and dissociation depend on the
intricate balance of colloidal, Brownian, and shear forces. Experiments of increasing and decreasing shear
rates show that the viscosity response to changes in shear rate occur in the order of seconds, implying
a relatively fast relaxation time (under negligible instrument inertia and comparing with Newtonian
viscosity controls). The substantial reduction in viscosity at shear rates of around 1 x 103 s−1 or higher
also points to a very fast relaxation time. This suggests that the mAb clusters are unable to form to full
extent due to the competing fast timescale associated with shearing motion.
Referring to the rheological profile, this implies that at low shear rates, the self-associating networks
are not influenced by the shear stress showing a Newtonian plateau. With increasing shear rate,
dissociation and/or alignment of the clusters may occur which manifests in the shear-thinning region and
eventually in the second Newtonian plateau with an optimally oriented microstructure or deformation
of the clusters. This has been observed through the anisotropic normal stresses measured in a related
study [40]. A detailed understanding of the relationship between shear-thinning behavior of a mAb
formulation indicated by the power law index and the occurrence of mAb clustering with increasing
protein concentration is subject of ongoing research.
3.4 Conclusion
Determination of injection forces of several highly concentrated protein formulations revealed a significant
reduction in injection forces compared to Newtonian fluids due to shear-thinning behavior. In order
to correctly predict injection forces from rheological data, different mathematical models considering
Newtonian and non-Newtonian flow behavior were compared and the assumptions, advantages, and
limitations were discussed.
The suggested model was used to determine viscosity data at high shear rates (3 x 104 to 1.6 x 105 s−1)
from injection force measurements of concentrated protein solutions. These data could be directly
combined to viscosity data from rotational plate/cone and capillary rheometry. The rheological profile
with a shear rate between 102 and 1.6 x 105 s−1 was described mathematically by the Carreau model.
Knowledge of the rheological characterization data allows to accurately predict injection forces for
different syringe-needle combinations as well as a large range of injection rates. The added value is that
by use of this model viscosity data from different measuring systems can be combined meaning that we
can now characterize viscosity at a much higher shear rate than what can be measured with commercial
available instruments up to date. This is highly relevant for the design of devices for combination
products (e.g. autoinjectors or injection pumps) to assess the limits and robustness during evaluation,
planning and design phases of development. Moreover, consideration of shear-thinning behavior may
extend the viscosity/concentration limit due to consequent reduction of injection forces while maintaining
the overall user requirements.
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3.7 Supporting information
The supporting information contains one Table 3.4 and three Figures 3.9, 3.10, and 3.11.
1. Figure 3.9 shows a detailed approach of data analysis of injection force measurements.
2. Figure 3.10 shows the temperature dependence of different protein concentrations of mAb1
described by the Arrhenius equation.
3. Table 3.4 and Figure 3.11 display data on protein integrity before and after injection for mAb1 at
a worst case injection rate (2 mL/10s).
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Figure 3.9: Representative injection force profiles and data analysis of injection force experiments. For
determination of the glide force, the plateau of the force profile was analyzed and the maximum of this
plateau was taken as representative for glide force at the end of injection. Examples are shown for a 60%
aqueous glycerol solution (2 mL/10s) and for a 150 mg/mL mAb1 formulation (1 mL/10s).
Figure 3.10: Arrhenius plot for mAb1 at 120, 170, 210, and 225 mg/mL. Dynamic viscosity was measured
as triplicates and the average is reported. (T = absolute temperature)
Data analysis of injection force profiles
For data analysis of injection force profiles, the maximal force of the plateau was read off from the force-
travel distance graph as representative for glide force at the end of injection as shown in Figure 3.9.
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Figure 3.11: Sub-visible particle characterization by micro-flow imaging of mAb1 before and after injec-
tion. Silicon oil droplets were identified as described by Koulov et al. [44],based on reference measurements
of pure silicon oil. Measurements were performed for a worst case scenario (injection rate 2 mL/10s) as
triplicates.
Temperature dependence of viscosity
The temperature dependence of viscosity can be described by the Arrhenius equation/plot [40]. Figure
3.10 shows that the Arrhenius equation is applicable to the mAb1 formulations indicated by a linear
profile with R2 = 0.995 – 0.997.
Protein integrity of mAb1 (225 mg/mL) before and after injection
Data on protein integrity measured by HP-SEC [42] and particle load (visible particles as described by
Kiese et al. [42] and sub-visible particles measured by light obscuration [42] and by micro-flow imaging
[43]) before and after injection were determined for a worst case scenario (injection rate 2 mL/10s) for
mAb1 at 225 mg/mL. The data are summarized in Table 3.4 and Figure 3.11. The measurements were
performed as triplicates and average and standard deviation are reported.
The data show no difference before and after injection force experiments for the visible particle and the
protein aggregate measurements. For the sub-visible particles, particle load increased after injection as
measured by light obscuration. However, micro-flow imaging measurements showed by differentiation of
the reported sub-visible particles between silicon oil droplets and others as reported previously [44], that
this increase is due to silicon oil droplets coming from the syringe wall during exertion of the syringe.
...
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Before injection After injection
Visible particles Free of particles Free of particles
≥2 µm 34 1402 ±696
Sub-visible particles ≥5 µm 11 682 ±303
(Light obscuration) ≥10 µm 4 359 ±168
[cumulative counts per mL] ≥25 µm 1 11 ±2
≥50 µm 0 1 ±1
Monomer 97.7 97.7 ±0.0
SEC High molecular weight species 1.3 1.3 ±0.0
Low molecular weight species 1.0 1.0 ±0.0
Table 3.4: Visible particles, sub-visible particle counts measured by light obscuration and characteri-
zation by micro-flow imaging, monomer content, and high and low molecular weight species (HP-SEC)
before and after injection. Measurements were performed for a worst case scenario (injection rate 2
mL/10s) for mAb1 at 225 mg/mL as triplicates. Average and standard deviation are reported.Needle and
syringe dimensions.
...
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Purpose:
Injection forces of parenterals are well understood and were intensively characterized in the past in
vitro. However, limited information is available about the in vivo situation and how in vitro testing is
actually representative of in vivo situations. Thus, the scope of the present study was to investigate the
contribution of the backpressure of the subcutaneous (sc) tissue layer to injection forces during in vivo
injection.
Methods:
Go¨ttingen minipigs were chosen based on the sc tissue of these animals best resembling humans compared
to other animal models. 10 Go¨ttingen minipigs received injections of isotonic dextran solutions (1 –
100 mPas) into the plica inguinalis using different injection rates and volumes (0.025 – 0.2 mL/s and 2.5
vs. 4.5 mL). The force related to sc backpressure was determined by use of an instrumental set-up built
for this purpose and defined as the difference in injection force between in vitro and in vivo measurement
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corrected by a temperature factor.
Results:
The contribution of the sc backpressure to injection forces was found to increase linearly with viscosity
and injection rate in the range of 0.6 – 1.0 N (1 mPas) and 1.8 – 4.7 N (20 mPas) for an injection rate
of 0.025 mL/s and 0.2 mL/s, and 6.7 N for 100 mPas at 0.025 mL/s. Variability increased with viscosity
and injection rate resulting in a minimum and maximum contribution of backpressure of 2.0 to 12.9 N
for 20 mPas at the highest injection speed tested. No difference was found between the tested injection
volumes of 2.5 and 4.5 mL for the conditions tested. Macroscopic evaluation of the injection sites showed
well-localized injection sites in the sc tissue layer. In this study, the contribution of the sc backpressure
to injection forces was differentiated from the contribution of the injection device as well as from a local
temperature effect leading to warming of the (equilibrated) sample in the needle and therefore smaller
injection forces than expected.
Conclusions:
The quantitative amount of sc tissue backpressure is significant and ranged in average from 0.6 to 4.7
N (1 – 20 mPas, 0.025 – 0.2 mL/s) with a maximum value of 12.9 N (20 mPas, 0.2 mL/s). Besides
the contribution of the tissue, local warming of the sample in the needle during injection has to be
considered when estimating injection forces representative for the in vivo situation.
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4.1 Introduction
Subcutaneous (sc) drug administration of parenterals is a convenient way for easier drug application
compared to the intravenous (iv) route of injection [1-7]. This offers the possibility of home-treatment
by the patient him-/herself or treating healthcare professional, especially if combination products like
pre-filled syringes, autoinjectors or injection pumps are used [8-10]. The development of these combination
products requires a comprehensive assessment and understanding of parameters contributing to injection
forces. These include (1) device components, (2) drug solution properties, and (3) human factors, such
as the capability of the end-user to apply the product. In particular, device components contribute to
the hydrodynamic component of injection forces, which can be described by the Hagen-Poiseuille’s law.
These are the syringe diameter, the needle inner diameter, and the needle length. Dynamic viscosity of
the solution (2) is itself dependent on temperature (described by Arrhenius equation), formulation, and
concentration of the active substance [9, 11-14]. Besides hydrodynamic forces, frictional forces between
stopper and plunger have to be considered as well. These are usually influenced by siliconization of the
syringe barrel and plunger dimensions among others [11, 15].
An anthropometric strength study showed that the force that a user can exert onto a syringe plunger is
determined by multiple (human) factors including the strength of the individual, the upper limb, and
hand posture required for injection (health status) [16]. It should also be considered that the personal
preference and training of the individual may influence their actual behavior [16]. In reality, users are
able to moderate the injection force (when using pre-filled syringes) by adjusting their injection speed
and may choose a slower injection resulting in a lower injection force to fit their capability or preference.
Human factor studies usually do not target actual sc administration but usage of injection pads. Thus,
deriving injection force data from these studies lack a potential impact of sc backpressure. The same
applies for in vitro testing of injection forces as well as syringe functionality testing (break loose and
glide force) which is usually performed into air, thus, ignoring the in vivo situation and potential impact
of sc backpressure.
Predictive in silico models were described in literature to estimate injection forces of parenterals [9, 11,
13]. However, only limited data is available dealing with the contribution of the tissue during injection.
Cilurzo et al. have recently performed an experiment where they injected a 19 mPas and a 101 mPas
solution into the abdominal skin (sc) from an Eurasian female who underwent cosmetic surgery. They
found an increase in injection force by a factor of 1.1 compared to injection into air due to tissue
resistance. This experiment was performed ex vivo at a constant injection speed of 1 mm/s, which
was equivalent to approximately 0.03 mL/s [17]. Vosseler and co-workers have measured the in-line
pressure during intradermal injection into pig ears using microneedles (ex vivo). They found significant
backpressure of the intradermal tissue when tested for a viscosity of 1 and 55 mPas at (slow) injection
rates of 0.1 and 0.5 mL/h. The authors reported that the backpressure is a non-linear function of flow
rate [18]. In different studies, the intestinal fluid pressure in the forelimb of Yorkshire pigs (3.9 ±1.4
mmHg) [19], in human foot skin (5.9 ±2.9 mmHg) [20], and in human sc tissue of the lower limb (2.5
±3.0 mmHg) [21) was measured giving a hint towards a contribution of the tissue pressure to injection
forces. However, up to date there is no in vivo study available which characterizes the contribution of
the sc backpressure to injection forces.
The aim of the present study is to investigate the contribution of the backpressure of the sc tissue layer
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to injection forces during injection into the plica inguinalis of Go¨ttingen minipigs. Go¨ttingen minipigs are
considered as a relevant animal model to study sc tissue as the structure of their hypodermis resembles
that in humans more than any other investigated animal (e.g. rodent, monkey) [2, 22-24]. Different
concentrations of isotonic dextran solutions corresponding to viscosities of 1, 10, 20, and 100 mPas were
administered at injection rates of 0.025, 0.1, and 0.2 mL/s and two injection volumes (2.5 and 4.5 mL)
were tested. The contribution of the sc backpressure to injection forces was defined and determined
by comparing subsequent in vitro and in vivo measurements of injection force profiles corrected by
a temperature factor by use of an instrumental set-up built for this purpose. After termination, the
injection sites were dissected and inspected macroscopically as well as histologically.
4.2 Materials and Methods
Materials
Dextran solutions
Isotonic dextran solutions were prepared in concentrations of 0%, 14.9%, 20.8%, and 34.8% by dissolution
of dextran 40 (BioChemica, Darmstadt, DE) in water for injection and by addition of sodium chloride
(Merck, Darmstadt, DE). The pH was determined as 5.5 ±0.4. The dextran concentrations corresponded
to viscosities of 1, 10, 20, and 100 mPas at room temperature characterized by plate/cone rheometry as
described previously [11]. For the tested injection rates, the dextran solutions showed Newtonian flow
behavior.
Disposable injection equipment
Disposable 5 mL plastic syringes (BD, Franklin Lakes, NJ) from a single lot with luer-lock tip were
connected by male or female luer fittings (1/16, Nylon) to a one-way stopcock with luer connection
obtained from Cole-Parmer (Vernon Hills, IL) and non-expanding PTFE tubing with an inner diameter
of 1.6 mm and a length of 100 cm (Scat Europe, Mo¨rfelden, DE). The tubing was connected to a
MicrolanceTM 3 26 G 3/8 needle (BD, Drogeda, IRL) as shown in Figure 4.1 (A).
Methods
Injection force measurements and data analysis
The instrumental set-up for the injection force measurements is shown in Figure 4.1 (A). A PHD 2000
Infusion syringe pump from Harvard Apparatus (Holliston, MA) was used in combination with a RSB5
Subminiature load cell (force sensor) with an accuracy of ±0.5% of the full calibrated scale (0 – 100
N). The load cell was connected to a DI-100U interface obtained from Loadstar Sensors (Fremont,
CA). Injection force measurements were performed at constant injection rates of 0.025, 0.1, and 0.2
mL/s applied by the syringe pump. An injection rate of 0.1 mL/s was chosen which is considered as
appropriate for the end-user and commonly used and accepted for functionality testing [11, 16]. 0.2 mL/s
was chosen as a maximum test rate, whereas 0.025 mL/s represents a slow injection rate as e.g. used
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Figure 4.1: Instrumental set-up for the injection force experiments (A), and injection sites for sc injection
into the plica inguinalis of the minipig (B). (1) Syringe pump, (2) load cell (force sensor), (3) sticking
metal platelet, (4)/(5) syringe with luer-lock tip, (6) one-way cock, (7)/(9) luer lock connections, (8)
PTFE tubing, (10) needle, (11) fixation, (12)/(13) computer and interface.
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by injection devices for high-volume sc dosing [8]. The force exerted to the plunger of the syringe was
recorded by the load cell each 0.1 s using the software Single-channel LV-1000 LoadVUE Pro (Loadstar
Sensors, Fremont, CA). The injection equipment and the test solutions were equilibrated to controlled
room temperature overnight. Before each experiment, the injection equipment was rinsed with the
sample under consideration. Directly before the in vivo measurements, control measurements into air
(in vitro) were performed to exclude differences in injection forces caused by differences in temperature
as well as differences in injection equipment. The temperature was monitored and found as 20◦C ±1.5
(MIN 17.6◦C and MAX 23.6◦C).
Data analysis of the injection force profiles was performed by calculating the average value of the
injection force plateau which was reached for all profiles between 0.25 – 2.5 mL for an injection rate
of 0.025 mL/s, between 0.5 – 1 mL for 0.1 mL/s, and between 1 – 2 mL for 0.2 mL/s. Representative
profiles are shown in Figure 4.2 for in vitro as well as for in vivo measurements for different injection
rates, viscosities, and injection volumes tested. Arrows indicate the range used for data analysis to
determine the average value of the plateau of the force profile.
Control for local temperature effect at the injection site
To account for the effect of body temperature on solution temperature in the needle and thus viscosity,
control measurements were performed (in vitro, N = 3) by injection of dextran solutions into water
which was tempered to 39◦C - equal to the body temperature of minipigs [25]. Only the needle was
inserted into the water to simulate in vivo injection. The instrumental set-up is shown in the Supporting
information Figure 4.7. A representative example of the injection force profile is shown in Figure 4.2
(B). The measurements were performed dependent on viscosity and injection rate, and were compared
to subsequent injections into air at room temperature. Based on the difference, the decrease in injection
force per degree Celsius caused by warming of the sample in the needle was calculated using the
Arrhenius equation [26]. This correction factor per degree Celsius was then applied to each individual in
vivo measurement. (No difference was measured between injections into air and injections into water at
the same temperature.)
For final data analysis, the correction factor was substracted from the difference between injection forces
determined by subsequent in vitro and in vivo measurement. To give an order of magnitude, correction
factors are presented in Table 4.1 of the Supporting information dependent on viscosity and injection
rate for a temperature increase from 20 – 39◦C (minipig) and additionally from 20 – 37◦C (humans).
In vivo testing set-up
Ten Go¨ttingen minipigs (male) with a body weight between 21.5 – 27.3 kg received four sc injections per
dosing occasion into the plica inguinalis as shown in Figure 4.1 (B). There were three dosing occasions
per pig during the study with a recovery period of at least 48 h before the next four injections. Prior to
dosing, the minipigs were anaesthetized using Zoletil R© dosed as 0.1 ml/kg. Before each injection, the
injection sites were inspected for absence of infections. Upon puncture, it was verified visually that the
needle was in the sc tissue layer indicated by loose movement of the needle in the tissue. The injection
angle was in parallel with the body surface to avoid penetration of the sc tissue layer. During and/or
after each injection, the injection site was inspected for successful injection into the sc tissue layer by
98
CHAPTER 4. MEASURING TISSUE BACKPRESSURE
– IN VIVO INJECTION FORCES DURING SUBCUTANEOUS INJECTION
(temporarily observed) blister formation.
The dextran concentrations were administered with different injection rates and volumes and per-
formed ten times for each condition. The injections were randomized for minipig, injection site,
viscosity, and injection rate. The study was approved and conducted in accordance with local legisla-
tion for animal welfare (Pipeline Biotech A/S license number 2011/561-2006, schedule C2 and extension).
Macroscopic evaluation after dissection of the injection sites and histology
At termination after the third dosing, macroscopic evaluation of the dissected injection sites was
conducted to ensure successful injection into the sc tissue layer. To facilitate the recognition of the
injection sites, 1 drop of ink (blue stamp ink, Carfa, Richterswil, CH) was added to 20 mL of sample
(which was determined to not affect viscosity). The length, width, and height of the injection sites (as
shown in Figure 4.5, B and C) was measured and recorded by the same person.
For histological characterization of the injection sites, the dissected tissue was transferred and fixed in
10% neutral buffered formalin, and embedded in paraffin. Slices of 4 µm were prepared, stained with
standard hematoxylin-eosin, and investigated under the light microscope.
4.3 Results
In vivo characterization of sc backpressure
The contribution of the backpressure of the sc tissue layer to injection forces was investigated in Go¨ttin-
gen minipigs dependent on solution viscosity (1 – 20 mPas) and injection rate (0.025 – 0.2 mL/s). Figure
4.3 (A) shows the force related to backpressure as a function of viscosity for the different injection rates
for an injection volume of 2.5 mL. It is presented as mean values from 10 randomized measurements
with standard deviation as well as minimum and maximum values. Overall, the force related to sc tissue
backpressure was measured between 0.1 to 12.9 N. In detail, it was found in the range of 0.6 – 1.0 N
for 1 mPas, 0.7 – 2.4 N for 10 mPas, and 1.8 – 4.7 N for 20 mPas for an injection rate of 0.025 to
0.2 mL/s (mean values). Variability of mean values increased with higher viscosity and injection rate as
indicated by error bars in Figure 4.3. Maximum contribution of tissue backpressure to injection forces of
1.7 N, 6.4 N, and 12.9 N were found for the samples with 1, 10, and 20 mPas for the highest injection
rate, respectively. The highest dextran concentration with a viscosity of 100 mPas was found to show an
additional force related to backpressure of 6.7 N (mean value) with a maximum value of 7.2 N measured
at an injection rate of 0.025 mL/s.
Figure 4.3 (A) shows that a linear increase of the contribution of sc backpressure to injection forces was
found with increasing viscosity for all three injection rates. This is emphasized in Figure 4.3 (A) for the
lowest injection speed of 0.025 mL/s indicating a linear increase (R2 = 0.99) of sc backpressure related
contribution to injection forces between 1 mPas up to the highest viscosity tested, which was 100 mPas.
A linear increase was also found dependent on injection rate for the tested solution viscosities (correlation
not shown separately).
In a follow-up experiment, the injection volume was increased to 4.5 mL and the sc backpressure was
tested for a viscosity of 10 mPas at an injection rate of 0.1 mL/s, in order to study potential impact of
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Figure 4.2: Representative examples of injection force profiles for in vitro (control) and in vivo mea-
surements. The injection force is presented as a function of injection volume for all profiles shown. (A)
Different viscosities (1 –20 mPas) and injection rates (0.025 – 0.2 mL/s) for an injection volume of 2.5
mL. (B) Viscosity of 100 mPas at 0.025 mL/s (2.5 mL) including injection force profile from temperature
control measurement (39◦C). (C) Injection volume of 4.5 mL for a viscosity of 10 mPas at 0.1 mL/s.
The arrows indicate the range used for data analysis to determine the average value of the plateau of
the profile which was 0.25 – 2.5 mL for an injection rate of 0.025 mL/s, 0.5 – 1 mL for 0.1 mL/s, and
between 1 – 2 mL for 0.2 mL/s.
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injection volume on sc tissue backpressure. Figure 4.3 (B) shows the corresponding mean values from 10
injections as well as minimum and maximum values with comparison of the 2.5 and 4.5 mL. No difference
in the contribution of injection forces of sc backpressure was found between the two injection volumes,
however variability as indicated by error bars of the mean value decreased for the larger injection volume
indicating a stabilization of the measured injection force signal.
For all tested conditions, the injection force profile reached a plateau as shown in Figure 4.2 for the
different viscosities and injection rates, including the higher injection volume of 4.5 mL (Figure 4.2, C).
This indicates that - up to the maximal tested injection volume - the visually observed blister formation
for some injection sites of the tissue due to the injected volume itself has a negligible influence on injection
force or is in the magnitude of the measurement error.
It has to be highlighted that the contribution of the sc backpressure was quantified in this study and
differentiated from the contribution of the injection device as well as separated from a local temperature
effect. This temperature effect was quantified as a temperature correction factor as outlined in the Meth-
ods section. To our knowledge, this is the first study to report a local temperature effect at the injection
site leading to warming of the (equilibrated) sample during sc injection in the needle and smaller injection
forces than expected. This will be discussed in detail later in this article.
Injections were performed ten times for each condition and were randomized for minipig, injection site,
viscosity, and injection rate. Figure 4.4 displays the box plots of the contribution of sc backpressure to
injection forces (average values) dependent on minipig (named as 1 to 10, Figure 4.4, A), injection site
(Figure 4.4, B), and observed blister formation after injection (Figure 4.4, C) showing no differences in sc
backpressure related injection force between these parameters. Most interestingly, Figure 4.4 (C) does not
show a difference in the contribution of backpressure to injection forces between injections where blister
formation after injection was observed and those where it was not observed. This confirms the previous
findings, that the sc backpressure does not increase with increasing injection volume (2.5 vs. 4.5 mL)
and that the visually observed blister formation due to the injected volume itself during injection has a
negligible contribution or is within the variation of injection force measurements for the conditions tested.
Thereby, the number of injection sites showing blister formation after injection was found to decrease
with increasing bodyweight of the minipig as shown in the Supporting information in Figure 4.8.
Verification of injection into the sc tissue layer
As the plica inguinalis has only a thickness of a few mm, a short needle (3/8”) was chosen to facilitate
injection into the sc tissue layer. It was verified for all injections that they were indeed occurring into
the sc space by: (1) visual inspection before in vivo injection indicated by loose movement of the needle
inserted into the tissue. (2) During injection, where differentiation between sc and intradermal (id)
injection is possible as id injection manifests in characteristic blister formation of the skin. Besides the
visual inspection of the injection sites, sc injection was verified on the last study day for the full set of
injections, including all different conditions for injection, by dissection of the injection sites followed by
(3) macroscopic evaluation and (4) histology.
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Figure 4.3: Contribution of sc backpressure to injection forces dependent on injection rate (0.025, 0.1,
and 0.2 mL/s), viscosity (1 – 100 mPas) of dextran solutions, and injection volume (2.5 mL, A, or
4.5 mL, B). The contribution of backpressure to injection forces was analyzed as value of the injection
force plateau. Measurements were performed as N = 10 randomized by minipig, injection site, injection
rate, and viscosity and were reported as mean value with standard deviation (squares), minimum and
maximum value (circle).
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Figure 4.4: Box plots of the contribution of sc backpressure to injection forces (mean value) dependent
on (A) minipig (1 to 10), (B) injection site, and (C) blister formation after injection. The box plot
represents mean, upper and lower quartile (box), minimum and maximum values (whiskers) as well as
outlier defined by >1.5 times of the interquartile range (circle).
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Figure 4.5: (A, B) Representative pictures of dissected injection sites (plica inguinalis) after injection of
a colored dextran solution (20 and 100 mPas/0.025 mL/s/2.5 mL and 10 mPas/ 0.1 mL/s/4.5 mL). The
white arrows (A) indicate how the measurement of the dimensions of the injection sites was performed.
(C, D) Representative histological sections before (C) and after (D) injection of an isotonic dextran
solution with a viscosity of 10 mPas at an injection rate of 1 mL/10s. I: epidermis, II: dermis with adnexe
e.g. hairs and sebeceous glands, III: subcutis, (*) subcutaneous edema due to injection.
Macroscopic evaluation after dissection of the injection site
On the last study day, a dye was added to the dextran solutions prior to injection and each injection site
was dissected and inspected. Each injection was recovered as defined, well-localized injection site in the
sc tissue layer for all conditions tested. Representative pictures of the injection sites are shown in Figure
4.5 (A, B). The width, height, and length of the sites were measured by the same person (indicated by
arrows in Figure 4.5, A).
Figure 4.6 shows the dimensions sorted according to viscosity and injection speed as well as injection
volume. For an injection volume of 2.5 mL, dimensions of 1.7 – 4.2 cm, 2.7 – 5.6 cm, and 0.3 – 1.9
cm were found for width, length, and height, respectively. With higher injection volume (4.5 mL), the
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dimensions increased to 2.0 – 3.3 cm, 2.7 – 9.0 cm, and 0.4 – 1.3 cm (width, length, and height). The
calculated distribution volume in the sc tissue based on these dimensions assuming oval spreading was
found as 3.7 and 7.2 mL for an injection volume of 2.5 and 4.5 mL. This corresponds to an increase
in distribution volume in the sc space by 50% compared to the initial injected volume. Overall, the
macroscopic evaluation of the injection sites at termination showed that all injections were located in
the subcutaneous tissue layer.
Histology
Figure 4.5 shows histological slices of the skin of the injection site (plica inguinalis) before (C) and after
(D) injection of a dextran solution with a viscosity of 10 mPas injected at an injection rate of 0.1 mL/s.
The histology shows the epidermis, dermis with adnexa like hairs and sebaceous glands, and subcutis.
Figure 4.5 (D) clearly shows a subcutaneous edema due to the dextran injection when compared to
Figure 4.5 (A). In general, there were no differences found in histology between the four injection sites.
4.4 Discussion
Go¨ttingen minipigs as in vivo model for sc tissue
The minipig is currently considered as the most appropriate translational animal model to study
the pharmacokinetics of biotherapeutics after sc injection e.g. for studies of monoclonal antibody
therapeutics [2, 27, 28]. Most importantly, the structure of the hypodermis of the pigs was reported to
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resemble that in humans more than any other animal (e.g. rodent, monkey) [2, 22-24]. The skin of the
pig is, like in humans, connected to the deep fascia via a fibrous network which defines the spreading
behavior of a sample. A relevant difference between humans and e.g. rodents, monkeys, and pigs is
the presence of the panniculus carnosus for the latter three animal species [3, 22, 24, 29]. However, the
panniculus carnosus is missing in some parts of the pig, like in the groin, and therefore ressembling
human tissue structure [22]. Thus, the plica inguinalis was chosen as injection site in minipigs for this
study. Only the height of the subcutaneous tissue layer differs between the human skin (approximately
11 mm) [30] and the plica inguinalis of the minipig (few mm). Therefore, a short needle with a length
of 3/8 was chosen to control and ensure injection of the solutions in the sc tissue space in our study.
Adsorption of the dextran was not investigated and not in scope of our study as only the injection
process was considered. The injections were randomized for each minipig animal, injection rate, viscosity,
and injection site.
In summary, mean values of the contribution of tissue backpressure to injection forces were determined
in the range of 0.6 to 4.7 N for injection rates between 0.025 and 0.2 mL/s and viscosities between 1 and
20 mPas. A minimum value of 0.1 N and a maximum value of 12.9 N were measured. The injection force
related to sc tissue backpressure was found to be linear dependent on injection rate as well as on viscosity.
Injection force profiles reached a plateau for all conditions as outlinedtested. No increase in the contribu-
tion of sc backpressure was observed for an increase in injection volume from 2.5 to 4.5 mL. Moreover, the
occurrence of blisters in the sc tissue during/after injection due to the injected volume per se was found to
be independent on the force related to sc backpressure. These findings together indicate that the contri-
bution of blister formation during/after injection to injection forces is smaller or in the magnitude of the
variation of the force measurement for the conditions tested. Based on these data, we may assume that
the dextran solution might rapidly diffuse to the connective tissue. However, the macroscopic evaluation
of the injection sites on the last study day has shown well-localized compartments for all conditions tested.
Influence of body temperature on injection forces
As outlined previously, the data analysis of the contribution of sc backpressure to injection forces
was performed by subtraction of the in vivo from the in vitro measurement which were determined
subsequently, corrected by an individual temperature factor. The in vitro and the in vivo experiment
were performed subsequently under same temperature conditions using the same injection equipment.
The injection equipment was rinsed before start of the experiment with the sample to be injected which
was equilibrated to room temperature over several hours in the facility.
An interesting observation was made when injecting the 100 mPas dextran solution. The data suggested
that the measured injection forces of the control measurements were significantly higher than the injection
forces of the in vivo experiment. However, as the in vitro experiment was performed prior the in vivo
experiment under same temperature conditions using the same injection equipment, the data suggested
another parameter to additionally influence injection forces under in vivo conditions. As the sample
was equilibrated to room temperature for several hours and most importantly the tubing/injection
equipment was not in contact with the body surface of the minipig at any time (except of the needle tip),
the hypothesis was that a local, fast decrease in viscosity in the needle tip may consequently lead to the
reduction in injection forces. This local decrease might be a result of the fast warming of the sample in
the needle during the injection process due to the body temperature of the minipig (39◦C). To proof this,
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a simple control measurement was performed. The dextran samples were injected into tempered water
of 39◦C, equal to the body temperature of minipigs [25], with only the needle inserted into the water
bath. Prior to this experiment as a control, the same injections were performed into air for comparison
under the same conditions (sample, temperature, equipment). The experiments confirmed that injection
forces were significantly decreased if the needle tip – although only few millimeters in length – faces
warmer environmental conditions than room temperature during injection than compared to injections
into air (at room temperature). This additional negative contribution to injection forces was found
and quantified to be dependent on viscosity and injection rate indicating a hydrodynamic process. In
detail, the contribution of the body temperature of the minipig to injection forces was separated for each
individual experiment from the contribution of the sc backpressure and the hydrodymanic component
as follows: the decrease in injection force per degree Celcius was obtained from the experimental data of
the control measurements (waterbath vs. air) using the Arrhenius equation dependent on injection rate
and viscosity. Based on these factors, the decrease in injection force was calculated (Arrhenius equation)
for each individual experiment based on the temperature difference between control measurement
(39◦C) and the actual monitored temperature during the in vitro/in vivo experiment. Examples for a
temperature difference of 20 – 39◦C and 20 – 37◦C are given in Table 4.1 in the Supporting Information.
In summary, we concluded, that the observed temperature effect manifests as a localized temperature
effect at the injection site. This leads to warming of the (equilibrated) sample in the needle during
injection, thus smaller viscosity and smaller injection forces than expected. As the temperature factor
was found to be dependent on viscosity and injection rate, this indicates a hydrodynamic process and
strengthens our conclusion that the temperature at the animal body/at the injection site leads to
adjustment of the fluid temperature in the needle during sc injection.
Implications of sc backpressure and local warming in context of user capability
As outlined in the introduction, injection forces of highly concentrated protein products are influenced
by device dimensions like needle inner diameter, product properties like viscosity – itself dependent
on temperature and concentration of active substance, and by the injection rate which is defined by
the capability of the end-user. Also frictional forces between plunger and syringe barrel contribute to
injection forces. These parameters are well understood and were investigated in detail in the past. Current
literature models use these factors to predict injection forces, however limited to the in vitro situation
neglecting actual in vivo conditions [11]. Dependent on the indication, patients might be limited in their
strength like e.g. for rheumatoid arthritis patients, stating a challenge to expel a syringe. Therefore, the
limits for maximal required injection force have to be carefully evaluated before design of an injection
device. A highly concentrated protein therapeutic with a viscosity of 100 mPas has been previously
studied [16]. This protein therapeutic was tested for injectability by Sheikhzadeh and co-workers in an
anthropometric study. The authors reported that rheumatoid arthritis patients were capable to exert a
force of approximately 17 N (95% percentile) and 48 N (mean) in average onto the syringe plunger [16].
Setting this into relation to our findings assuming a constant, slow injection speed of 0.025 mL/s, the
injection force of this product would be higher by approximately 7 N due to the contribution of the
sc backpressure compared to in vitro injection forces which are in general tested against air. The local
temperature effect for a body temperature of 37◦C leading to warming of the sample in the needle would
decrease injection forces by approximately 4 N assuming similar viscosity-temperature dependence of
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the therapeutic as dextran. This would result in an overall higher injection force by 3 N compared to
the estimated or measured injection force in the in vitro situation. Testing of injection force ex vivo
still remains questionable of being representative of in vivo injection forces. Moreover, it may lead to
unexpected modifications/distortions and may therefore not be representative for the in vivo situation.
The data indicate that consideration of the actual in vivo sc backpressure is essential when assessing
injection forces. Moreover, compensation of the increase in injection forces by the tissue backpressure
due to the local temperature effect, as observed for the minipig, should be considered.
Based on the above findings, the current in silico model to predict injection forces [11] can be extended to:
Ftotal = F (Q, η)hydrodynamic + F (Q)friction + F (Q, η)tissue backpressure - F (Q, η)body temperature
(F = force, Q = volumetric flow, η = dynamic viscosity)
Sc injection volume
The present study showed that injection volumes up to 4.5 mL into the sc tissue space were forming
localized, well-defined injection sites, without any observed leakage. This is of high importance as the sc
tissue layer of the plica inguinalis of the minipig is even thinner than the one of humans. The localized
injection sites were found for all conditions tested independent on viscosity and injection rate. Compared
to literature, the current sc injectable volume is considered to be limited to 1 to 1.5 mL for human
use [31]. Frost et al. described the volume for sc injection to be generally limited to less than 2 mL due to
compliance of the tissue space to injected fluids [32]. This is driven by the fibrous bands in the panniculus
adiposus that reach into the deep fascia for humans and other furless animals [22, 33, 34] which might
lead to pain and tissue distortion upon sc injection. Current marketed products for sc administration
are to date limited to 1 to 1.5 mL volume of administration [1].
Recent approaches have shown that higher injection volumes are feasible for sc injection by co-injection
with recombinant human hyaluronidase, an enzyme that temporarily and reversibly degrades hyaluronan
which is a major component of the extracellular matrix of the skin besides collagen. This facilitates
the penetration and diffusion of the co-administered drug [34-37]. Shpilberg and colleagues showed that
administration of up to 15 mL of a co-formulation of hyaluronidase and a monoclonal antibody into
healthy volunteers (phase Ib study) was feasible [7, 38].
The present study showed that injection of up to 4.5 mL was feasible from the point of view that the sc
tissue was capable to keep the solution at a defined injection site as outlined above. Moreover, another
study suggested local tolerance in beagles with good tolerability up to an injection volume of 5 mL into
the sc tissue space [39].
4.5 Conclusions
The development of injection devices for combination products (e.g. autoinjectors or pre-filled syringes)
requires a detailed understanding of injection forces dependent on device dimensions like needle diameter,
and formulation properties like viscosity. Current literature provides experimentally verified in silico
models for prediction of injection forces into air. To our knowledge, this is the first study which provides
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quantitative data on the backpressure of the sc tissue contributing to injection forces measured during in
vivo injection. In summary, mean values were determined in the range of 0.6 to 4.7 N for injection rates
between 0.025 and 0.2 mL/s and viscosities between 1 and 20 mPas. A minimum value of 0.1 N and a
maximum value of 12.9 N were measured. These data demonstrate that the sc tissue backpressure during
injection can be significant. All force profiles reached a plateau during injection, even for the higher
injection volume of 4.5 mL forming well-localized compartments in the sc tissue layer. Moreover, we
reported that a local temperature effect led to warming of the (equilibrated) drug solution in the needle
due to the body temperature of the minipig . This led to smaller measured injection forces than expected
relieving the increase in injection forces due to sc backpressure – to some parts. As the structure of the
sc tissue layer was shown to be comparable between the plica inguinalis of minipigs and humans, the
current data set presents – to our knowledge – the first appropriate quantitative data on injection forces
during sc administration considering in vivo conditions representative for humans.
The present study separates the contribution of the tissue backpressure from the contribution of the
injection device as well as from the local temperature effect which was quantified dependent on viscosity
and injection rate. Based on these findings, the current in silico model to predict injection forces [11] can
be extended to:
Ftotal = F (Q, η)hydrodynamic + F (Q)friction + F (Q, η)tissue backpressure - F (Q, η)body temperature
(F = force, Q = volumetric flow, η = dynamic viscosity)
To conclude, this knowledge is of key importance to further develop and define limits and setup for
testing of device robustness during the evaluation, planning, and design phase of the development of
injection devices.
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4.8 Supporting Information
Temperature correction factor [N] 0.025 mL/s 0.1 mL/s 0.2 mL/s
for 20-39◦C / 20-37◦C
1 mPas 0.0 /0.0 -0.2 /-0.1 0.0 /0.0
10 mPas 0.3 /0.2 1.0 /0.7 1.4 /0.9
20 mPas 1.4 /0.9 2.8 /1.9 4.2 /2.8
100 mPas 6.2 /4.2
Table 4.1: Temperature correction factor for sc backpressure related injection force to account for local
temperature effect in the needle/at the injection site of the minipig. The correction factor is presented in
this table as an example for a temperature increase from 20 – 39◦C (minipig) and additionally from 20 –
37◦C (humans) between in vivo and control measurement (injection into tempered water bath) dependent
on viscosity and injection rate. As outlined in the Methods section, the temperature correction factor
was calculated individually for each in vivo injection according to the Arrhenius equation based on
temperature monitoring.
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Figure 4.7: Instrumental set-up of control measurements (in vitro, 39◦C) for correction of local temper-
ature effect at the body surface of the minipig/at the injection site. Injections were performed with only
the needle inserted into the water bath to simulate in vivo conditions. The water was tempered to 39◦C
which is the body temperature of minipigs.
Figure 4.8: Number of injection sites showing blister formation after injection per number of total
injections as a function of body weight of the minipigs.
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During filtration within the aseptic drug product manufacturing process of biologics, differences in
filtration behavior of highly concentrated protein formulations can be observed dependent on the
formulation composition. Filtration time can be influenced by filtration pressure, filter material with a
distinct filter area, filter resistance, which is defined by surface properties and pore size distribution, by
viscosity, and by physical properties of the solution (e.g. hydro-/lipophilicity).
The present study investigates the filtration forces of monoclonal antibody formulations in a small-scale
setup using PVDF (polyvinylidene difluoride) or PES (polyethersulfone) filters. Different factors like
formulation composition (buffer system, excipients, presence and absence of surfactant) and protein
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concentration, which are linked to viscosity, as well as different filtration rates were evaluated.
Shear rates during the filtration process, which are defined by pore size distribution interdependent
with filtration pressure (in the magnitude of 0.4 – 1.0 bar), were shown to lead to non-Newtonian
behavior of the protein formulations with increasing protein concentration and filtration rate. Therefore,
smaller absolute filtration forces than expected were found for highly concentrated protein formulations
dependent on the formulation composition when compared to Newtonian control solutions of the same
low-shear viscosity. Different buffer valences of the formulations (histidine vs. citrate buffer) showed
significant impact on the non-Newtonian behavior, whereas excipients like arginine-HCl or sucrose did
not impact the extent of shear thinning for the monoclonal antibody tested.
The addition of polysorbate was shown to have a significant influence on filter resistance dependent on
filter material. An increase in filter resistance was found for the PES but not for the PVDF filter in
comparison to surfactant-free solutions.
The current study highlights the influence of formulation composition on the filtration process and
emphasizes the relevance to assess possible limitations during manufacture caused by elevated viscosity
of highly concentrated protein formulations.
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5.1 Introduction
Highly concentrated protein formulations which are administered by subcutaneous injection are desirable
for chronic indications which require a frequent dosing regimen. They may also offer the possibility for
either self-administration by the patient or home-treatment by a healthcare professional. [1-3] Especially
the rheological behavior of these concentrated solutions have a major impact on processing during
product manufacture (e.g. aseptic filling and filtration [4-6]) and parenteral administration of the
product. [7-9] For filtration of parenteral products, hydrophilic PVDF (polyvinylidene difluoride) and
PES (polyethersulfone) filters are routinely used during the fill-finish process. [6, 10, 11] Besides filter
area, filtration pressure, pore size, and surface properties of the filter material, the filtration process can
be influenced by different parameters including solution viscosity and formulation. [6, 11, 12]
To protect the protein from interfacial stress occurring during manufacture (e.g. filtration, freeze/thawing)
and storage (e.g. glass as primary packaging, shaking stress), protein formulations often require the
addition of stabilizers like surfactants. [13-21] Currently, most commonly used surfactants of marketed
protein therapeutics are polysorbate 20 or 80. [10, 11, 22, 23] These nonionic surfactants bind with a
higher affinity to interfaces than proteins, such as to the air-liquid or ice-liquid interfaces, thus preventing
interfacial protein adsorption and protein aggregation. [20, 24] However, it was recently reported, that
polysorbate 80 significantly adsorbs to PES sterilizing-grade filters. [11] Furthermore, Zhou et al. have
recently shown that polysorbate 20 also adsorbs to filter material (PES and PVDF) suggesting a
non-specific hydrophobic binding mechanism. [10] They furthermore reported that PES filters adsorb
polysorbate 20 to a much greater extent than the PVDF membranes. Both articles therefore suggested
pre-conditioning of the filters for saturation of the binding sites with formulation buffer or protein
formulation, or the evaluation of more suitable and compatible filter membranes.
Little information is available about the influence of the formulation composition (e.g. surfactants,
isotonizers, viscosity reducers, buffer systems) on filtration behavior especially for highly concentrated
protein solutions. In own observations, differences in filtration behavior of highly concentrated protein
formulations were found during aseptic filtration within the fill-finish process of monoclonal antibody
solutions dependent on the composition of the formulation (data not shown).
Therefore, the present study aimed to investigate filtration forces of different monoclonal antibody
formulations during filtration in a standardized lab-scale set-up. Different filter materials, i.e. hydrophilic
PVDF and PES filters, were tested with a nominal pore size of 0.2 µm. Filtration behavior of two
different monoclonal antibody formulations (mAb 1 and mAb2) was tested in particular in dependence
on protein concentration and viscosity. The influence of filtration rate on filtration forces as well
as of formulation composition (buffer systems, excipients) at high protein concentration was further
investigated. Differences in filtration forces between the two tested filter materials were linked to filter
resistance and pore size distribution. Additionally, solution with or without polysorbate were investigated
with regard to filter resistance.
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5.2 Materials and Methods
Materials
Monoclonal antibody formulations
The purified monoclonal antibodies mAb1 (IgG1, pI 8.4; estimated Mw 146) and mAb2 (IgG1,pI 9.4;
estimated Mr 148 kD) were provided by F. Hoffmann-La Roche Ltd (Basel, Switzerland). mAb1 was
formulated in an arginine succinate buffer (Ajinomoto, Louvain-la-Neuve, Belgium; Merck, Darmstadt,
Germany) at pH 6.5 with addition of methionine (Ajinomoto, Louvain-la-Neuve, Belgium) and 0.06%
(m/v) polysorbate 20 (Croda, Edison, NJ, USA) at a protein concentration between 20 and 180 mg/mL.
For investigation of different formulation properties, mAb1 was additionally formulated at a protein
concentration of 20 and 150 mg/mL at pH 6.5 in either a 20 mM histidine-HCl buffer (Ajinomoto,
Louvain-la-Neuve, Belgium) or a 20 mM sodium citrate buffer (Jungbunzlauer, Basel, Switzerland)
with addition of 0.06% (m/v) polysorbate 20 and either (A) no excipient, (B) 150 mM arginine-HCl
(Ajinomoto, Louvain-la-Neuve, Belgium), or (C) 200 mM sucrose (Ferro Pfanstiehl, IL, USA).
mAb2 was formulated at protein concentrations between 20 and 180 mg/mL in a histidine-HCl buffer
(pH 6.0) with addition of arginine-HCl (Ajinomoto, Louvain-la-Neuve, Belgium) and 0.02% (m/v)
polysorbate 80 (Croda, Edison, NJ, USA). Surfactant concentrations are above the critical micelle
concentration (CMC) for all tested solutions, which are 0.006% and 0.001% (m/v) for PS 20 and 80,
respectively. [24]
Surrogate solutions
Glycerol solutions were used as surrogate for viscous solutions. Aqueous glycerol solutions were prepared
by dilution of 99.5% (m/v) glycerol (Acros Organics, Morris Planes, NJ) with either water for injection,
20 mM histidine-HCl, or 20 mM sodium citrate buffer in concentrations between 0 – 60% (m/v, pH 6.0
and 6.5) with addition of 0.06% (m/v) polysorbate 20.
Aqueous 0.001 M potassium chloride solution (Metrohm, Zofingen, Switzerland) was prepared at a pH
of 6.5 with and without addition of 0.06% (m/v) polysorbate 20. The pH was adjusted by addition of
0.1 N sodium hydroxide solution (Merck, Darmstadt, Germany).
Syringe filters with a hydrophilic PVDF (polyvinylidene difluoride) or a PES (polyethersulfone) filter
membrane from the same supplier were used for the filtration experiments in combination with 5 mL
plastic syringes with luer-lokTM tip (BD, Franklin Lakes, NJ, USA). The syringe filters had a nominal
pore size diameter of 0.2 µm and a filter area of 3.9 cm2.
Methods
Small-scale filtration
Filtration experiments were performed using a standardized small-scale set-up on a TA.HDplus Texture
analyzer (Stable Micro Systems, Surrey, UK). A plastic syringe was filled with the sample under
consideration and all air bubbles were removed. A syringe filter was mounted on the syringe and placed
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on the texture analyzer with the syringe pointing to the bottom. A constant speed was applied to the
plunger and the restoring force was measured during filtration of the sample. Filtration forces can be
easily converted to filtration pressure by knowledge of filtration area. The experiments were performed as
triplicates at room temperature (23 ±1◦C). Before each filtration, the filter was tested for filter integrity
and washed/equilibrated with water and placebo subsequently to saturate the surfactant binding sites
as suggested by Mahler et al. and Zhou et al. [10, 11] Data analysis was performed using the Exponent
Stable Micro Systems software (Stable Micro Systems, Surrey, UK). The filtration force was determined
as average value from the plateau of the force-travel distance graph. A representative example for data
analysis is shown in Figure 5.7 of the supporting information.
Characterization of samples
Viscosity measurement
Dynamic viscosity was measured by plate/cone rheometry at 20◦C as duplicates at a shear rate of 2 x
103 s−1 as recently described by Allmendinger et al. [25]
Light obscuration
Sub-visible particles were counted by light obscuration as described by Kieseet al. using a low-volume
method. [21]
Zeta potential measurement
Zeta potential of the protein samples was determined as duplicates by laser Doppler electrophoresis as
outlined in Lehermayr et al. [26]
Dynamic light scattering
The protein-protein interaction parameter A2 was determined for the protein samples by DLS (dynamic
light scattering) as described by Lehermayr et al. [27] The measuring time was adjusted to 5 s and
20 consecutive measurements were performed per dilution (N = 3). This method measures A2 at low
protein concentrations (1 – 10 mg/mL) as there are currently only limited methods available to measure
PPIs at high concentrations. [27, 28] However, A2 is considered to be a good qualitative predictive factor
for PPIs in highly concentrated protein formulations as previously reported by Yadav et al. [29]
Size exclusion chromatography
Monomer, high molecular and low molecular weight species were analyzed for the protein samples by
size exclusion chromatography (SEC) according to Kiese et al. [21] The monomer content was found
>98% for all samples.
Characterization of syringe filter
Filter resistance
Filter resistance β [m−1] was determined by filtration force experiments (N = 3). The filtration process
can be described by the modified Darcy equation [12] if cake formation is neglected:
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∆P =
∆F + Ffriction
A
=
Q
A
· η · β + ∆Ffriction
A
(5.1)
∆P [Pa] = pressure drop
F [N] = filtration force
A [m2] = filter cross-sectional area (3.9 x 10−4 m2)
Q [m3/s] = volumetric flow = ∂V/∂t
V [m3] = filtration volume
t [s] = filtration time
η [Pas] = dynamic viscosity
β [m−1] = filter resistance
Therefore, the filter resistance β [m−1] was determined from the slope of the filtration force F as a
function of (a) dynamic viscosity η or (b) filtration rate Q/A [m/s]. Method (a) was applied to the
different aqueous glycerol concentrations in histidine or sodium citrate buffer, respectively. Method (b)
was used for determination of the filter resistance for the 0.001 M potassium chloride solution with and
without addition of 0.06% (m/v) polysorbate 20 (η = 1 mPas) at 1.85, 9.25, and 18.5 x 103 L/m2h.
Mercury porosimetry
Pore size distribution of the two different syringe filters was analyzed by mercury porosimetry as outlined
in Stirnimann et al. [30] using four filters within one measurement.
Scanning electron microscopy
Scanning electron microscopy (SEM) pictures of the syringe filter were taken at 3.4 x 103 and 6.7
x 103 times magnification using a FEI/Philips XL30 FEG apparatus (Philips, Netherlands). Sample
preparation was performed as described by Stirnimann et al. [30]
5.3 Results
Protein concentration
Sterile filtration of two monoclonal antibody formulations mAb1 and mAb2 was investigated using PES
and hydrophilic PVDF filters with a nominal pore size of 0.2 µm. Filtration forces were measured on
a small-scale set-up at a filtration rate of 1.85 x 103 L/m2h for increasing protein concentration of 20,
50, 80, 150, and 180 mg/mL. Figure 5.1 shows the filtration force of mAb1 (A, B) and mAb2 (C, D)
for the PES and PVDF filter respectively as a function of dynamic viscosity (2 x 103 s−1). mAb1 and
mAb2 both showed increasing filtration force with increasing viscosity. In general, absolute filtration
forces through the PVDF filter (Figure 5.1 B, D) were lower than those of the PES filter (Figure 5.1
A, C) for the formulation tested (containing polysorbate (PS) 20 or 80). Figure 5.1 also compares the
filtration forces of the protein solutions with control measurements of aqueous glycerol solutions of
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different concentrations (0 – 60%, m/v), also containing PS (20). The reason for the addition of PS to the
control solution and differences on filtration forces between PS 20 (mAb1 formulation) and PS 80 (mAb2
formulation) including surfactant concentration will be outlined later in this text. Linear correlation of
absolute filtration force and viscosity was found for the control measurements using glycerol solutions
(R2PV DF = 0.995 and R
2
PES = 0.979) indicating Newtonian flow behavior of the control solutions and
exclusion of warming of the sample during the small-scale filtration process. However, clear deviation
from Newtonian model was found for both mAbs through the PES filter and minor deviation for the
PVDF filter with increasing viscosity (protein concentration) when compared to the control.
Filter material
Both filters assessed have a nominal pore size of 0.2 µm. The FDA defines the sterilizing grade filters
on the basis of its ability to sustain a bacterial challenge of 1 x 107 CFU of Brevundimonas diminuta
per cm2 of filter surface, grown and challenged under specific, standardized parameters. Therefore,
sterilizing filters – although nominally labeled as 0.2 µm – can have different actual pore sizes/pore size
distributions and still be able to retain the bacterial challenge. [31]
Filter materials were characterized by electron scanning microscopy (SEM). Figure 5.2 shows the pictures
of the PES and PVDF filter in two different magnifications revealing structural differences in pore shape
and pore size distribution. The pictures show larger pore sizes for the PVDF filter as compared to the
PES filter.
The pore size distribution was further investigated using mercury porosimetry. Figure 5.3 shows the
pore volume as a function of pore size of the PES filter and the PVDF filter. The PVDF filter consists
of two filter layers which showed the comparable pore size distribution. The PES filter showed a narrow
pore size distribution with a maximum of 8.31 mL/g at 0.43 µm whereas the PVDF filter showed a
wide pore size distribution with maximum values of 1.2 mL/g. This reflects the results from the SEM
measurements and indicates that the PES filter consists of a large number of small pores (modus of
0.43µm) compared to the PVDF filter with a smaller amount of more heterogeneous pores.
Besides pore size distribution which was found to differ between the two filters, filter materials were
characterized by their surface properties (e.g. electrostatic and hydrophilic properties) influencing
filtration forces interdependent with physical properties of the solution under consideration (hydro-
/lipophilicity). These (surface) properties can be quantified as the filter resistance β at a defined pH
which is the proportional factor between volumetric flow per cross-sectional area, viscosity, and filtration
pressure as outlined in the Materials and Methods section. The filter resistance was found to be 20.7 m−1
and 8.8 m−1 for the PES and PVDF filter, respectively, determined for the control solutions (aqueous
glycerol solution with 0.06% PS 20).
Surfactant: polysorbate 20 and 80
In a side experiment, a 0.001 M potassium chloride solution with and without addition of 0.06% (m/v)
PS 20 was filtered through the PES and PVDF filter. Filter resistance was found to increase from
7.0 m−1 to 20.8 m−1 for the PES filter revealing a significant influence of the surfactant on filtration
forces. The filter resistance of the PVDF filter did not change by addition of PS 20 and was found as
10.4 m−1. Figure 5.7 of the supporting information also shows that there was no difference in filtration
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Figure 5.1: Filtration forces of different concentrations of mAb1 (circle), mAb2 (diamond), and aqueous
glycerol solutions (square) at a filtration rate of 1.85 x 103 L/m2h (N = 3) as a function of dynamic
viscosity (20◦C, 2 x 103 s−1) for two different filters (PES, PVDF). Mean values and standard deviation
are reported. The solid lines show the linear fit to the glycerol solutions with R2 = 0.995 (PVDF) and
0.979 (PES).
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Figure 5.2: Scanning electron microscopy pictures of PES and PVDF filters at different magnifications.
123
5.3. RESULTS
Figure 5.3: Representative example of pore size distribution measured by mercury porosimetry for PES
and PVDF filter. The pore volume is shown as a function of pore diameter. The PVDF filter consisted
of two filter layers which were measured independently.
forces found for the potassium chloride solution between addition of PS 20 versus PS 80 in amounts
above the CMC for both filters. Due to its impact on filter resistance, PS 20 was added to the control
solutions, in order to guarantee comparable filter resistance during filtration of the control solutions
as well as for the protein solutions. The findings highlight that the filter resistance is defined by the
(surface) properties of the filter material interdependent with the hydrophilicity - and consequentially -
by the surface-active properties of the solution to be filtered.
Filtration rate
To further investigate the deviation of filtration forces of monoclonal antibody formulations from linear
flow behavior of the control solutions with increasing viscosity, filtration forces of mAb2 at the highest
protein concentration (180 mg/mL) were assessed. Figure 5.4 shows the filtration force normalized by
dynamic viscosity (measured at low shear rate of 2 x 103 s−1 showing Newtonian behavior) for mAb2
through a PES filter in comparison to the control solution (60% (m/v) glycerol solution with PS) as a
function of filtration rate. In comparison to the control solution, mAb2 showed an increasing deviation
from Newtonian flow behavior indicating significant influence of filtration rate on the parameter which
led to reduced filtration forces.
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Figure 5.4: Filtration forces for mAb2 at 180 mg/mL (filled circle) and 60% (m/v) aqueous glycerol
solution (open circle, control) normalized by viscosity (20◦C, 2 x 103 s−1) for the PES filter as a function
of filtration rate. Mean values and standard deviation are reported. The dotted lines were drawn to guide
the eye.
Excipients
To investigate the influence of different excipients in solution, mAb1 was formulated in either a 20 mM
histidine hydrochloride or a 20 mM sodium citrate buffer at a protein concentration of 20 and 150 mg/mL
with further addition of the following excipients: (1) no further addition of excipients, (2) addition of
150 mM arginine-HCl, or (3) addition of 200 mM sucrose. These were selected in order to evaluate different
ionic strength (e.g., arginine-HCL), viscosities (i.e., viscosity increase in sucrose-containing formulation
and decrease in arginine-HCl containing solutions), and to compare formulations with different buffer
valences. All formulations contained PS 20. Figure 5.5 shows the filtration forces measured at a filtration
rate of 1.85 x 103 L/m2h for the different formulations at 20 mg/mL (A) and 150 mg/mL (B) as white
(PES) and hatched (PVDF) bars (left y-axis) and the corresponding dynamic viscosity as black dots
(right y-axis). Clear differences between the PES and the PVDF were found for both protein concentra-
tions: in general, lower filtration forces were found for the PVDF filter as already shown in the previous
experiments. For the 20 mg/mL, Figure 5.5 (A) shows that there are no significant differences in filtration
forces between the mAb1 formulations. This was consistent with the dynamic viscosity which also showed
no difference between the formulations. For the 150 mg/mL formulations, differences in filtration forces
were found between the solutions with different excipients, consistent with the extent of viscosity if a
single buffer system is considered. Significant differences of filtration forces were found between the two
buffer systems – especially as viscosities were approximately similar between the corresponding formula-
tions or did not differ in the same direction as filtration forces.
Table 5.1 lists the zeta potential of the mAb1 formulations measured at 150 mg/mL and the interaction
parameter A2 which was measured between 1 – 10 mg/mL. The zeta potential representing the elec-
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Figure 5.5: Filtration forces of different formulations of mAb1 at (A) low protein concentration
(20 mg/mL) and (B) high protein concentration (150 mg/mL), (left y-axis). The white bars correspond to
filtration forces through the PES filter and the hatched bars to the PVDF filter. Corresponding viscosity
data to the formulations (2 x 103 s−1, 20◦C) are shown as filled symbols (circles), (right y-axis). Mean
values and standard deviation are reported.
trokinetic potential of the formulation was found positive for the formulations consisting of histidine-HCl
buffer with no addition of excipients or addition of sucrose, and around zero for the other formulations
due to the increase in ionic strength. The parameter A2, which characterizes protein-protein interactions
(PPI) between two molecules, was also found positive for the formulations consisting of histidine-HCl
buffer with no addition of excipients or addition of sucrose indicating repulsive PPIs. For the other for-
mulations with a higher ionic strength, A2 was found smaller by the factor of 10 indicating a reduction
in repulsive and increase in attractive PPIs, respectively, due to ion shielding. After normalization of
the filtration forces by low-shear viscosity which are also reported in Table 5.1, no correlation was found
between filtration forces and the investigated parameters. Additionally, sub-visible particle counts were
determined before filtration to assess possible particle burden of the solution. However, particle counts
between 0 – 14 (≥10µm) and 0 – 9 (≥25µm) cumulative counts/mL were found, which were far below
compendial requirements with ≤600 and ≤6 000 counts/mL for particles ≥10 and ≥25µm, respectively.
Detailed counts are provided in Table 5.2 in the supporting information.
Figure 5.6 shows the filtration forces of the different mAb1 formulations as presented in Figure 5.5 as
a function of dynamic viscosity in comparison to a Newtonian control which showed linear correlation
with R2PES = 0.993 and R
2
PV DF = 0.997 in citrate buffer and R
2
PES = 0.968 and R
2
PV DF = 0.994 in
histidine buffer. The control solutions consisted of different concentrations of glycerol (0 – 60%, m/v) in
either a histidine-HCl or sodium citrate buffer with addition of polysorbate 20. The filter resistance was
found consistent with the previous controls (aqueous) of 20.8 and 20.6 m−1 (PES) and 9.8 and 10.1 m−1
(PVDF) for the histidine and citrate buffer system, respectively, indicating that the surface properties
were mainly defined by the interaction of filter membrane with the added polysorbate in aqueous solution
and not by the buffer system. Figure 5.6 shows filtration forces through the PES (A) and PVDF (B) filter,
generally with smaller filtration forces for the PVDF compared to the PES filter, as already found for the
previous experiments (Figure 5.1). For both filters, filtration forces of mAb1 showed systematic deviation
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Formulation F/η [N/mPas] F/η [N/mPas] ζ A2
(PES) (PVDF) [mV] [mol mL/g2]
No excipient 3.09 ±0.08 2.37 ±0.17 3.6 10.1 ±0.1
20 mM HisHCl 150 mM ArgHCl 3.08 ±0.13 2.28 ±0.03 0.1 1.0 ±0.1
200 mM Sucrose 2.98 ±0.12 2.19 ±0.09 2.8 9.7 ±0.1
No excipient 2.48 ±0.14 1.93 ±0.04 0.0 0.8 ±0.1
20 mM NaCit 150 mM ArgHCl 2.64 ±0.02 2.19 ±0.21 0.9 1.4 ±0.1
200 mM Sucrose 2.17 ±0.22 1.86 ±0.08 0.3 -0.7 ±0.1
Table 5.1: Filtration force F for PES and PVDF filter normalized by dynamic viscosity η20◦C,2x103 s−1
(Newtonian behavior, N = 2), zeta potential ζ (N = 2), and interaction parameter A2 (N = 3) for different
formulations of mAb1. Mean values and standard deviation are reported.
Figure 5.6: Filtration forces of mAb1 at 20 mg/mL (grey symbols) and 150 mg/mL (black symbols)
in HisHCl (circle) or NaCit buffer (square) with different excipients, and glycerol solutions (Newtonian
control, empty symbols) through a PES (A) and a PVDF filter (B). Filtration forces are presented as
mean values with standard deviation (N = 3) as a function of dynamic viscosity (2 x 103 s−1, 20◦C) and
were measured at a filtration rate of 1.85 x 103 L/m2h.
from the Newtonian control with increasing viscosity/protein concentration. However, this deviation was
smaller for the PVDF filter than for the PES filter. These findings were also consistent with the results
of Figure 5.1. Interesting to note, that the deviation of the different mAb1 formulations was found to
be systematic (increasing with higher viscosity) when a single buffer system was considered, and thus
independent on the tested excipients. Figure 5.6 (A) also showed that the deviation increased for the
citrate buffer compared to the histidine formulations.
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5.4 Discussion
Bioburden-reduction and sterile filtration are unit operations performed during aseptic drug product
manufacturing for parenteral pharmaceutical products, such as monoclonal antibodies. The filtration
pressure needed is determined besides solution contaminants by filter area, filtration rate/volumetric
flow, solution viscosity, and filter resistance. The latter is defined by pore size distribution and surface
properties of the filter material. The present study shows that besides these parameters, particular
properties of protein solutions, depending on protein concentration can have an additional, significant
influence on the filtration process.
Non-Newtonian behavior
Filtration of two monoclonal antibody formulations mAb1 and mAb2 revealed systematic deviation
from Newtonian control solutions with increasing viscosity and protein concentration depending on filter
material (PES and PVDF filter, Figure 5.1). The control solutions followed the linear hydrodynamic
model which is described by the Hagen-Poiseuilles law. [32-34] Further analysis of mAb2 at the highest
protein concentration (180 mg/mL) showed that this deviation after normalization of filtration forces
to viscosity (measured at low shear rates showing Newtonian behavior) increased with filtration rate
(Figure 5.4). An increase in filtration force is consistent with an increase in shear rate (= first derivative
of velocity). Having excluded warming effects by the Newtonian control, we therefore conclude that
the deviation from linear filtration forces - which is shear rate dependent - is most likely due to shear
thinning (non-Newtonian) behavior.
The higher extent of shear thinning observed for mAb1 and mAb2 for the PES filter (compared to the
PVDF filter) was consistent with our findings from the filter characterization experiments: The PES
filter showed a narrow pore size distribution at small pore sizes (maximum pore volume at 0.43 µm)
compared to the PVDF filter with a broader pore size distribution with no clear maximum (Figure 5.3).
The shear rate γ˙ [s−1] is defined by the following equation dependent on volumetric flow ∂V /∂t [m3/s],
[7]:
......................................................................... γ˙ = 16/∂t3piD3 ................................................................. (5.2)
..
As the shear rate is inverse proportional to the third power of pore diameter D [m], the shear rate for
the PES filter is supposed to be much higher than the shear rate for the PVDF filter. This supports
the observation that stronger shear thinning behavior was found for mAb1 and mAb2 when using the
PES filter compared to the PVDF filter. However, exact calculation of the shear rate during filtration
is challenging and needs further investigation as the shear rate is defined by the smallest pore size
interdependent with the number of pores of the respective size as well as the distribution within the
filter. A smaller pore size distribution also influences absolute filtration forces. This is reflected in our
data with higher filtration forces for the tested PES filter than for the tested PVDF filter and quantified
by the higher filter resistance.
In a related study, we have already shown shear thinning behavior for mAb1 at high protein concen-
trations. [7] We found an increase in non-Newtonian behavior at high shear rates (105 – 106 s−1) with
increasingly high protein concentration. This is consistent with the increase in deviation from the Newto-
nian control solutions with increasing viscosity and protein concentration in the first experiment (Figure
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5.1). In literature, it is proposed that the reason for shear thinning behavior might be a deformation of
self-associating mAb networks/clusters to the flow field. These (reversible) clusters are likely to form
at higher protein concentrations and are held together by weak non-covalent, attractive interactions
being electrostatic and hydrophobic in nature. These clusters seem to be also responsible for increasing
viscosity. [35-41] In the related study, we showed that mAb1 was not sensitive to shear stress, which was
representative for shear stress during injection, as no influence on protein integrity (protein aggregation)
and particle formation (visible and sub-visible) was observed by shear thinning behavior for this mAb.
Furthermore, Kiese et al. reported that the addition of polysorbate reduces aggregation of a monoclonal
antibody induced by shear stress by protecting the protein from interaction with hydrophobic surfaces.
[21] Liu et al. have recently shown that the influence of filtration pressure on product quality might not
be the limiting parameter during filtration. They suggested that the shear stress exposure found during
usual manufacturing processes of an IgG1 formulation (100 mg/mL) was not considered important
for final product quality. More important causes of aggregation were suggested to be the presence of
air-bubbles, adsorption to solid surfaces, or contamination by particulates. [42] However, sensitivity to
shear stress representative for the filtration process needs to be investigated on a case-by case basis
in particular for higher protein concentrations and formulations showing pronounced shear-thinning
behavior dependent on product and process characteristics.
Setting our small-scale filtration set-up (3.9 cm2) into relation to large scale production where e.g. 10
inch filter capsules are used (0.69 m2), the filtration of a sample with a dynamic viscosity of 5 mPas
or 10 mPas corresponds to a filtration pressure of 0.58 bar and 1.13 (PES) or 0.34 bar and 0.60 bar
(hydrophilic PVDF) at the chosen filtration rate of 1.85 x 103 L/m2h (equivalent to 2 mL in 10 s for the
tested set-up). Filtration forces in the magnitude of 15 – 40 N as shown in Figure 5.1, Figure 5.5, and
Figure 5.6, where shear thinning behavior of the different mAb formulations was shown, correspond to a
filtration pressure in the range of 0.4 – 1.0 bar which is consistent with routinely used filtration pressures
during production of biotech products.
Change of filter resistance by addition of polysorbate
Zhou et al. have previously reported that PS 20 adsorbs to PES as well as PVDF aseptic filter membranes
although to the latter to a much less extent. They proposed a hydrophobic-based, non-specific binding
to the filter membrane and found that protein concentration did not have an influence on the amount
of adsorbed surfactant. [10] Mahler et al. have reported significant adsorption of PS 80 to PES filters.
[11] Both authors therefore suggest to carefully select filter material for processing and/or – if quality
systems allow – pre-conditioning of the filter (independent on flow rate) as also performed within this
study. This ensures appropriate PS concentration in the final product and mitigates the possible impact
of PS adsorption.
By the investigation of filter resistance, our data strengthen the reported findings that polysorbates
significantly adsorb to the PES filter membranes. The filter resistance of the PES filter significantly
increased upon addition of PS (filtration of a simple salt solution) whereas the filter resistance of the
PVDF filter did not change. Moreover, a slower increase of filtration force during pre-conditioning with
the salt solution was found for both filters (filtration profile) as when compared to the increase in
filtration force after pre-conditioning on a comparable time-scale. The increase was slower for the PES
filter (data/filtration profile not shown). This also suggests a higher adsorption of PS to the PES filter
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than to the PVDF filter. However, this needs to be further characterized. In summary, the presence
or absence of surfactant in combination with intrinsic surface properties of the filter and its pore size
distribution can have a major influence on filter resistance and thus, filtration forces.
Formulation properties
The impact of different excipients on filtration forces was investigated for mAb1 at low (20 mg/mL)
and high (150 mg/mL) protein concentrations. The formulation composition differed in their ionic
strength (type of buffer, addition of arginine-HCL), viscosity (increased by addition of sucrose, decreased
by addition of arginine-HCl), and buffer valence (histidine-HCl and citrate buffer). At low protein
concentration (20 mg/mL), the tested formulations did not show significant differences in filtration
forces, consistent with no differences in viscosity. Lower filtration forces were generally found using the
PVDF filter than compared to the PES filter – for both protein concentrations containing PS, which
was consistent with the previous experiments. However, at high protein formulations (150 mg/mL),
differences in filtration forces between the solutions with different excipients were found. The forces
normalized by viscosity (as measured at low shear rates indicating Newtonian behavior) could neither be
correlated to zeta potential measurements (150 mg/mL) as a measure for the electrochemical potential
of the formulations, neither to the particle burden in solution prior filtration (cumulative sub-visible
particle counts), nor to the interaction parameter A2 as a measure for protein-protein interactions.
In detail, although the formulations which contained either histidine or citrate buffer showed identical
viscosity if the same excipient was added, the formulations with the citrate buffer showed significantly
lower filtration forces than compared to the histidine formulations (for both filter materials). If a single
buffer system is considered, the differences between the formulations were found to change in line with
viscosity. Additionally, if the filtration forces of those formulations are considered as a function of
viscosity (Figure 5.6), a systematic deviation from control samples was found with the latter showing
linear relation of filtration forces and viscosity as expected from Newtonian flow behavior. These findings
are consistent with the data shown in Figure 5.1: Deviation from linear increase in filtration forces with
increasing viscosity with the difference that in Figure 5.1 the increase in viscosity was due to increasing
protein concentration (and not due to the addition of different excipients). Moreover, the behavior with
respect to the different filter material was consistent with in general higher filtration forces and also
higher deviation of the linear relation for the PES filter. The PES filter showed a smaller pore size
distribution and therefore potentially higher shear rates during the filtration process leading to more
pronounced shear thinning behavior with increasing viscosity. The data shown in Figure 5.6 thus support
the conclusion, that shear thinning behavior significantly influences filtration forces, and should be
considered as an important factor during sterile filtration of highly concentrated protein formulations.
We have shown in a related study that mAb1 – in a different formulation – exhibits viscosity behavior
following the Carreau model with a Newtonian plateau at low shear rates, a shear thinning region
converging to a secondary Newtonian plateau at higher shear rates. To date, the relation between
the level of viscosity, the beginning and shear rate range of the shear thinning region, as well as the
relation to formulation properties (excipients) remained unclear. [7] However, the current findings suggest
that the buffer ions/valence seems to have a possible influence on shear thinning behavior of mAb1
independent on the excipients tested. These excipients may only trigger the extent of viscosity of the first
Newtonian plateau (an increase in viscosity by addition of sucrose and a decrease in viscosity by addition
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of arginine-HCl). Open question remains if shear rates during filtration are likely to be in the range of
the shear thinning region or even in the secondary Newtonian plateau, which is subject to further research.
5.5 Conclusion
The rheological behavior of highly concentrated protein solutions have a major impact on hydrodynamic
processes for example during parenteral drug administration, as investigated in a related study [7], as
well as during manufacture of the product like during filtration within the drug product manufacturing
process. With the present study, the impact by various factors on filtration forces were evaluated. Besides
the commonly known parameters as filter area, filtration rate/volumetric flow, solution viscosity, and
filter resistance (defined by pore size distribution and surface properties), the following parameters were
identified to significantly influence filtration forces: (a) the presence/absence of surfactant (polysorbate)
was observed to have a major influence on filter resistance dependent on filter material. It was shown
that the addition of polysorbate 20 significantly increased the filter resistance of the PES filter, whereas
it remained relatively unchanged for the PVDF filter. (b) the interaction of (1) pore size distribution,
which was found significantly different for the tested filter materials, and (2) filtration pressure, which
trigger the shear rate, were found to lead to non-Newtonian, shear thinning behavior, which increased
with higher protein concentration and filtration rate. The study showed that non-Newtonian behavior
led to differences in filtration dependent on formulation composition. Differences in buffer valences
of the formulation showed a major impact on the non-Newtonian behavior with a higher extent of
shear thinning for the citrate buffer compared to the histidine buffer independent on the addition of
excipients like arginine-HCl or sucrose. The latter were found to not contribute to the extent of shear
thinning behavior. These findings emphasize the importance of considering formulation composition on
hydrodynamic processes like filtration and highlights the relevance to assess possible limitations during
manufacture caused by elevated viscosity of highly concentrated protein formulations.
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5.8 Supporting information
Buffer Excipient ≥10 µm ≥25 µm
[cumulative counts/mL] [cumulative counts/mL]
20 mM HisHCl No excipient 10 1
0.06% PS 20 150 mM ArgHCl 1 1
200 mM Sucrose 0 0
20 mM NaCit No excipient 3 3
0.06% PS 20 150 mM ArgHCl 10 9
200 mM Sucrose 14 0
Table 5.2: Sub-visible particle count as cumulative count per mL ≥10 and ≥25 µm for the different
formulations of mAb1 at 150 mg/mL. Measurements were performed as duplicates and mean values are
reported.
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Figure 5.7: Representative example of a filtration profile of a 60% (m/v) glycerol solution (20 mM
HisHCl buffer, 0.06% (m/v) PS 20) through a PES (open circle) and a PVDF (filled circle) filter at a
filtration rate of 1.85 x 103 L/m2h. Filters were pre-conditioned with the respective solution before the
experiment.
Figure 5.8: Comparison of filtration forces of a 0.001 M potassium chloride solution with 0.06% (m/v)
polysorbate 20 or 80 through PES and PVDF filter at a filtration rate of 1.85 x 103 L/m2h.
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Discussion
Highly concentrated protein therapeutics can offer a convenient way for subcutaneous drug adminis-
tration by the patient him-/herself or a healthcare professional. During the manufacturing process,
concentration of the protein leads to a decrease in volume available to the protein which may favor
self-association/aggregation and increases viscosity. Severe limitations are thus given by the rheological
behavior during pharmaceutical formulation, processing, and drug administration. The elevated viscosity
at high protein concentrations leads to an increase in pressure required to manufacture or administer
the protein solution.
The focus of this work was to investigate the rheological behavior of protein solutions at high protein
concentrations. The main objective was to obtain a profound understanding of the drug administration as
well as of the filtration process and to elucidate the role of viscosity with regard to potential limitations.
In summary, the present work provides an overview of commercial highly concentrated protein for-
mulations as well as of methods used for viscosity characterization including a new high-throughput
method using CE equipment. Based on these studies, the role of viscosity of highly concentrated protein
formulations was investigated in two critical aspects which were: i) the impact of viscosity on filtration
within the fill-finish process and ii) the rheological behavior during drug administration of concentrated
protein solutions.
Commercial highly concentrated protein solutions
Chapter 1 provides a technical overview of commercial highly concentrated biotherapeutics. The products
which are intended to be administered using the sc or im route of injection were characterized for
formulation properties including pH, osmolality, physical stability like the extent of soluble aggregates, as
well as requirements defined by the European Pharmacopoeia, such as visible and sub-visible particles.
Thus, this study may be used as reference for formulation development of highly concentrated protein
therapeutics. The study revealed significant differences between the products especially for viscosity
which was determined by plate/cone rheometry and found in the range of 2 mPas to 102 mPas (20◦C)
for protein concentrations between 50 and 200 mg/mL. A viscosity of 100 mPas was thus chosen as a
benchmark for highest viscosity in the following studies, like for the study described in Chapter 4, which
characterized the contribution of sc backpressure to injection forces.
The current benchmark for maximum protein concentration as well as of viscosity was a liquid
formulation at 200 mg/mL with a dynamic viscosity of 102 mPas measured at 20◦C. Interestingly,
this commercial product is indicated for rheumatoid arthritis, with patients who are limited in their
dexterity/flexibility. This was likewise addressed by the design of the pre-filled syringe of the product
using an extended finger flunge and a special ring-shaped RNS to facilitate removal. Most importantly,
this product also had the largest inner needle diameter of 25 G compared to other commercial products
using a 27 G needle for the injection device. Increasing the needle inner diameter facilitates injection
and reduces injection forces significantly, which was investigated in the following chapters in detail.
The viscosity of each commercial product investigated was reflected in the corresponding injection forces
which were tested both in respective marketed injection device and a generic device. The latter served
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to normalize the data. The viscosity data was correlated to injection forces applying currently described
models based on the Hagen-Poiseuilles’ law, dependent on viscosity, injection rate/volumetric flow, and
frictional forces as follows:
Ftotal = F (Q, η)hydrodynamic/Hagen−Poiseuille + F (Q)friction
(F = force, Q = volumetric flow, η = dynamic viscosity)
Deviations from linear correlation were found for some of the commercial products leading to deeper
investigation of injection forces of protein solutions at high protein concentrations (Chapter 3). Moreover,
injection forces were calculated and experimentally verified by simulated injection into air, and thus
neglecting the in vivo situation. The present data were used as a basis for further investigation of the
correlation between viscosity and injection forces representative for the in vivo situation as outlined in
Chapter 4.
High-throughput method for viscosity measurement
Viscosity characterization of protein formulations is challenging requiring methods involving low material
consumption (in the microliter range) and a high throughput at a viscosity range between approximately
1 and 100 mPas. Commercially available methods are time-consuming and require large sample volumes
in the range of hundreds of microliters to a few milliliters. Therefore, an automated, high-throughput
method to measure dynamic viscosity of Newtonian solutions using standard capillary electrophoresis
equipment was developed. Chapter 2 describes the development of this method as well as the application
to protein therapeutics by comparison to our routinely used method for viscosity determination during
protein formulation development which is plate/cone rheometry. Typical viscosities in the range of 5 to
40mPas were accurately measured with measurement times between 1 and 15 minutes, small sample
volumes (few microliters) by use of a capillary with a diameter of 50 µm and a length of 20.5 cm.
Compared to other rheological methods used in protein formulation development, such as capillary
viscosimeters [2 – 4 mL], falling ball viscosimeters [150 – 300 µL], or standard plate/cone rheometer
[80µL], the established CE instrumentation-based method requires a small sample volume in the storage
vial of 100 µL and a sample consumption of only a few microliters. The volume of 100 µL is a limitation
of the instrument used and may be optimized by vial design or optimization of the inlet position. Most
importantly, a unique feature of the CE instrumentation is that no time-consuming cleaning is needed
due to automation of the method and cleaning process. This constitutes an advantage over the above
mentioned viscosimeters, which require at least about 10 minutes per measurement. As a result, the CE
instrumentation allows for measurements in an automated manner with a throughput of approximately
30 samples per load defined by the capacity of the sample tray of the instrument used.
A limitation of the CE instrumentation-based method may be the potential for clogging of the capillary
with particles. However, since filtration of protein samples (using sterilizing-grade filters) is routinely
performed during sample preparation, particles >0.2 µm are typically excluded. Furthermore, potential
interaction of the sample with the capillary wall at high protein concentration might require coated
capillaries. An alternative approach is the calibration of the capillary with the specific product itself or
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the measurement of relative viscosity values.
Our method reliably determined the viscosity of Newtonian solutions between 5 and 40 mPas. Variation
in capillary length and capillary diameter led to different minimal and maximal viscosities. The subject
of ongoing research is the variation of the applied pressure which leads to measurements at differ-
ent/adjustable shear rates. Therefore, the method would also be applicable to non-Newtonian liquids
showing shear-rate-dependent behavior. This is of considerably importance as we have recently reported
that protein formulations can show shear-thinning behavior especially at high protein concentrations
(Chapter 3). CE is an analytical method routinely used for the separation and characterization of
proteins. Therefore, this instrument is usually available in most protein formulation development
laboratories and can be used straight forward for viscosity determination.
Injection forces (in vitro/in silico)
Based on the preliminary study on characterization of commercial products (Chapter 1), which
showed smaller injection forces than estimated from currently described models, injectability of highly
concentrated protein formulations was further investigated in Chapter 3 and 4. In Chapter 3, injection
forces of a monoclonal antibody (mAb, IgG1) at maximum protein concentration considered feasible
(250 mg/mL) as well as of the different commercial products were characterized dependent on various
parameters like injection rate, and linked to rheological behavior. Based on the law of Hagen-Poiseuille,
injection forces were found to be linearly dependent on viscosity. However, deviation from linear flow
behavior was found for some of the products compared to the Newtonian control. Based on these
findings, a mathematical in silico model was established to predict injection forces from viscosity data
applicable for Newtonian and non-Newtonian fluids. It was experimentally verified (in vitro) by use of
surrogate samples (Carbopol gels). Subsequent viscosity characterization of our model antibody mAb1
at high shear rates (105−6 s−1) as well as of some commercial products revealed non-Newtonian, shear
thinning behavior which was increasing with higher shear rates as well as protein concentration and
viscosity. The rheological profile of mAb1 at high protein concentrations was thereby described by the
Carreau model indicating a first Newtonian plateau (104 s−1), a shear thinning region, and potentially
converging to a secondary Newtonian plateau at >106 s−1. The detailed characteristics of the secondary
plateau depending on type of antibody, protein concentration, and formulation composition need to be
further investigated. The findings of this study emphasize that shear thinning behavior leads to smaller
injection forces than expected from linear flow behavior. This is of outmost importance as the limits (e.g.
used for device robustness and device design) currently predicted based on Newtonian behavior would
significantly overestimate injection forces. The presence of non-Newtonian flow behavior at high shear
rates may offer the possibility to exceed these limits and to consider even higher protein concentrations
and viscosities.
However, the crucial factor for the definition of injection force limits likely remains the patient population
or health care professionals and their capability to administer the product. Anthropometric strength
studies showed that the force that a user can exert onto a syringe plunger is determined by multiple
factors including the health status and the strength of the individual, and the upper limb and hand
posture required for injection.[1] These human factors also include the personal preference and training
of the individual. In reality, users moderate the injection force by adjusting their injection speed and
may choose a slower injection resulting in a lower injection force to fit their capability or preference.
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Injection forces (in vivo)
A mathematical model for prediction of injection forces was described in Chapter 3. It is based on the
Hagen-Poiseuille’s law and representative for simulated injections into air. This model depends on a
hydrodynamic part which is influenced by dimensions of the device components (e.g. needle inner di-
ameter), injection rate, and formulation properties like viscosity. Besides hydrodynamic forces, frictional
forces between stopper and plunger are considered which are among others driven by siliconization of
the syringe barrel and dimensions of the stopper. However, for a comprehensive picture of parameters
contributing to injection forces, they should be tested in an in vivo situation and parameters like
hydrodynamic contribution, tissue backpressure, and other factors should be separately assessed.
Chapter 4 investigated injection forces during sc administration in Go¨ttingen minipigs (in vivo) depen-
dent on viscosity, injection rate, and injection volume providing quantitative data on the backpressure
of the sc tissue. The quantitative amount of the contribution of sc tissue backpressure to injection forces
is significant and ranged in average from 0.6 to 4.7 N (1 – 20 mPas, 0.025 – 0.2 mL/s) with a maximum
value of 12.9 N (20 mPas, 0.2 mL/s).
The minipig is currently considered as the most appropriate translational animal model to study
the pharmacokinetics of biotherapeutics after sc injection e.g. for studies of monoclonal antibody
therapeutics [2, 3, 4]. Most importantly, the structure of the hypodermis of the pigs was reported to
resemble that in humans more than any other animal (e.g. rodent, monkey) [2, 5-7]. The skin of the
pig is, like in humans, connected to the deep fascia via a fibrous network which defines the spreading
behavior of a sample. A relevant difference between humans and e.g. rodents, monkeys, and pigs is
the presence of the panniculus carnosus for the latter three animal species [3, 5, 7, 8]. However, the
panniculus carnosus is missing in some parts of the pig, like in the groin, and therefore ressembling
human tissue structure [5]. Thus, the plica inguinalis was chosen as injection site in minipigs for this
study. Only the height of the subcutaneous tissue layer differs between the human skin (approximately
11 mm) [9] and the plica inguinalis of the minipig (few mm). Therefore, a short needle with a length
of 3/8” used for injection in parallel to the body surface, was chosen to control and ensure injection
of the solutions in the sc tissue space in our study. The two differences between injection into the skin
of minipigs versus injection into human tissue are on the one hand the difference in the height of the
sc tissue layer and of the injection angle on the other hand. This might lead to the question whether
and how the obtained results may be translated to humans. This question cannot be fully answered at
this point of time as this study is the first one to provide quantitative data on the contribution of the
tissue backpressure to sc injection forces in an in vivo situation. However, the structure of the skin is
considered comparable between humans and the inguinal region of the minipig, as previously outlined.
Therefore, similar spreading/distribution of the injected sample in the sc tissue layer is expected. Up to
date, current literature only provides a study which was conducted by Cilurzo et al. dealing with the
contribution of the tissue to injection forces during sc injection. They have recently performed an ex
vivo experiment where they injected a 19mPas and a 101mPas solution into the abdominal skin (sc)
from an Eurasian female who underwent cosmetic surgery. They found an increase in injection force
by a factor of 1.1 compared to injection into air due to tissue resistance. Although only measured at a
constant injection speed of 1mm/s (approximately 0.03mL/s), this study also suggested a significant
contribution of the tissue to injection forces [10]. However, testing of injection forces ex vivo is not yet
fully understood. It may lead to unexpected modifications/distortions. Therefore, further investigation
is needed to show if and how ex vivo testing may be representative for the in vivo situation.
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Besides the contribution of the tissue, the study showed that local warming of the (equilibrated) sample
in the needle during injection has to be considered when estimating injection forces representative for
the in vivo situation. This local temperature effect led to reduced viscosity of the sample in the needle
and therefore smaller injection forces than initially expected. The temperature effect was experimentally
quantified dependent on viscosity and injection rate and is applicable to any desired body temperature
(e.g. also to humans). The control experiments in a tempered water bath confirmed that injection
forces were significantly decreased if the needle tip – although only few millimeters in length – faces
warmer environmental conditions than room temperature during injection than compared to injections
into air (at room temperature). This additional negative contribution to injection forces was found and
quantified to be linear dependent on viscosity and injection rate indicating a hydrodynamic process.
The positive contribution of the sc backpressure and the negative contribution of the local temperature
effect were described to compensate each other to some extent. This is of utmost importance with respect
to potential limitations given by the user capability of the patient. Dependent on the indication, patients
might be limited in their strength like e.g. for rheumatoid arthritis patients, stating a challenge to expel
a syringe. Therefore, the limits for maximal required injection force have to be carefully evaluated before
design of an injection device. A highly concentrated protein therapeutic with a viscosity of 100 mPas
has been previously studied [1]. This protein therapeutic was tested for injectability by Sheikhzadeh and
co-workers in an anthropometric study. The authors reported that rheumatoid arthritis patients were
capable to exert a force of approximately 17N (95% percentile) and 48 N (mean) in average onto the
syringe plunger [1]. Setting this into relation to our findings assuming a constant, slow injection speed
of 0.025 mL/s, the injection force of this product would be higher by approximately 7 N due to the
contribution of the sc backpressure compared to in vitro injection forces, which are in general tested
against air. The local temperature effect for a body temperature of 37◦C (human) leading to warming
of the sample in the needle would decrease injection forces by approximately 4N assuming similar
viscosity-temperature dependence of the therapeutic as dextran. This would result in an overall higher
injection force by 3 N compared to the estimated or measured injection force in the in vitro situation.
The data indicate that consideration of the actual in vivo sc backpressure is essential when assessing
injection forces. Moreover, compensation of the increase in injection forces due to tissue backpressure by
the local temperature effect, as observed for the minipig and reported to our knowledge for the first time,
needs to be evaluated and confirmed in humans. In summary, the in vivo study provides a detailed insight
into injection forces and led to the following extension of the in silico model to predict injection forces [11]
Ftotal = F (Q, η)hydrodynamic + F (Q)friction + F (Q, η)tissue backpressure - F (Q, η)body temperature
(F = force, Q = volumetric flow, η = dynamic viscosity)
The final limiting parameter for the injection process is given by the user capability of the patient
population. However, the needle inner diameter was shown to have major influence on injection forces
as outlined in detail in Chapter 3. The inner diameter of the needle is related to injection forces by the
power of four compared to other parameters, like viscosity, injection rate, and sc tissue backpressure
being directly proportional.
This study is of key importance during the development of injection devices like e.g. for combination
products (e.g. autoinjectors or pre-filled syringes). Furthermore, the reported findings of this study
suggest additional studies to be performed to fully understand the in vivo situation. With regards to
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the observation of the local temperature effect, e.g. the development of tempered injection pads might
be considered. These pads could be used for device testing or patient training.
Within this study, we found that the force profiles for all tested conditions reached a plateau and no
difference in backpressure was found when two injection volumes (2.5 and 4.5 mL) were compared.
Therefore, also even higher injection volumes might be tested to investigate if there is a limit in volume
when the force profile starts to leave the plateau and start to further increase during injection due to the
backpressure/lifting of the skin. This would also trigger reconsideration of maximum feasible injection
volume as discussed in Chapter 4.
The potential of the instrumental set-up which was built for this study might be still huge. Especially the
use of the injection equipment (including some modifications) to measure injection forces in human beings
like e.g. during clinical studies would be beneficial. These studies might provide detailed information on
actual injection forces and potentially confirm the findings of our in vivo study. Moreover, the measured
injection force data might be directly linked to other human factors as well as providing information on
related pain.
Last but not least, the instrumental set-up might be also used in upcoming in vivo studies to simulate
injection by an autoinjector by application of an artificial pressure on the injection site mimicking the
depression of the needle shield and activation of the autoinjector.
Filtration of highly concentrated protein formulations
Besides drug administration, the increase in viscosity with higher protein concentration may cause
limitations during process development like during manufacture. Filtration was identified as the most
critical process step related to viscosity during the manufacturing process. Therefore, filtration of
different mAb formulations was investigated in detail in a lab-scale set-up as the second hydrodynamic
process to complete this work. Chapter 5 provides a detailed look into filtration of highly concentrated
protein formulations and summarized key factors having an impact on filtration forces. Filtration forces
were determined dependent on filter material, protein concentration, and viscosity, and differences were
linked to filter resistance, pore size distribution, and formulation composition. Most important, the
study showed that dependent on the pore size distribution of the filter (which defines the shear rate
dependent on the filtration pressure), the model antibodies mAb1 and mAb2 showed shear thinning
behavior increasing with increasing filtration rate and protein concentration, thus confirming the findings
from the injection force experiments. However, subject of ongoing research is the exact calculation of the
shear rate during filtration due to distribution of the pressure over the pores of the cross-sectional area
of the filter.
The study showed that the non-Newtonian behavior of mAb1 and therefore differences in filtration
forces were influenced by the formulation composition. Especially differences in buffer valences of the
formulation showed a major impact on the non-Newtonian behavior. This effect was independent on the
addition of further excipients which were found to define the viscosity of the first Newtonian plateau (at
low shear rates), however did not contribute to the extent of shear thinning behavior. These findings
emphasize the importance of formulation composition on hydrodynamic processes like filtration.
Limitations for the filtration process may be discussed controversially. The study showed that the fil-
tration pressure, which also triggered the rheological behavior at high protein concentrations dependent
on filtration rate, is mainly defined by the pore size distribution of the filter material besides the other
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investigated parameters like viscosity. Moreover, literature data reported that the influence of filtration
pressure on product quality might not be the limiting parameter during filtration. For the formulations
previously tested (up to a protein concentration of 100mg/mL at 250 000 s−1), the shear stress exposure
during manufacture was not considered important for final product quality. More important causes of
aggregation were suggested to be the presence of air-bubbles, adsorption to solid surfaces, or contami-
nation by particulates. [12] However, future studies have to show the impact of shear-thinning behavior
triggered by the applied pressure on product quality dependent on protein, formulation compositions,
and especially protein concentration. This has to be evaluated on a case-by-case basis dependent on
product and process characteristics.
Molecular consideration for shear-thinning behavior
The presented studies within this work have demonstrated that highly concentrated protein formulations
may exhibit non-ideal flow behavior under high shear like e.g. during drug administration through a
27/25 G needle (Chapter 3) or during filtration (Chapter 5). The molecular mechanism for this shear
thinning behavior is not yet fully understood and subject of ongoing research. One hypothesis is that
monoclonal antibodies may form so-called self-associating clusters at high protein concentrations, as
outlined. [13-18] Experiments showed that these mAb clusters are likely to be governed by anisotropic,
colloidal interactions with hydrophobic attractive wells and heterogeneously distributed surface charges.
[15] These clusters may be responsible for the increase in viscosity at higher protein concentrations as
reported by Lilyestrom et al. [14] Similar findings are reported in literature for polymers like carbopols
forming three-dimensional networks at high volume fractions. [19] These entanglements were shown
to be responsible for an increase in viscosity. Furthermore, non-Newtonian rheological behavior was
observed of these polymers at high shear rates potentially caused by alignment of these entanglements to
the flow field. [19, 20] Therefore, shear thinning behavior of our mAbs may be caused by cluster aligning
to the flow field if shear stress is applied, although Zarraga and colleagues have recently reported that the
mAb self-associations are likely to be reversible and unlikely to be physical entanglements or long range
elasticity, such as observed in polymer systems. Ongoing studies have to show if different formulations
of mAb1, which were in some parts characterized during the injection experiments of Chapter 3, exhibit
heterogeneous, self-associating structures dependent on protein concentration and how this relates to
viscosity. Studies are ongoing using e.g. small-angel neutron scattering experiments which is one of
the few methods capable to investigate protein-protein interactions and molecular structures at high
protein concentrations as outlined in the ’Introduction’. Besides cluster formation, these data will also
help to understand and to identify differences in attractive and repulsive PPIs of mAb1 dependent on
formulations composition and the relation to viscosity data.
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Conclusions
The demand for highly concentrated protein concentrations for sc administration is still increasing due
to patient convenience offering the possibility for home treatment. The development of concentrated
formulations exceeding 50 – 100 mg/mL includes several challenges like solution viscosity. Viscosity of
concentrated protein solutions is governed by multiple factors including but not limited to formulation
composition, temperature, and formulation pH, and increases in an exponential fashion with higher
protein concentration. The increase in viscosity leads to an increase in pressure needed to manufacture
the product and to an increase of the force which is required by the patient or healthcare professional
to administer the product. Thereby, high shear rates exceeding 105 s−1 may occur during processing,
especially during filtration, and injection dependent on the flow rate, which significantly influence the
rheological behavior of the protein solution.
The present work investigated the rheological behavior of protein solutions at high protein concen-
trations. The detailed investigation of two hydrodynamic processes considered critical with regard to
increased viscosity, which were filtration and drug administration by injection, showed that the potential
limitation defined by the proportional increase in pressure based on Newtonian flow behavior was
overestimated due to the presence of shear-thinning behavior, which was shown for highly concentrated
protein formulations.
In the first study, the current work has provided a detailed overview on highly concentrated marketed
product characteristics including formulation properties like viscosity, physico-chemical properties,
as well as injection device properties. This study showed that the benchmark for maximum protein
concentration and viscosity was a commercial protein therapeutic with a protein concentration of
200mg/mL and a viscosity of 102mPas (20◦C) being administered using an injection device/pre-filled
syringe with a 25 G needle.
In the second study, a high-throughput method was established providing an automated, time-saving,
and low-volume method for measuring dynamic viscosity of protein solutions. This method was discussed
in context of advantages and limitations of different methods for viscosity determination used during
pharmaceutical development of protein formulations.
Based on these two initial studies, the present work has investigated and characterized in detail the
subcutaneous drug administration process of highly concentrated protein formulations and provided
quantitative in vitro and in vivo data (Go¨ttingen minipigs) of injection forces. An in silico model to
predict injection forces was established depending on syringe and needle dimensions, solution viscosity,
and injection rate and extended for shear thinning behavior (non-Newtonian flow behavior). The needle
inner diameter was shown to have major influence on injection forces. It is related to injection forces
by the power of four compared to other parameters, like viscosity, and injection rate being directly
proportional. The study demonstrated that lower effective injection forces were obtained for highly
concentrated protein solutions due to shear-thinning behavior than expected from current literature
models.
To address the in vivo situation, the contribution of the subcutaneous tissue backpressure was quantified
and specifically the additional influence of the body temperature on injection forces was reported. Both
were found to be significant and linear dependent on viscosity and injection rate. The quantitative
amount of the contribution of sc tissue backpressure to injection forces ranged in average from 0.6 to 4.7
N (1 – 20 mPas, 0.025 – 0.2 mL/s) with a maximum value of 12.9 N (20 mPas, 0.2 mL/s). However, the
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positive contribution of the sc backpressure and the negative contribution of the local temperature effect
were described to compensate each other to some extent dependent on viscosity and injection rate, as
outlined.
Correct prediction of injection forces is of utmost importance, especially when intended for use by
patients who are limited in their dexterity/flexibility. These are e.g. rheumatoid arthritis patients.
Although the needle inner diameter was shown to have the major influence on injection forces as
outlined, the final limiting parameter for the injection process is still given by the user capability of the
patient population.
Overall, an extended model to predict injection forces representative for the in vivo situation was
developed, which addresses the injection force as a function of viscosity, volumetric flow/injection
rate, needle/device dimensions, shear-thinning behavior, sc backpressure, and body temperature. This
knowledge is of key importance for the development of injection devices for combination products (e.g.
autoinjectors or pre-filled syringes), which requires a detailed understanding of injection forces dependent
on device dimensions like needle diameter and formulation properties like viscosity. This knowledge may
be used for the definition of limits as well as for testing of device robustness and design during the
evaluation, planning, and design phase of the development of injection devices.
Besides drug administration, filtration was investigated as the second critical hydrodynamic process for
highly concentrated protein formulations, dependent on formulation composition and filter material.
Similar to the drug administration process by injection, shear thinning behavior was found for some of
the products during the filtration process depending on viscosity and protein concentration, formulation
composition, and shear rate. The data demonstrate that the potential limitation defined by the propor-
tional increase in pressure based on Newtonian flow behavior was overestimated for highly concentrated
protein formulations. The stability behavior of mAb formulations was tested in previous studies at shear
rates up to 250 000 s−1 and protein concentrations of up to 100mg/mL. The study showed that high
shear was not critical for final product quality. More important causes of aggregation were suggested to
be the presence of air-bubbles, adsorption to solid surfaces, or contamination by particulates. However,
the stability of a formulation showing pronounced shear-thinning behavior at high shear rates, which
will most likely only be the case for higher protein concentrations than previously tested, needs further
experiments.
The present work provided a deeper insight into the filtration and injection processes of highly concen-
trated mAb formulations. Still, open questions arose during the different studies. These questions need
further investigation as outlined in the ’Discussion’s’ section in detail and will be summarized in the
following. This includes at a first place the investigation of the molecular mechanism of shear thinning
behavior based on the hypothesis of alignment of mAb clusters to the applied flow field. Information on
the structure on a molecular level and on interaction potentials between two molecules can be obtained
by using small-angle neutron scattering. Characterization of shear-thinning, non-Newtonian behavior
may be obtained by extension and further optimization of the established viscosity method using CE
instrumentation for higher shear rates. Although the stability behavior of mAb formulations under high
shear was tested in previous studies showing to be not critical for final product quality, the stability of a
formulation showing pronounced shear-thinning behavior at high shear rates, which will most likely only
be the case for higher protein concentrations than previously tested (up to 100mg/mL), needs further
investigation.
Confirmational studies in humans would be valuable to verify if our in vivo data from minipigs are
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representative with regard to sc backpressure and influence of body temperature on injection forces.
However, ethical concerns might be given. Moreover, investigation of ex vivo testing would be beneficial
to obtain an understanding if and how ex vivo and in vivo testing (minipig) relate to each other
depending on tissue material used. This would provide a potential rational on substitution of in vivo
experiments by ex vivo testing.
The present studies targeting in vivo injection forces used injection volumes up to 4.5 mL showing no
difference in injection forces compared to smaller injection volumes tested (2.5 mL). Therefore, higher
injection volumes >4.5 mL will have to be evaluated for sc drug administration to investigate the impact
on sc backpressure and especially if there is a threshold in injection volume, which leads to a rapid
increase in injection forces from the initial injection force plateau. Last but not least, the influence of
the contribution of devices to injection forces requires further experiments. As an example, testing of
the impact of an artificial pressure on the skin before injection, which is needed for activation of most
autoinjectors prior to injection to remove the needle shield, would be valuable.
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